



### **16.1.9.3 BIOANALYTICAL REPORTS**

Determination of S-Benzyl Mercapturic Acid (SBMA) and S-Phenyl Mercapturic Acid (SPMA) in Human Urine Samples by LC-MS/MS (Study AA99602-01)



Celerion Switzerland AG  
Allmendstrasse 32  
8320 Fehraltorf  
Switzerland  
www.celerion.com  
Tel: +41 43 355 76 76 Fax: +41 43 355 76 74

**Determination of S-Benzyl Mercapturic Acid (SBMA) and S-Phenyl Mercapturic Acid (SPMA) in human urine samples from “A randomized, controlled, open-label, 3-arm parallel group, single-center study to demonstrate reductions in exposure to selected smoke constituents in smoking, healthy subjects switching to the Tobacco Heating System 2.2 (THS 2.2) or smoking abstinence, compared to use conventional cigarettes, for 5 days in confinement” by LC-MS/MS**

Study: AA99602-01  
Bioanalytical Report No. AAA99602-01

Bioanalytical Final Report

Philip Morris Products S.A.  
Quai Jeanrenaud 3  
2000 Neuchâtel, Switzerland

Protocol ZRHR-REXC-03-EU

Report Date: 29 August 2014



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01**STUDY LOCATION****TEST FACILITY**Celerion Switzerland AG  
Allmendstrasse 32  
8320 Fehraltorf, Switzerland  
Phone: +41 43 355 76 76  
Fax: +41 43 355 76 74

Role	Name, Title	E-mail address
Bioanalytical Principal Investigator	Matthias Jecklin, PhD (12-Aug-2013 to 23-Oct-2013)	Matthias.Jecklin@celerion.com
	Werner Meyer (from 23-Oct-2013)	Werner.Meyer@celerion.com
Test Facility Manager	Petra Struwe, PhD	Petra.Struwe@celerion.com
Quality Assurance Manager	Diana Bürgin	Diana.Buergin@celerion.com

**SPONSOR**Philip Morris Products S.A.  
Quai Jeanrenaud 3  
2000 Neuchâtel, Switzerland  
Phone: +41 58 242 2625

Role	Name, Title	E-mail address
Manager Clinical Science	Christelle Haziza, Ph.D.	Christelle.Haziza@pmi.com

**Clinical Central Laboratory \***Covance CCLS  
Rue Moïse Marcinhes 7  
CH-1216 Meyrin, Geneva Switzerland  
Phone: +41 58 822 7732  
Fax: +41 58 822 6999

Role	Name, Title	E-mail address
Project Manager	Nathalie Mathieux, Ph.D.	Nathalie.Mathieux@Covance.com

\* Samples were received at Celerion Lincoln and the appropriate aliquots were forwarded from Lincoln to Celerion Switzerland.



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01


---


**APPROVAL SIGNATURES**

**TEST FACILITY**


**Celerion Switzerland AG:**


Bioanalytical Principal Investigator

  
\_\_\_\_\_  
Werner Meyer

  
\_\_\_\_\_  
Date

Test Facility Management

  
\_\_\_\_\_  
Christine Schiebl, PhD

  
\_\_\_\_\_  
Date



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

**SPONSOR**

**Philip Morris Products, S.A.:**

Manager Clinical Science

A handwritten signature in black ink, appearing to read "Christelle Haziza".

Christelle Haziza, PhD

11.03.2014

Date



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

#### STATEMENT OF COMPLIANCE

Herewith it is confirmed, that the Celerion study AA99602-01 was performed according to the standards described in the Swiss Ordinance relating to Good Laboratory Practice, adopted 18 May 2005 [RS 813.112.1]. This Ordinance is based on the OECD Principles of Good Laboratory Practice, as revised in 1997 and adopted 26 November 1997 by decision of the OECD Council [C(97)186/Final] [1].

The OECD Principles of Good Laboratory Practice are accepted by Regulatory Authorities throughout the European Union, the United States of America and Japan.

In addition, the analysis of clinical trial samples including the validation of the applied analytical methods was conducted in accordance with the relevant standards of Good Clinical Practice and Standard Operating Procedures based on the recommendations of the EMA 'Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples' (EMA/INS/GCP/532137/2010) [2] and the EMA 'Guideline on bioanalytical method validation' (EMA/CHMP/EWP/192217/2009) [3].

This study was conducted in accordance with the guidelines documented in the bioanalytical study plan. To ensure the integrity of the reported data, the bioanalytical laboratory verified all results. The Quality Assurance unit of Celerion audited the study. A Quality Assurance statement was then issued and is included within this document in the following page.

The data summaries, results, and conclusions in this bioanalytical report have been reviewed and were found to be consistent and scientifically rational. All deviations from the protocol and/or significant deviations from SOPs documented in this report have been reviewed and are scientifically valid.

I accept responsibility for the scientific validity of the data.

Werner Meyer  
Bioanalytical Principal Investigator

Date



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

**QUALITY ASSURANCE STATEMENT**

Phase Audited	Audit Date(s)	Date reported to the Bioanalytical Principal Investigator	Date Audit Report Signed by Management
Bioanalytical Study Plan	08-Aug-2013	08-Aug-2013	09-Aug-2013
Bioanalytical Study Plan Amendment No. 1	16-Sep-2013	16-Sep-2013	17-Sep-2013
Bioanalytical Study Plan Amendment No. 2	18-Oct-2013	18-Oct-2013	18-Oct-2013
Study-based Inspection / Sample transfer and thawing process	26,27-Sep-2013, 01,11-Oct-2013	11-Oct-2013	11-Oct-2013
Raw Data Audit	06,10,11-Feb-2014	11-Feb-2014	23-Jun-2014
Bioanalytical Report (Final Draft)	20,23,24-Jun-2014	24-Jun-2014	05-Aug-2014
Bioanalytical Report (Final)	The date of the QA review of the Final Report is identical to the signature date of the QA Statement.		

Celerion Quality Assurance audited various phases of this study as shown above. This statement confirms that the methods, procedures, and results as presented in this report accurately reflect the raw data of the study.

Amandine Rabany  
QA Auditor

29 AUG 2014

Date:



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01**TABLE OF CONTENTS**

STUDY LOCATION.....	2
APPROVAL SIGNATURES.....	3
STATEMENT OF COMPLIANCE.....	5
QUALITY ASSURANCE STATEMENT .....	6
TABLE OF CONTENTS.....	7
1. INTRODUCTION.....	11
2. EXPERIMENTAL .....	11
2.1. Test Item .....	11
2.2. Reference Items and Internal Standards.....	11
2.3. Blank Matrix .....	12
2.4. Test System .....	12
2.4.1. Procedure and Instruments.....	12
2.4.2. Computer Application Software .....	12
2.5. Calibration Standards, Quality Control Samples and Dilution Quality Control Samples .....	12
2.6. Study Samples.....	13
2.6.1. Sample Source and Date of Receipt.....	13
2.6.2. Sample Identification .....	13
2.6.3. Sample Storage and Stability .....	13
2.6.4. Sample Summary .....	14
3. SAMPLE ANALYSIS.....	14
3.1. Analytical Method.....	14
3.2. Acceptance Criteria.....	14
3.2.1. Analytical Run Acceptance Criteria.....	14
3.2.2. Acceptance Criteria for Sample Dilution .....	15
3.2.3. Acceptance Criteria for ISR .....	15
4. RESULTS.....	15
4.1. Quality Control and Dilution Quality Control Sample Performance.....	15
4.2. Calibration Standard Performance .....	16



---

SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

---

4.3. Standard Curve Parameters .....	16
4.4. Study Sample Concentrations .....	16
4.5. Reassays .....	16
4.5.1. Reassays for Analytical Reasons .....	16
4.5.2. Reassays for Non-analytical Reasons (Value requiring confirmation, VRC) .....	16
4.5.3. Sponsor Selected Reassays .....	16
4.5.4. Incurred Sample Reproducibility .....	16
5. CHROMATOGRAMS .....	17
6. DEVIATIONS .....	17
7. EVENTS .....	17
7.1. Event Resolution dated 04-Oct-2013 .....	17
8. ANALYTICAL NOTES .....	17
8.1. Schedule nominal time points .....	17
9. ARCHIVES .....	18
10. CONCLUSION .....	18
11. REFERENCES .....	18
RESULT TABLES .....	20
FIGURES .....	128
ATTACHMENTS .....	130



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01**RESULT TABLES**

Table 1	Summary of Analytical Runs Performed .....	20
Table 2	Quality Control and Dilution Quality Control Sample Data (Between-Analytical Run Precision and Accuracy) for SBMA .....	22
Table 3	Quality Control and Dilution Quality Control Sample Data (Between-Analytical Run Precision and Accuracy) for SPMA .....	24
Table 4	Back-calculated Calibration Standard Concentrations for SBMA .....	26
Table 5	Back-calculated Calibration Standard Concentrations for SPMA .....	27
Table 6	Standard Curve Parameters for SBMA .....	28
Table 7	Standard Curve Parameters for SPMA .....	29
Table 8	Study Sample Concentrations for SBMA .....	30
Table 9	Study Sample Concentrations for SPMA .....	70
Table 10	Summary of Reassay for Analytical Reasons for SBMA .....	110
Table 11	Summary of Reassay for Analytical Reasons for SPMA .....	114
Table 12	Summary of Reassay for Non-analytical Reasons (VRC, Value Requiring Confirmation) for SBMA .....	118
Table 13	Summary of Reassay for Non-analytical Reasons (VRC, Value Requiring Confirmation) for SPMA .....	119
Table 14	Incurred Sample Reproducibility Assessment for SBMA .....	120
Table 15	Incurred Sample Reproducibility Assessment for SPMA .....	124

**FIGURES**

Figure 1	Calibration Curve for SBMA in human urine, Watson Run ID 1 .....	128
Figure 2	Calibration Curve for SPMA in human urine, Watson Run ID 1 .....	129

**ATTACHMENTS**

Attachment 1	General List of Abbreviations used at Celerion .....	130
Attachment 2	Temperature Definitions at Celerion .....	133
Attachment 3	Procedure for VCR and SSR Reassays and Reporting of Reassay Results .....	134
Attachment 4	General List of Calculation Formulae .....	135
Attachment 5	Reassay Descriptions .....	136
Attachment 6	Statement of GLP Compliance (Swissmedic) .....	137
Attachment 7	Certificates of Analysis .....	138



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

---

Attachment 8	Summary of the Method Validation Data .....	142
Attachment 9	Chromatograms .....	148

<b>Total number of pages</b>	<b>242</b>
------------------------------	------------

SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

## 1. INTRODUCTION

The purpose of this bioanalytical study (hereafter referred to as study) was to determine the concentration of SBMA and SPMA in human urine samples using a validated LC-MS/MS method [4]. The study samples were collected in the clinical study ZRHR-REXC-03-EU entitled "A randomized, controlled, open-label, 3-arm parallel group, single-center study to demonstrate reductions in exposure to selected smoke constituents in smoking, healthy subjects switching to the Tobacco Heating System 2.2 (THS 2.2) or smoking abstinence, compared to continuing to use conventional cigarettes, for 5 days in confinement" [5]. Sample analysis was conducted between 23-Sep-2013 (experimental start) to 18-Nov-2013 (experimental end).

This report provides the results and supporting documentation from the analysis of study samples and includes an evaluation of assay performance.

## 2. EXPERIMENTAL

### 2.1. Test Item

The test item (product name) is defined the clinical study protocol [5].

### 2.2. Reference Items and Internal Standards

All calculations were based on the purity provided.

	Analyte	Internal Standard (IS)
ID	S-BMA DCHA salt	S-BMA- <sup>15</sup> N- <sup>13</sup> C <sub>3</sub> DCHA salt
Source	(b) (4)	(b) (4)
Lot No.	AC0102296	AC0102275
Purity/Potency (%)	Chromatographic purity/Potency 99.7%	Chromatographic purity 99.8%
Retest date	24 Sep 2014	14 Aug 2014
Storage conditions	5 C	5 C

	Analyte	Internal Standard (IS)
ID	S-PMA DCHA salt	S-PMA- <sup>15</sup> N- <sup>13</sup> C <sub>3</sub> DCHA Salt ( <sup>13</sup> C <sub>3</sub> <sup>15</sup> N-SPMA)
Source	(b) (4)	(b) (4)
Lot No.	AC0102293	AC0102302
Purity/Potency (%)	Chromatographic purity 100%	Chromatographic purity 99.9%
Retest date	11 Sep 2014	20 Sep 2014
Storage conditions	5 C	5 C

The certificate of analysis for the reference items and internal standards are presented in [Attachment 7](#). Reference items and internal standards are retained under the conditions that are specified until they become expired.



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

### 2.3. Blank Matrix

Human urine was collected from volunteers in-house. Human urine, free of significant interference at the retention times and mass transitions of the internal standards was used to prepare quality control (QC) samples. Human urine stored at -20°C. UriSub<sup>®</sup>, a synthetic urine, was used to prepare calibration standards and quality control samples (QC A), as control matrix for blanks and STD 0 and for sample dilution (if required). UriSub<sup>®</sup> was purchased from (b) (4), stored at room temperature and was used within the given expiry date.

### 2.4. Test System

#### 2.4.1. Procedure and Instruments

Procedure and Instrumentation	
Extraction Method	Solid-phase extraction
Chromatography system	Perkin Elmer Series 200 Micropump HPLC*
MS/MS system	Applied Biosystems/MDS SCIEX API 4000 mass spectrometer*
Regression Type	Weighted linear regression curve ( $1/\text{concentration}^2$ ) for both analytes
Quantitation Method	Area ratio
Assay Volume	0.500 mL

\* = Qualified systems

#### 2.4.2. Computer Application Software

Software	
LC-MS/MS software	Applied Biosystems Analyst <sup>®</sup> 1.5.2*
LIMS	Thermo Electron Corporation Watson <sup>™</sup> 7.3 Bioanalytical LIMS 7.3*
Laboratory Documentation System	Terrington Data Management Labnotes <sup>®</sup> 5.18, 1.20 and 1.21 (Web application)*
Office applications	Microsoft <sup>®</sup> Office 2007 and 2010 Package

\* = Validated systems

### 2.5. Calibration Standards, Quality Control Samples and Dilution Quality Control Samples

Non-zero calibration standards at the concentration levels of 0.100, 0.200, 0.500, 1.00, 2.00, 4.00, 8.00, 16.0, 21.0 and 25.0 ng/mL of SBMA and 0.0250, 0.0500, 0.125, 0.250, 0.500, 1.00, 2.00, 4.00, 5.25 and 6.25 ng/mL of SPMA were prepared in bulk on 15-Aug-2013 (as part of study AA98876-01 [6]), on 16, 18 and on 22-Oct-2013 aliquoted and stored at -20°C and were used during the validated stability period [7].

Quality control (QC) samples at the concentration levels of 0.282 ng/mL, 0.705 ng/mL, 1.51 ng/mL, 5.21 ng/mL and 18.2 ng/mL of SBMA and of 0.0690 ng/mL, 0.469 ng/mL, 1.19 ng/mL and 4.44 ng/mL of SPMA and dilution quality control (DQC) samples at the concentration levels of 140 ng/mL of SBMA and of 35.0 ng/mL of SPMA were prepared by



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

spiking human urine with the desired volumes of the appropriate WS QC containing SBMA and SPMA. The low level QC (QC A) sample of SBMA was prepared by diluting blank human urine 2.5-times with Urisub<sup>®</sup>. The actual (D)QC concentration was calculated by adding the basal concentration to the spiked concentrations. (D)QC samples were prepared in bulk on 17, 20-Sep-2013 (as part of study AA98876-01 [6]), on 03 and on 16-Oct-2013, aliquoted and stored at -20°C and were used during the validated stability period [4]. QC samples were stored under identical conditions as the clinical samples.

Standard calibrators and quality control samples were prepared from separate stock solutions.

## 2.6. Study Samples

### 2.6.1. Sample Source and Date of Receipt

Study samples were collected between 11-Jul-2013 and 18-Sep-2013 and were received frozen on dry ice between 16-Aug-2013 and 22-Nov-2013 from Celerion Lincoln, Nebraska, USA.

### 2.6.2. Sample Identification

Study samples were identified based on the Watson custom ID.

### 2.6.3. Sample Storage and Stability

Study samples were stored from sample arrival to the end of sample analysis at a nominal temperature of -20°C. Samples were stored from sample collection to sample analysis for a duration of 130 days.

Long-term stability of 130 days in urine will be evaluated in Celerion study ZZ42381 [7].

Study samples were analyzed without exceeding short-term, freeze-thaw, or post-preparative stability. The following evaluations have been conducted:

Stability Summary [4], [7]	SBMA and SPMA
Long-term stability	at least 76 days in polypropylene tubes at -20 °C in human urine at least 116 days in polypropylene tubes at -20 °C in Urisub <sup>®</sup> [7]
Short-term stability	21 hours in UV-shielded polypropylene tubes at 5 °C protected from light 21 hours in polypropylene tubes at 5 °C protected from light
Freeze-thaw stability	5 hours in polypropylene tubes at ambient temperature under yellow light 4 cycles at -20 °C to 5 °C in UV-shielded polypropylene tubes protected from light 4 cycles at -20 °C to ambient temperature in polypropylene tubes under yellow light
Post-preparative stability	181 hours in a polypropylene 96 well plate at 5 °C
Processed sample integrity	135 hours in a polypropylene 96 well plate at 5 °C
Sample shipping stability	9 days in polypropylene tubes at -80 °C



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

#### 2.6.4. Sample Summary

The Sponsor's protocol specifies 160 subjects, 7 sampling times for 24-hour urine collections [5]. During the study nine subjects (0211, 0242, 0245, 0247, 0269, 0288, 0299, 0309 and 0312) discontinued during the clinical phase. No samples from these subjects were analyzed. Subject 0085 resigned from the study. Four samples were analyzed and reported for this subject.

	No. of Samples
Number of expected study samples/received in Zurich	1120 (primary samples) and 1120 (back-up samples) / 1117 (primary samples) and 1117 (back-up samples)
Specified "for analysis" samples in protocol/received	1120 primary samples / 1117 primary samples
Time points lost due to subject discontinuance	3
Back-up samples received	1117
Total number of study samples analyzed	1117

Following analysis, the study samples were kept frozen at -20°C and will be destroyed after the completion of the clinical study report and sponsor notification.

### 3. SAMPLE ANALYSIS

#### 3.1. Analytical Method

The determination of S-Benzyl Mercapturic Acid (SBMA) and S-Phenyl Mercapturic Acid (SPMA) in human urine samples was carried out over a calibration range of 0.100 ng/mL to 25.0 ng/mL (SBMA), and 0.0250 ng/mL to 6.25 pg/mL (SPMA). The method and its validation are described in the method validation AA98877-02 [4] performed at Celerion Lincoln. The cross-site validation AA98876-01 [6] was performed at Celerion Switzerland, and the method is described in the method standard operating procedure (SOP) SM1-382B [8]. Method validation was conducted in accordance with what was performed in accordance with Celerion standard procedures, which follow the FDA guidance for the validation of bioanalytical methods [9] and the EMA guideline on bioanalytical method validation [3].

Human urine samples spiked with IS were extracted using a solid-phase extraction procedure. Sample extracts were injected onto an LC-MS/MS system with negative ions monitored in multiple-reaction monitoring mode.

#### 3.2. Acceptance Criteria

##### 3.2.1. Analytical Run Acceptance Criteria

An analytical run was acceptable if all of the following criteria were met:

- at least 75% of the non-zero calibration standards were within  $\pm 15.0\%$  ( $\pm 20.0\%$  for the lower limit of quantification (LLOQ) calibration standard) of their nominal concentration,
- at least two-thirds of the QC samples and at least 50% at each concentration level were within  $\pm 15.0\%$  of their nominal concentration,



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

- at least 50% of the standard zero samples are free of interference at the retention time of the analyte(s) of interest,
- at least 50% of the blank samples are free of interference both at the retention time of the analyte(s) of interest and at the retention time of the IS,
- at least two-thirds of all blank and standard zero samples fulfilled the above described interference criteria.

Interference at the retention time of the analyte of interest is defined as a response greater than 20% of the mean analyte response of the LLOQ calibration standard(s).

Interference at the retention time of the IS is defined as a response greater than 5% of the mean IS response of the LLOQ calibration standard(s).

Individual data of QC samples (including DQCs) that were out of their acceptance criteria are flagged appropriately in the study file and in the bioanalytical report. QCs will be excluded from statistics only for analytical reasons (see [Attachment 5](#)).

### 3.2.2. Acceptance Criteria for Sample Dilution

The accuracy of study sample dilution is verified by the DQC samples. At least 50% of the DQC samples must be within  $\pm 15.0\%$  of their nominal concentration for the respective dilution factor to be accepted.

### 3.2.3. Acceptance Criteria for ISR

The % difference was calculated for each pair of original and repeat analyses as follows:

$$\% \text{difference} = 100 * \frac{|\text{repeat value} - \text{original value}|}{(\text{repeat value} + \text{original value}) / 2}$$

If the %difference was less than or equal to 20%, a pair of results was considered a passing match. Any pair with a %difference of more than 67% (indicating that the repeat value is either less than half or more than twice the original concentration) was considered an event and was investigated. The analytical method will be considered reproducible if at least 67% of the result pairs match. If less than 67% of the pairs match, an event investigation was initiated.

## 4. RESULTS

Due to rounding procedures, recalculations using the results presented in this report may differ slightly from the reported statistics.

A summary of analytical runs performed is presented in [Table 1](#).

### 4.1. Quality Control and Dilution Quality Control Sample Performance

Between-analytical run precision and accuracy results for QC samples prepared at 0.282, 0.705, 1.51, 5.21 and 18.2 ng/mL are summarized in [Table 2](#) for SBMA and QC samples prepared at 0.0690, 0.469, 1.19 and 4.44 ng/mL are summarized in [Table 3](#) for SPMA. The accuracy of sample dilution was verified by the performance of dilution QC samples. Results for dilution QC samples prepared at 140 ng/mL for SBMA are summarized in [Table 2](#) and dilution QC samples prepared at 35.0 ng/mL for SPMA are summarized in [Table 3](#).





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

#### 4.2. Calibration Standard Performance

Back-calculated calibration curve standard concentrations are provided in [Table 4](#) and [Table 5](#) for SBMA and SPMA, respectively.

#### 4.3. Standard Curve Parameters

Standard curve parameters from 21 successful analytical runs are provided in [Table 6](#) and [Table 7](#) for SBMA and SPMA, respectively. Representative calibration curves are illustrated in [Figure 1](#) and [Figure 2](#) for SBMA and SPMA, respectively. The standard zero samples (blank samples with IS added) were not used to plot the calibration curve.

#### 4.4. Study Sample Concentrations

Study sample concentrations are provided in [Table 8](#) and [Table 9](#) for SBMA and SPMA, respectively. The column “Split” refers to the “for analysis” or “back-up” sample collected.

Study samples, if any, with no significant peak at the mass transition and retention time of SPMA and SBMA, respectively, or with peak area ratios below that of the LLOQ standard, are reported as being below the limit of quantitation (BLQ).

#### 4.5. Reassays

##### 4.5.1. Reassays for Analytical Reasons

Study samples needing re-analysis according to [Attachment 5](#) for SBMA and SPMA in human urine are identified in [Table 10](#) and [Table 11](#), respectively. Reassay descriptions are provided in [Attachment 5](#).

##### 4.5.2. Reassays for Non-analytical Reasons (Value requiring confirmation, VRC)

The results of two samples (subject: 0008, custom ID: 05113200000006 and subject: 0013, custom ID: 05113200000445) required confirmation, as original and ISR results showed discrepancies. As part of the event resolution dated 04-Oct-2013 ([section 7.1](#)), these two samples were re-analyzed in triplicate in run AA99602-01\_P15. The original results could not be confirmed and the mean result of the triplicate measurements is reported, according to the decision tree in the study plan bioanalysis [10]. Data are shown in [Table 12](#) and [Table 13](#). The procedure for VRC reassays and reporting of reassay results is provided in [Attachment 3](#).

##### 4.5.3. Sponsor Selected Reassays

There were no Sponsor selected reassays.

##### 4.5.4. Incurred Sample Reproducibility

The method for the determination of SBMA and SPMA in human urine was considered reproducible, 83% out of 106 repeat analyses for SBMA and 83% out of 106 repeat analyses for SPMA met acceptance criteria as defined in [section 3.2.3](#). Results are presented in [Table 14](#) and [Table 15](#). Two original and ISR results showed discrepancies and were measured in triplicate as part of the event resolution dated 04-Oct-2013 ([section 7.1](#)).



---

SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

---

## 5. CHROMATOGRAMS

Representative chromatograms from analytical run AA99602-01\_P1 are provided in [Attachment 9](#).

## 6. DEVIATIONS

There were no deviations during the conduct of the study.

## 7. EVENTS

### 7.1. Event Resolution dated 04-Oct-2013

One part of the ISR assessment was performed in run AA99602-01\_P11, where a total of 56 ISR samples were analyzed. More than 67% of the pairs matched for both analytes, indicating that the overall reproducibility of the method passed for this first part of ISR assessment. However, one pair (the sample of subject: 0013, time: day 3, custom ID: 05113200000445) has a % difference of >67% for both analytes. The original value could not be confirmed by triplicate measurement of the sample in run AA99602-01\_P15. According to the decision tree in the study plan bioanalysis [10], the mean result of the triplicate measurements is reported. Moreover, one sample (subject: 0008, time: day 5, custom ID: 05113200000006) showed a difference of >55% for SBMA, and a difference of >-55% for SPMA. The fact that the approx. double concentration for SBMA, but the approx. half concentration for SPMA was found in this sample was investigated as well with triplicate measurements. The original value could not be confirmed by triplicate measurement of the sample in run AA99602-01\_P15. According to the decision tree in the study plan bioanalysis [10], the mean result of the triplicate measurements is reported. Data are shown in [Table 12](#) and [Table 13](#) for SBMA and SPMA, respectively.

No systematic error or obvious reason was determined.

## 8. ANALYTICAL NOTES

### 8.1. Schedule nominal time points

Urine was collected over 24 hours, the following relation exists:

Start day nominal	Nominal time, Nominal Day
-1	0
0	1
1	2
2	3
3	4
4	5
5	6





---

SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

---

## 9. ARCHIVES

At a minimum the following records will be retained:

- Study Plan Bioanalysis (and all amendments)
- Raw data
- Study related correspondence
- Bioanalytical report (and all amendments, if applicable)

These documents will be kept in the archives of Celerion for at least ten (10) years, taken from the date of Bioanalytical Principal Investigator's signature on the final bioanalytical report. After this time the Sponsor will be contacted to decide if the records should be retained for a further defined time at Celerion, returned to the Sponsor or disposed of.

## 10. CONCLUSION

In this bioanalytical study the concentration of SBMA and SPMA were determined in a total of 1117 human urine samples collected in the Philip Morris International Research and Development clinical study ZRHR-REXC-03-EU by validated LC-MS/MS methods [4] and [6]. The overall performance of the LC-MS/MS methods met acceptance criteria and the results obtained were of the required integrity and quality. These data can be used for further interpretation.

## 11. REFERENCES

- [1] OECD Principles of Good Laboratory Practice (as revised in 1997), ENV/MC/CHEM(98)17, OECD, Paris, 1998. (No.1 in OECD Series on Good Laboratory Practice and Compliance Monitoring).
- [2] EMA. GCP Inspectors Working Group. Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples. EMA/INS/GCP/532137/2010 of 28 February 2012.
- [3] EMA. Committee for Medicinal Products for Human Use. Guideline on bioanalytical method validation. EMEA/CHMP/EWP/192217/2009 of 21 July 2011.
- [4] Validation of an LC-MS/MS Method for the Determination of S-Benzyl Mercapturic Acid (SBMA) and S-Phenyl Mercapturic Acid (SPMA) in human urine, Celerion Lincoln, Study AA98877-02, Validation Final Report, date of issue 08-Jul-2013.
- [5] A randomized, controlled, open-label, 3-arm parallel group, single-center study to demonstrate reductions in exposure to selected smoke constituents in smoking, healthy subjects switching to the Tobacco Heating System 2.2 (THS 2.2) or smoking abstinence, compared to continuing to use conventional cigarettes, for 5 days in confinement, Clinical Study Protocol ZRHR-REXC-03-EU, Version number: Final, Revision date: 25 April 2013.
- [6] Cross site validation of a LC-MS/MS method for the determination of S-Benzyl Mercapturic Acid (SBMA) and S-Phenyl Mercapturic Acid (SPMA) in human urine, Method Validation Report VAA98876-01, effective date 23-Oct-2013.



---

SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

---

- [7] Long-term stability and partial validation for the determination of S Benzyl Mercapturic Acid (SBMA) and S Phenyl Mercapturic Acid (SPMA) in human urine using liquid handling robots. Celerion Switzerland AG, Study ZZ42381.
- [8] Determination of S-Benzyl Mercapturic Acid (SBMA) and S-Phenyl Mercapturic Acid (SPMA) in human urine, Celerion Method SOP SM1-382B, Celerion Switzerland AG, effective date 06-Sep-2013.
- [9] Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), May 2001.
- [10] Determination of S-Benzyl Mercapturic Acid (SBMA) and S-Phenyl Mercapturic Acid (SPMA) in human urine samples from "A randomized, controlled, open-label, 3-arm parallel group, single-center study to demonstrate reductions in exposure to selected smoke constituents in smoking, healthy subjects switching to the Tobacco Heating System 2.2 (THS 2.2) or smoking abstinence, compared to continuing to use conventional cigarettes, for 5 days in confinement" by LC-MS/MS. Celerion Switzerland AG, Study Plan Bioanalysis PAA99602-01, effective date 12-Aug-2013, and amendment no.1 to the study plan, effective date 17-Sep-2013 and amendment no. 2 to the study plan, effective date 23-Oct-2013.



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

## RESULT TABLES

Table 1 Summary of Analytical Runs Performed

Watson Run ID	Run ID	Regression Status (SBMA/SPMA)	Extraction Date	Assay Date	Description	Comment
1	AA99602-01_P1	Accepted/Accepted	24-Sep-2013	24-Sep-2013	Subj 0001, 0004, 0008, 0010, 0011, 0013, 0014, 0016, 0017, 0020	OK
2	AA99602-01_P2	Accepted/Accepted	24-Sep-2013	24-Sep-2013	Subj 0021, 0023, 0025, 0028, 0029, 0030, 0031, 0034, 0035, 0037	OK
3	AA99602-01_P3	Accepted/Accepted	25-Sep-2013	26-Sep-2013	Subj 0038, 0039, 0042, 0044, 0049, 0051, 0052, 0053, 0055, 0060	OK
4	AA99602-01_P4	N/AP / N/AP	26-Sep-2013	N/AP	Subj 0063, 0064, 0066, 0067, 0069, 0071, 0074, 0076, 0080, 0112	not injected, due to ISP *
5	AA99602-01_P5	Accepted/Accepted	27-Sep-2013	27-Sep-2013	Subj 0083, 0086, 0087, 0088, 0090, 0104, 0105, 0106, 0107, 0110	OK
6	AA99602-01_P6	Accepted/Accepted	27-Sep-2013	27-Sep-2013	Subj 0062, 0093, 0114, 0121, 0122, 0123, 0126, 0127, 0128, 0129	OK
7	AA99602-01_P7	Accepted/Accepted	27-Sep-2013	28-Sep-2013	Subj 0063, 0064, 0066, 0067, 0069, 0071, 0074, 0076, 0080, 0112	OK
8	AA99602-01_P8	Accepted/Accepted	30-Sep-2013	30-Sep-2013	Subj 0130, 0133, 0134, 0136, 0137, 0139, 0140, 0145, 0147, 0148	OK
9	AA99602-01_P9	Accepted/Accepted	01-Oct-2013	01-Oct-2013	Subj 0149, 0150, 0152, 0153, 0155, 0156, 0160, 0162, 0167, 0169	OK
10	AA99602-01_P10	Accepted/Accepted	02-Oct-2013	02-Oct-2013	Subj 0117, 0118, 0170, 0177, 0183, 0185, 0187, 0190, 0191, 0192	OK
11	AA99602-01_P11	Accepted/Accepted	03-Oct-2013	03-Oct-2013	ISR, repeats	OK
12	AA99602-01_E12	N/AP/ N/AP	14-Oct-2013	14-Oct-2013	SL Check #	No regression
13	AA99602-01_E13	N/AP/ N/AP	15-Oct-2013	15-Oct-2013	SL Check #	No regression
14	AA99602-01_E14	Accepted/Accepted	17-Oct-2013	17-Oct-2013	Spiking check ##	OK





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Watson Run ID	Run ID	Regression Status (SBMA/SPMA)	Extraction Date	Assay Date	Description	Comment
15	AA99602-01_P15	Accepted/Accepted	18-Oct-2013	18-Oct-2013	VRCs, repeats	OK
16	AA99602-01_E16	Accepted/Accepted	18-Oct-2013	18-Oct-2013	Spiking check ##	OK
17	AA99602-01_E17	Accepted/Accepted	23-Oct-2013	23-Oct-2013	Spiking check ##	OK
18	AA99602-01_P18	Accepted/Accepted	28-Oct-2013	28-Oct-2013	Subj 0181, 0189, 0193, 0195-0198, 0200, 0202 and 0203	OK
19	AA99602-01_P19	N/AP /N/AP	31-Oct-2013	N/AP	Subj 0204, 0206, 0210, 0216, 0218, 0220, 0224, 0228 to 0230	not injected, due to ISP **
20	AA99602-01_P20	Accepted/Accepted	04-Nov-2013	04-Nov-2013	Subj 0232, 0234, 0240, 0241, 0244, 0249, 0251, 0252, 0255, 0256	OK
21	AA99602-01_P21	Accepted/Accepted	04-Nov-2013	04-Nov-2013	Subj 0262, 0264, 0265, 0266, 0015, 0057, 0072, 0085 + reassay 0053	OK
22	AA99602-01_P22	Accepted/Accepted	01-Nov-2013	01-Nov-2013	Subj 0204, 0206, 0210, 0216, 0218, 0220, 0224, 0228-0230	OK
23	AA99602-01_P23	Accepted/Accepted	04-Nov-2013	04-Nov-2013	Subj 0272, 0273, 0276 - 0279, 0281 to 0283 and 0285	OK
24	AA99602-01_P24	Accepted/Accepted	05-Nov-2013	05-Nov-2013	Subj 0287, 0289, 0291, 0292, 0296, 0298, 0300, 0301, 0306, 0307	OK
25	AA99602-01_P25	Accepted/Accepted	05-Nov-2013	05-Nov-2013	Subj 0308, 0313, 0315-0318, 0320-0322 and 0325	OK
26	AA99602-01_P26	Accepted/Accepted	06-Nov-2013	06-Nov-2013	Subj 0022 and 0328	OK
27	AA99602-01_P27	Accepted/Accepted	07-Nov-2013	07-Nov-2013	ISR 50 samples - 2AAR samples for SPMA	OK
28	AA99602-01_P28	Accepted/Accepted	18-Nov-2013	18-Nov-2013	Subject: 0022 and 1 ISR for SPMA	OK

"Regression Status" reflects the status of the run with respect to run acceptance criteria

\*: Methanol was used instead of hydrochloric acid solution The whole plate (run) was considered ISP and was not further evaluated Samples were reassayed

\*\*: SPE plate used not according to method SOP SM1-382B Samples were not injected No data generated The run was considered ISP Samples were reassayed

#: Testing of stock solutions

##: Testing of STDs and QC samples

Analytical runs (Watson Run IDs 12-14, 16 and 17) to support study set up or tests that were required during the course of the study did not include any study samples The content of these runs is described in the raw data



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Table 2 Quality Control and Dilution Quality Control Sample Data (Between-Analytical Run Precision and Accuracy) for SBMA

Assay Date	Watson Run ID	QC A 0.282 ng/mL	QC BL 0.705 ng/mL	QC B 1.51 ng/mL	QC E 5.21 ng/mL	QC C 18.2 ng/mL	QC D 140 ng/mL
24-Sep-2013	1	0.283	0.688	1.43	4.72	16.4	N/AP
		0.286	0.706	1.38	4.75	16.7	N/AP
24-Sep-2013	2	0.290	0.706	1.46	4.88	16.8	N/AP
		0.288	0.728	1.45	4.73	15.6	N/AP
26-Sep-2013	3	0.277	0.686	1.40	4.94	16.3	N/AP
		0.286	0.694	1.40	4.94	16.6	N/AP
27-Sep-2013	5	0.295	0.719	1.44	4.83	17.0	N/AP
		0.301	0.713	1.47	4.86	16.9	N/AP
27-Sep-2013	6	0.303	0.742	1.49	5.04	17.6	N/AP
		0.308	0.751	1.47	5.07	17.1	N/AP
28-Sep-2013	7	0.298	0.754	1.50	4.92	16.9	N/AP
		0.298	0.725	1.48	4.89	17.1	N/AP
30-Sep-2013	8	0.288	0.707	1.44	4.74	16.7	N/AP
		0.268	0.717	1.42	4.77	16.3	N/AP
01-Oct-2013	9	0.302	0.725	1.41	4.88	-0.289	N/AP
		~16.4	0.707	1.44	4.88	16.4	N/AP
02-Oct-2013	10	0.282	0.700	1.46	4.72	16.5	N/AP
		0.283	0.706	1.43	4.82	16.6	N/AP
03-Oct-2013	11	0.276	0.697	1.43	4.93	16.6	N/AP
		-0.357	0.774	1.42	4.70	16.7	N/AP
18-Oct-2013	15	0.295	0.753	1.61	5.22	18.7	146
		0.292	0.720	1.52	5.09	18.6	144
		N/AP	N/AP	N/AP	N/AP	N/AP	141
28-Oct-2013	18	0.275	0.693	1.40	4.85	16.9	N/AP
		0.283	0.686	1.41	4.78	17.5	N/AP
01-Nov-2013	22	0.279	0.658	1.44	5.05	18.0	N/AP
		0.273	0.689	1.48	5.02	18.1	N/AP
04-Nov-2013	20	0.282	0.665	1.39	5.05	17.6	N/AP
		0.276	0.680	1.45	4.94	17.7	N/AP
04-Nov-2013	21	0.280	0.666	1.42	4.87	17.8	N/AP
		0.264	0.679	1.40	4.86	17.1	N/AP
04-Nov-2013	23	0.283	0.677	1.45	4.96	17.4	N/AP
		0.291	0.686	1.39	4.80	17.1	N/AP
05-Nov-2013	24	0.283	0.673	1.46	5.16	18.0	N/AP
		0.288	0.714	1.54	5.15	18.4	N/AP
05-Nov-2013	25	0.271	0.685	1.42	5.03	17.7	N/AP
		0.272	0.690	1.45	5.01	17.7	N/AP
06-Nov-2013	26	0.272	0.684	1.41	5.01	17.7	N/AP
		0.289	0.710	1.45	4.91	17.2	N/AP
07-Nov-2013	27	0.270	0.656	1.38	4.84	17.1	124
		0.260	0.661	1.40	4.76	16.1	128





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Assay Date	Watson Run ID	QC A 0.282 ng/mL	QC BL 0.705 ng/mL	QC B 1.51 ng/mL	QC E 5.21 ng/mL	QC C 18.2 ng/mL	QC D 140 ng/mL
18-Nov-2013	28	0.272	0.680	1.40	4.91	16.8	124
		0.270	0.688	1.39	4.73	17.1	131
		N/AP	N/AP	N/AP	N/AP	N/AP	129
Mean		0.669	0.701	1.44	4.91	16.7	133
S.D.		2.490	0.028	0.05	0.13	2.7	9
%CV		372.2*	3.9	3.2	2.7	16.1**	6.7
%Theoretical		237.2*	99.4	95.4	94.2	91.8**	95.0
n		42	42	42	42	42	8

~bias > 15.0%, included in statistics.

In run 9 the positions of QC A and QC C appear to have been swapped during pipetting. Back-calculated concentrations would have been acceptable for these QCs if positions were swapped. \*Precision and accuracy were 5.6% and 101.1% excluding the single value of 16.4 within run 9. \*\* Precision and accuracy were 4.0% and 92.2% excluding the single value of 0.289 within run 9.



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Table 3 Quality Control and Dilution Quality Control Sample Data (Between-Analytical Run Precision and Accuracy) for SPMA

Assay Date	Watson Run ID	QC BL 0.0690 ng/mL	QC B 0.469 ng/mL	QC E 1.19 ng/mL	QC C 4.44 ng/mL	QC D 35.0 ng/mL
24-Sep-2013	1	0.0592	0.498	1.28	4.82	N/AP
		0.0656	0.477	1.30	5.02	N/AP
24-Sep-2013	2	0.0687	0.510	1.31	~5.19	N/AP
		0.0666	0.489	1.27	4.67	N/AP
26-Sep-2013	3	0.0668	0.498	~1.38	4.89	N/AP
		0.0694	0.490	1.32	5.02	N/AP
27-Sep-2013	5	0.0692	0.496	1.32	4.89	N/AP
		0.0714	0.506	1.35	4.94	N/AP
27-Sep-2013	6	0.0621	0.477	1.32	~5.18	N/AP
		0.0643	0.486	1.32	4.95	N/AP
28-Sep-2013	7	0.0715	0.487	1.27	4.83	N/AP
		0.0667	0.511	1.29	4.88	N/AP
30-Sep-2013	8	0.0638	0.490	1.29	4.85	N/AP
		0.0690	0.477	1.27	4.80	N/AP
01-Oct-2013	9	0.0645	0.491	1.33	~0.0283	N/AP
		0.0652	0.499	1.33	4.90	N/AP
02-Oct-2013	10	0.0653	0.501	1.24	4.96	N/AP
		0.0646	0.506	1.28	4.95	N/AP
03-Oct-2013	11	0.0628	0.463	1.31	4.84	N/AP
		0.0671	0.489	1.29	4.91	N/AP
18-Oct-2013	15	0.0697	0.485	1.15	4.62	36.4
		0.0675	0.458	1.15	4.55	35.0
		N/AP	N/AP	N/AP	N/AP	34.4
28-Oct-2013	18	~0.0561	0.426	1.06	4.18	N/AP
		0.0597	0.427	1.08	4.18	N/AP
01-Nov-2013	22	~0.0563	0.430	1.09	4.21	N/AP
		0.0611	0.438	1.12	4.29	N/AP
04-Nov-2013	20	0.0604	0.446	1.08	4.15	N/AP
		0.0609	0.428	1.10	4.22	N/AP
04-Nov-2013	21	0.0642	0.428	1.09	4.19	N/AP
		~0.0571	0.440	1.07	4.16	N/AP
04-Nov-2013	23	0.0611	0.453	1.08	4.19	N/AP
		0.0605	0.433	1.03	4.18	N/AP
05-Nov-2013	24	0.0612	0.437	1.10	4.10	N/AP
		~0.0586	0.467	1.12	4.19	N/AP
05-Nov-2013	25	0.0621	0.439	1.12	4.17	N/AP
		~0.0581	0.432	1.04	4.01	N/AP
06-Nov-2013	26	0.0592	0.434	1.09	4.09	N/AP
		0.0591	0.430	1.11	4.17	N/AP
07-Nov-2013	27	0.0634	0.422	1.09	4.07	30.0
		~0.0565	0.411	1.06	3.96	30.7



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Assay Date	Watson Run ID	QC BL 0.0690 ng/mL	QC B 0.469 ng/mL	QC E 1.19 ng/mL	QC C 4.44 ng/mL	QC D 35.0 ng/mL
18-Nov-2013	28	0.0650	0.425	1.09	4.05	31.3
		0.0638	0.440	1.07	4.27	32.2
		N/AP	N/AP	N/AP	N/AP	31.3
Mean		0.0635	0.464	1.19	4.42	32.7
S.D.		0.0042	0.031	0.11	0.80	2.3
%CV		6.7	6.7	9.4	18.0*	7.1
%Theoretical		92.0	98.9	100.0	99.5*	93.4
n		42	42	42	42	8

~bias > 15.0%, included in statistics.

Since SBMA and SPMA were analyzed in the same run, in run 9 the positions of QC A (SBMA) and QC C (SPMA) appear to have been swapped during pipetting. Back-calculated concentrations would have been acceptable for these QCs if positions were swapped. \* The precision and accuracy was 8.7% and 102.0%, respectively excluding the single value of 0.0283 within run 9.



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Table 4 Back-calculated Calibration Standard Concentrations for SBMA

Assay Date	Watson Run ID	STD B 0.100 ng/mL	STD C 0.200 ng/mL	STD D 0.500 ng/mL	STD E 1.00 ng/mL	STD F 2.00 ng/mL	STD G 4.00 ng/mL	STD H 8.00 ng/mL	STD I 16.0 ng/mL	STD J 21.0 ng/mL	STD K 25.0 ng/mL
24-Sep-2013	1	0.0984	0.202	0.508	1.06	2.03	4.28	8.10	14.8	19.8	24.0
24-Sep-2013	2	0.0982	0.203	0.513	1.04	2.01	4.13	8.10	15.1	19.9	24.9
26-Sep-2013	3	0.0976	0.203	0.532	1.03	2.06	4.08	7.89	15.2	20.1	24.2
27-Sep-2013	5	0.0972	0.206	0.524	1.02	2.03	4.15	8.02	15.4	19.9	24.0
27-Sep-2013	6	0.0986	0.202	0.511	1.03	2.06	4.15	7.90	15.6	20.3	23.9
28-Sep-2013	7	0.0991	0.200	0.508	1.04	2.04	4.24	7.90	15.3	20.3	24.1
30-Sep-2013	8	0.0981	0.201	0.523	1.05	2.06	4.10	8.00	15.3	19.8	24.1
01-Oct-2013	9	0.0968	0.209	0.515	1.03	2.04	4.16	7.93	15.4	20.2	24.0
02-Oct-2013	10	0.0966	0.210	0.514	1.03	2.01	4.12	8.18	15.3	20.0	24.0
03-Oct-2013	11	0.0994	0.199	0.509	1.03	1.97	4.30	7.99	15.2	20.4	24.5
18-Oct-2013	15	0.0987	0.203	0.505	1.03	1.99	4.15	8.20	15.7	20.1	24.1
28-Oct-2013	18	0.0998	0.196	0.526	1.01	1.97	4.09	7.85	16.1	20.3	24.9
01-Nov-2013	22	0.101	0.191	0.515	1.03	1.99	4.15	8.03	16.3	19.9	24.3
04-Nov-2013	20	0.101	0.195	0.506	1.01	1.97	4.15	7.88	16.3	20.3	24.9
04-Nov-2013	21	0.101	0.196	0.511	0.999	1.98	4.18	7.99	16.1	20.4	24.5
04-Nov-2013	23	0.0993	0.202	0.504	1.01	1.98	4.18	7.79	16.5	20.3	24.4
05-Nov-2013	24	0.102	0.192	0.497	1.02	1.98	4.14	8.13	16.3	20.1	24.8
05-Nov-2013	25	0.0994	0.202	0.506	0.988	2.04	4.09	7.97	16.2	20.3	24.5
06-Nov-2013	26	0.101	0.195	0.516	0.989	1.99	4.03	8.03	16.5	20.4	24.6
07-Nov-2013	27	0.0990	0.204	0.504	0.995	1.95	4.08	8.07	16.3	20.4	24.8
18-Nov-2013	28	0.0992	0.202	0.510	0.992	2.00	4.16	7.89	16.3	20.3	24.4
Mean		0.0991	0.201	0.512	1.02	2.01	4.15	7.99	15.8	20.2	24.4
SD		0.0015	0.005	0.008	0.02	0.03	0.07	0.11	0.5	0.2	0.3
%CV		1.5	2.5	1.6	2.0	1.7	1.6	1.4	3.4	1.0	1.4
%Bias		-0.9	0.5	2.4	2.0	0.5	3.8	-0.1	-1.3	-3.8	-2.4
n		21	21	21	21	21	21	21	21	21	21





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Table 5 Back-calculated Calibration Standard Concentrations for SPMA

Assay Date	Watson Run ID	STD B 0.0250 ng/mL	STD C 0.0500 ng/mL	STD D 0.125 ng/mL	STD E 0.250 ng/mL	STD F 0.500 ng/mL	STD G 1.00 ng/mL	STD H 2.00 ng/mL	STD I 4.00 ng/mL	STD J 5.25 ng/mL	STD K 6.25 ng/mL
24-Sep-2013	1	0.0251	0.0502	0.120	0.257	0.489	1.07	2.05	3.84	5.21	6.16
24-Sep-2013	2	0.0248	0.0504	0.127	0.251	0.502	1.04	1.96	3.86	5.08	6.42
26-Sep-2013	3	0.0249	0.0504	0.127	0.246	0.483	1.04	1.98	3.92	5.23	6.39
27-Sep-2013	5	0.0250	0.0488	0.134	0.249	0.492	1.01	1.96	3.95	5.10	6.39
27-Sep-2013	6	0.0249	0.0505	0.124	0.250	0.506	1.03	2.04	3.90	5.13	6.17
28-Sep-2013	7	0.0249	0.0496	0.129	0.249	0.503	1.04	1.99	3.84	5.19	6.17
30-Sep-2013	8	0.0260	0.0451	0.129	0.250	0.523	1.01	2.03	3.88	5.16	6.24
01-Oct-2013	9	0.0248	0.0508	0.126	0.248	0.494	1.03	2.04	3.91	5.15	6.22
02-Oct-2013	10	0.0253	0.0481	0.129	0.253	0.495	1.05	2.04	3.88	5.10	6.16
03-Oct-2013	11	0.0247	0.0497	0.133	0.256	0.473	1.05	1.98	3.88	5.12	6.26
18-Oct-2013	15	0.0249	0.0504	0.127	0.241	0.482	1.02	2.04	3.95	5.31	6.31
28-Oct-2013	18	0.0259	0.0467	0.124	0.245	0.474	1.05	2.02	4.12	5.27	6.34
01-Nov-2013	22	0.0256	0.0482	0.122	0.253	0.482	1.03	2.06	4.11	5.06	6.32
04-Nov-2013	20	0.0258	0.0467	0.126	0.247	0.489	1.04	1.98	4.16	5.16	6.35
04-Nov-2013	21	0.0256	0.0472	0.129	0.242	0.494	0.998	1.96	4.21	5.27	6.33
04-Nov-2013	23	0.0250	0.0498	0.128	0.246	0.487	1.03	1.93	4.16	5.19	6.23
05-Nov-2013	24	0.0260	0.0471	0.118	0.245	0.515	1.06	2.01	3.99	5.12	6.45
05-Nov-2013	25	0.0253	0.0489	0.125	0.252	0.485	1.04	2.00	4.16	5.06	6.15
06-Nov-2013	26	0.0250	0.0498	0.125	0.251	0.503	0.983	1.99	4.08	5.20	6.24
07-Nov-2013	27	0.0252	0.0502	0.121	0.244	0.485	1.03	2.03	4.04	5.31	6.27
18-Nov-2013	28	0.0249	0.0502	0.127	0.245	0.496	1.01	1.99	4.17	5.10	6.18
Mean		0.0252	0.0490	0.126	0.249	0.493	1.03	2.00	4.00	5.17	6.27
S D		0.0004	0.0016	0.004	0.004	0.013	0.02	0.04	0.13	0.08	0.09
%CV		1.7	3.3	3.1	1.7	2.5	2.0	1.8	3.2	1.5	1.5
%Bias		0.8	-2.0	0.8	-0.4	-1.4	3.0	0.0	0.0	-1.5	0.3
n		21	21	21	21	21	21	21	21	21	21



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Table 6 Standard Curve Parameters for SBMA

Assay Date	Watson Run ID	Slope	Intercept	R-Squared
24-Sep-2013	1	0.2301	0.0002341	0.9973
24-Sep-2013	2	0.2230	0.0004649	0.9987
26-Sep-2013	3	0.2272	0.0004631	0.9983
27-Sep-2013	5	0.2052	0.001034	0.9984
27-Sep-2013	6	0.2013	0.0004608	0.9989
28-Sep-2013	7	0.2084	0.0003047	0.9986
30-Sep-2013	8	0.2154	0.001569	0.9982
01-Oct-2013	9	0.2161	0.0007745	0.9984
02-Oct-2013	10	0.2190	-0.0003446	0.9982
03-Oct-2013	11	0.2123	0.0001155	0.9985
18-Oct-2013	15	1.347	-0.0007838	0.9991
28-Oct-2013	18	1.114	0.006240	0.9992
01-Nov-2013	22	1.067	0.004013	0.9987
04-Nov-2013	20	1.097	-0.004919	0.9994
04-Nov-2013	21	1.113	-0.003474	0.9994
04-Nov-2013	23	1.104	-0.004906	0.9992
05-Nov-2013	24	1.099	-0.003432	0.9991
05-Nov-2013	25	1.108	0.001555	0.9996
06-Nov-2013	26	1.171	-0.001867	0.9994
07-Nov-2013	27	1.157	-0.008568	0.9996
18-Nov-2013	28	0.2241	0.0008735	0.9994
Mean		0.6553	-0.0004853	0.9988
S.D.		0.4745	0.0032246	0.0006
%CV		72.4	-664.4	0.1
n		21	21	21



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Table 7 Standard Curve Parameters for SPMA

Assay Date	Watson Run ID	Slope	Intercept	R-Squared
24-Sep-2013	1	0.9926	0.0002153	0.9987
24-Sep-2013	2	0.9586	-0.001530	0.9993
26-Sep-2013	3	0.9731	-0.001026	0.9994
27-Sep-2013	5	0.8880	-0.0007090	0.9990
27-Sep-2013	6	0.8923	0.002030	0.9996
28-Sep-2013	7	0.9251	-0.00003440	0.9993
30-Sep-2013	8	0.9405	0.0005752	0.9978
01-Oct-2013	9	0.9326	0.0008619	0.9996
02-Oct-2013	10	0.9849	-0.0005239	0.9990
03-Oct-2013	11	0.9613	-0.0004975	0.9984
18-Oct-2013	15	0.2548	-0.00003247	0.9994
28-Oct-2013	18	0.2184	0.0003066	0.9983
01-Nov-2013	22	0.2125	-0.0001543	0.9989
04-Nov-2013	20	0.2147	0.00006866	0.9987
04-Nov-2013	21	0.2159	-0.0002732	0.9987
04-Nov-2013	23	0.2143	-0.0003499	0.9993
05-Nov-2013	24	0.2185	0.0002228	0.9979
05-Nov-2013	25	0.2180	-0.0001961	0.9991
06-Nov-2013	26	0.2269	-0.0007788	0.9999
07-Nov-2013	27	0.2232	-0.0001702	0.9995
18-Nov-2013	28	1.047	-0.001182	0.9995
Mean		0.6054	-0.0001513	0.9990
S.D.		0.3763	0.0007622	0.0006
%CV		62.2	-503.7	0.1
n		21	21	21





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Table 8 Study Sample Concentrations for SBMA

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000414	1	0001	Urine	-1	0	0.708	1	OK	
05113200000415	1	0001	Urine	0	1	1.51	1	OK	
05113200000416	1	0001	Urine	1	2	1.66	1	OK	
05113200000417	1	0001	Urine	2	3	2.18	1	OK	
05113200000418	1	0001	Urine	3	4	2.01	1	OK	
05113200000419	1	0001	Urine	4	5	5.44	1	OK	
05113200000420	1	0001	Urine	5	6	7.59	1	OK	
05113200000428	1	0004	Urine	-1	0	2.19	1	OK	
05113200000429	1	0004	Urine	0	1	2.90	1	OK	
05113200000430	1	0004	Urine	1	2	1.96	1	OK	
05113200000431	1	0004	Urine	2	3	1.56	1	OK	
05113200000432	1	0004	Urine	3	4	2.94	1	OK	
05113200000433	1	0004	Urine	4	5	1.90	1	OK	
05113200000434	1	0004	Urine	5	6	1.55	1	OK	
05113200000001	1	0008	Urine	-1	0	4.18	1	OK	
05113200000002	1	0008	Urine	0	1	4.90	1	OK	
05113200000003	1	0008	Urine	1	2	3.15	1	OK	
05113200000004	1	0008	Urine	2	3	2.50	1	OK	
05113200000005	1	0008	Urine	3	4	5.09	1	OK	
05113200000006	15	0008	Urine	4	5	5.78	1	OK	Mean of VRC reported
05113200000007	1	0008	Urine	5	6	8.42	1	OK	
05113200000008	1	0010	Urine	-1	0	4.42	1	OK	
05113200000009	1	0010	Urine	0	1	1.64	1	OK	
05113200000010	1	0010	Urine	1	2	3.08	1	OK	
05113200000011	1	0010	Urine	2	3	2.11	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000012	1	0010	Urine	3	4	2.43	1	OK	
05113200000013	1	0010	Urine	4	5	3.50	1	OK	
05113200000014	1	0010	Urine	5	6	3.63	1	OK	
05113200000015	1	0011	Urine	-1	0	3.29	1	OK	
05113200000016	1	0011	Urine	0	1	5.68	1	OK	
05113200000017	1	0011	Urine	1	2	6.26	1	OK	
05113200000018	1	0011	Urine	2	3	2.09	1	OK	
05113200000019	1	0011	Urine	3	4	2.92	1	OK	
05113200000020	1	0011	Urine	4	5	4.92	1	OK	
05113200000021	1	0011	Urine	5	6	5.68	1	OK	
05113200000442	1	0013	Urine	-1	0	2.40	1	OK	
05113200000443	1	0013	Urine	0	1	3.00	1	OK	
05113200000444	1	0013	Urine	1	2	1.63	1	OK	
05113200000445	15	0013	Urine	2	3	2.79	1	OK	Mean of VRC reported
05113200000446	1	0013	Urine	3	4	7.08	1	OK	
05113200000447	1	0013	Urine	4	5	6.80	1	OK	
05113200000448	1	0013	Urine	5	6	5.61	1	OK	
05113200000022	1	0014	Urine	-1	0	3.34	1	OK	
05113200000023	1	0014	Urine	0	1	9.18	1	OK	
05113200000024	1	0014	Urine	1	2	4.10	1	OK	
05113200000025	1	0014	Urine	2	3	2.58	1	OK	
05113200000026	1	0014	Urine	3	4	2.85	1	OK	
05113200000027	1	0014	Urine	4	5	2.55	1	OK	
05113200000028	1	0014	Urine	5	6	5.86	1	OK	
05113200000029	21	0015	Urine	-1	0	2.57	1	OK	
05113200000030	21	0015	Urine	0	1	2.54	1	OK	
05113200000031	21	0015	Urine	1	2	2.04	1	OK	
05113200000032	21	0015	Urine	2	3	2.43	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000033	21	0015	Urine	3	4	1.19	1	OK	
05113200000034	21	0015	Urine	4	5	2.22	1	OK	
05113200000035	21	0015	Urine	5	6	2.51	1	OK	
05113200000036	1	0016	Urine	-1	0	3.21	1	OK	
05113200000037	1	0016	Urine	0	1	1.28	1	OK	
05113200000038	1	0016	Urine	1	2	2.35	1	OK	
05113200000039	1	0016	Urine	2	3	1.33	1	OK	
05113200000040	1	0016	Urine	3	4	1.35	1	OK	
05113200000041	1	0016	Urine	4	5	1.82	1	OK	
05113200000042	1	0016	Urine	5	6	3.68	1	OK	
05113200000043	1	0017	Urine	-1	0	5.17	1	OK	
05113200000044	1	0017	Urine	0	1	3.87	1	OK	
05113200000045	1	0017	Urine	1	2	6.89	1	OK	
05113200000046	1	0017	Urine	2	3	5.48	1	OK	
05113200000047	1	0017	Urine	3	4	3.41	1	OK	
05113200000048	1	0017	Urine	4	5	4.70	1	OK	
05113200000049	1	0017	Urine	5	6	9.52	1	OK	
05113200000050	1	0020	Urine	-1	0	3.16	1	OK	
05113200000051	1	0020	Urine	0	1	3.66	1	OK	
05113200000052	1	0020	Urine	1	2	2.46	1	OK	
05113200000053	1	0020	Urine	2	3	3.55	1	OK	
05113200000054	1	0020	Urine	3	4	2.41	1	OK	
05113200000055	1	0020	Urine	4	5	2.69	1	OK	
05113200000056	1	0020	Urine	5	6	4.31	1	OK	
05113200000456	2	0021	Urine	-1	0	5.12	1	OK	
05113200000457	2	0021	Urine	0	1	7.33	1	OK	
05113200000458	2	0021	Urine	1	2	5.32	1	OK	
05113200000459	2	0021	Urine	2	3	18.4	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000460	2	0021	Urine	3	4	5.38	1	OK	
05113200000461	2	0021	Urine	4	5	2.72	1	OK	
05113200000462	2	0021	Urine	5	6	6.88	1	OK	
05113200000057	26	0022	Urine	-1	0	6.47	1	OK	
05113200000058	26	0022	Urine	0	1	13.3	1	OK	
05113200000059	26	0022	Urine	1	2	5.30	1	OK	
05113200000060	26	0022	Urine	2	3	4.74	1	OK	
05113200000061	26	0022	Urine	3	4	6.22	1	OK	
05113200000062	28	0022	Urine	4	5	7.93	1	OK	
05113200000259	26	0022	Urine	5	6	12.5	2	OK	
05113200000064	2	0023	Urine	-1	0	7.48	1	OK	
05113200000065	2	0023	Urine	0	1	7.55	1	OK	
05113200000066	2	0023	Urine	1	2	6.88	1	OK	
05113200000067	2	0023	Urine	2	3	5.21	1	OK	
05113200000068	2	0023	Urine	3	4	5.97	1	OK	
05113200000069	2	0023	Urine	4	5	4.45	1	OK	
05113200000070	2	0023	Urine	5	6	7.40	1	OK	
05113200000071	2	0025	Urine	-1	0	1.06	1	OK	
05113200000072	2	0025	Urine	0	1	2.03	1	OK	
05113200000073	2	0025	Urine	1	2	1.90	1	OK	
05113200000074	2	0025	Urine	2	3	1.56	1	OK	
05113200000075	2	0025	Urine	3	4	0.982	1	OK	
05113200000076	2	0025	Urine	4	5	1.84	1	OK	
05113200000077	2	0025	Urine	5	6	4.53	1	OK	
05113200000078	2	0028	Urine	-1	0	4.85	1	OK	
05113200000079	2	0028	Urine	0	1	4.26	1	OK	
05113200000080	2	0028	Urine	1	2	3.33	1	OK	
05113200000081	2	0028	Urine	2	3	3.01	1	OK	





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000082	2	0028	Urine	3	4	1.00	1	OK	
05113200000083	2	0028	Urine	4	5	2.69	1	OK	
05113200000084	2	0028	Urine	5	6	1.70	1	OK	
05113200000085	2	0029	Urine	-1	0	3.07	1	OK	
05113200000086	2	0029	Urine	0	1	0.935	1	OK	
05113200000087	2	0029	Urine	1	2	1.19	1	OK	
05113200000088	2	0029	Urine	2	3	0.960	1	OK	
05113200000089	2	0029	Urine	3	4	0.545	1	OK	
05113200000090	2	0029	Urine	4	5	0.793	1	OK	
05113200000091	2	0029	Urine	5	6	1.91	1	OK	
05113200000092	2	0030	Urine	-1	0	4.11	1	OK	
05113200000093	2	0030	Urine	0	1	3.26	1	OK	
05113200000094	2	0030	Urine	1	2	2.76	1	OK	
05113200000095	2	0030	Urine	2	3	1.13	1	OK	
05113200000096	2	0030	Urine	3	4	1.39	1	OK	
05113200000097	2	0030	Urine	4	5	3.69	1	OK	
05113200000098	2	0030	Urine	5	6	4.28	1	OK	
05113200000099	2	0031	Urine	-1	0	3.97	1	OK	
05113200000100	2	0031	Urine	0	1	5.23	1	OK	
05113200000101	2	0031	Urine	1	2	4.06	1	OK	
05113200000102	2	0031	Urine	2	3	3.11	1	OK	
05113200000103	2	0031	Urine	3	4	4.04	1	OK	
05113200000104	2	0031	Urine	4	5	2.12	1	OK	
05113200000105	2	0031	Urine	5	6	2.89	1	OK	
05113200000106	2	0034	Urine	-1	0	4.40	1	OK	
05113200000107	2	0034	Urine	0	1	4.05	1	OK	
05113200000108	2	0034	Urine	1	2	7.04	1	OK	
05113200000109	2	0034	Urine	2	3	4.71	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000110	2	0034	Urine	3	4	5.78	1	OK	
05113200000111	2	0034	Urine	4	5	8.29	1	OK	
05113200000112	2	0034	Urine	5	6	5.94	1	OK	
05113200000113	2	0035	Urine	-1	0	2.20	1	OK	
05113200000114	2	0035	Urine	0	1	2.87	1	OK	
05113200000115	2	0035	Urine	1	2	1.38	1	OK	
05113200000116	2	0035	Urine	2	3	1.01	1	OK	
05113200000117	2	0035	Urine	3	4	0.947	1	OK	
05113200000118	2	0035	Urine	4	5	1.51	1	OK	
05113200000119	2	0035	Urine	5	6	3.71	1	OK	
05113200000470	2	0037	Urine	-1	0	3.88	1	OK	
05113200000471	2	0037	Urine	0	1	5.75	1	OK	
05113200000472	2	0037	Urine	1	2	5.16	1	OK	
05113200000473	2	0037	Urine	2	3	4.42	1	OK	
05113200000474	2	0037	Urine	3	4	7.25	1	OK	
05113200000475	2	0037	Urine	4	5	6.04	1	OK	
05113200000476	2	0037	Urine	5	6	7.91	1	OK	
05113200000120	3	0038	Urine	-1	0	22.2	1	OK	
05113200000121	3	0038	Urine	0	1	11.4	1	OK	
05113200000122	3	0038	Urine	1	2	11.2	1	OK	
05113200000123	3	0038	Urine	2	3	4.65	1	OK	
05113200000124	3	0038	Urine	3	4	5.67	1	OK	
05113200000125	3	0038	Urine	4	5	10.2	1	OK	
05113200000126	3	0038	Urine	5	6	11.4	1	OK	
05113200000127	3	0039	Urine	-1	0	6.82	1	OK	
05113200000128	3	0039	Urine	0	1	6.54	1	OK	
05113200000129	3	0039	Urine	1	2	6.29	1	OK	
05113200000130	3	0039	Urine	2	3	1.99	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000131	3	0039	Urine	3	4	3.08	1	OK	
05113200000132	3	0039	Urine	4	5	5.29	1	OK	
05113200000133	3	0039	Urine	5	6	12.9	1	OK	
05113200000484	3	0042	Urine	-1	0	3.97	1	OK	
05113200000485	3	0042	Urine	0	1	11.4	1	OK	
05113200000486	3	0042	Urine	1	2	8.43	1	OK	
05113200000487	3	0042	Urine	2	3	4.61	1	OK	
05113200000488	15	0042	Urine	3	4	41.4	1	OK	
05113200000489	15	0042	Urine	4	5	33.9	1	OK	
05113200000490	3	0042	Urine	5	6	13.6	1	OK	
05113200000134	3	0044	Urine	-1	0	4.16	1	OK	
05113200000135	3	0044	Urine	0	1	6.84	1	OK	
05113200000136	3	0044	Urine	1	2	5.41	1	OK	
05113200000137	3	0044	Urine	2	3	3.96	1	OK	
05113200000138	3	0044	Urine	3	4	5.24	1	OK	
05113200000139	3	0044	Urine	4	5	5.46	1	OK	
05113200000140	3	0044	Urine	5	6	6.55	1	OK	
05113200000141	3	0049	Urine	-1	0	3.31	1	OK	
05113200000142	3	0049	Urine	0	1	1.46	1	OK	
05113200000143	3	0049	Urine	1	2	6.19	1	OK	
05113200000144	3	0049	Urine	2	3	2.81	1	OK	
05113200000145	3	0049	Urine	3	4	5.17	1	OK	
05113200000146	3	0049	Urine	4	5	6.20	1	OK	
05113200000147	3	0049	Urine	5	6	5.28	1	OK	
05113200000498	3	0051	Urine	-1	0	6.48	1	OK	
05113200000499	3	0051	Urine	0	1	9.13	1	OK	
05113200000500	3	0051	Urine	1	2	10.5	1	OK	
05113200000501	3	0051	Urine	2	3	3.89	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000502	3	0051	Urine	3	4	16.4	1	OK	
05113200000503	3	0051	Urine	4	5	18.3	1	OK	
05113200000504	3	0051	Urine	5	6	17.5	1	OK	
05113200000148	3	0052	Urine	-1	0	5.02	1	OK	
05113200000149	3	0052	Urine	0	1	4.97	1	OK	
05113200000150	3	0052	Urine	1	2	3.48	1	OK	
05113200000151	3	0052	Urine	2	3	3.82	1	OK	
05113200000152	3	0052	Urine	3	4	2.08	1	OK	
05113200000153	3	0052	Urine	4	5	3.84	1	OK	
05113200000154	3	0052	Urine	5	6	6.38	1	OK	
05113200000155	3	0053	Urine	-1	0	1.79	1	OK	
05113200000156	3	0053	Urine	0	1	2.62	1	OK	
05113200000353	11	0053	Urine	1	2	2.27	2	OK	
05113200000158	3	0053	Urine	2	3	1.51	1	OK	
05113200000159	3	0053	Urine	3	4	1.20	1	OK	
05113200000160	3	0053	Urine	4	5	1.34	1	OK	
05113200000161	3	0053	Urine	5	6	3.77	1	OK	
05113200000162	3	0055	Urine	-1	0	4.40	1	OK	
05113200000163	3	0055	Urine	0	1	4.63	1	OK	
05113200000164	3	0055	Urine	1	2	3.95	1	OK	
05113200000165	3	0055	Urine	2	3	3.24	1	OK	
05113200000166	3	0055	Urine	3	4	2.03	1	OK	
05113200000167	3	0055	Urine	4	5	3.97	1	OK	
05113200000168	3	0055	Urine	5	6	5.54	1	OK	
05113200000169	21	0057	Urine	-1	0	1.16	1	OK	
05113200000170	21	0057	Urine	0	1	2.26	1	OK	
05113200000171	21	0057	Urine	1	2	2.04	1	OK	
05113200000172	21	0057	Urine	2	3	0.991	1	OK	





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000173	21	0057	Urine	3	4	1.42	1	OK	
05113200000174	21	0057	Urine	4	5	1.80	1	OK	
05113200000175	21	0057	Urine	5	6	1.12	1	OK	
05113200000176	3	0060	Urine	-1	0	14.9	1	OK	
05113200000177	3	0060	Urine	0	1	3.08	1	OK	
05113200000178	3	0060	Urine	1	2	8.12	1	OK	
05113200000179	3	0060	Urine	2	3	5.01	1	OK	
05113200000180	3	0060	Urine	3	4	4.33	1	OK	
05113200000181	3	0060	Urine	4	5	5.73	1	OK	
05113200000182	3	0060	Urine	5	6	11.4	1	OK	
05113200000183	6	0062	Urine	-1	0	2.79	1	OK	
05113200000184	6	0062	Urine	0	1	4.86	1	OK	
05113200000185	6	0062	Urine	1	2	3.51	1	OK	
05113200000186	6	0062	Urine	2	3	3.80	1	OK	
05113200000187	6	0062	Urine	3	4	1.76	1	OK	
05113200000188	6	0062	Urine	4	5	4.80	1	OK	
05113200000189	6	0062	Urine	5	6	12.0	1	OK	
05113200000512	7	0063	Urine	-1	0	2.82	1	OK	
05113200000513	7	0063	Urine	0	1	6.79	1	OK	
05113200000514	7	0063	Urine	1	2	4.05	1	OK	
05113200000515	7	0063	Urine	2	3	2.85	1	OK	
05113200000516	7	0063	Urine	3	4	6.31	1	OK	
05113200000517	7	0063	Urine	4	5	5.35	1	OK	
05113200000518	7	0063	Urine	5	6	6.70	1	OK	
05113200000190	7	0064	Urine	-1	0	4.40	1	OK	
05113200000191	7	0064	Urine	0	1	12.9	1	OK	
05113200000192	7	0064	Urine	1	2	4.40	1	OK	
05113200000193	7	0064	Urine	2	3	3.52	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000194	7	0064	Urine	3	4	5.29	1	OK	
05113200000195	7	0064	Urine	4	5	5.74	1	OK	
05113200000196	7	0064	Urine	5	6	8.87	1	OK	
05113200000526	7	0066	Urine	-1	0	2.24	1	OK	
05113200000527	7	0066	Urine	0	1	4.12	1	OK	
05113200000528	7	0066	Urine	1	2	1.64	1	OK	
05113200000529	7	0066	Urine	2	3	1.91	1	OK	
05113200000530	7	0066	Urine	3	4	5.08	1	OK	
05113200000531	7	0066	Urine	4	5	2.44	1	OK	
05113200000532	7	0066	Urine	5	6	3.65	1	OK	
05113200000540	7	0067	Urine	-1	0	2.32	1	OK	
05113200000541	7	0067	Urine	0	1	5.46	1	OK	
05113200000542	7	0067	Urine	1	2	3.19	1	OK	
05113200000543	7	0067	Urine	2	3	3.50	1	OK	
05113200000544	7	0067	Urine	3	4	2.39	1	OK	
05113200000545	7	0067	Urine	4	5	1.81	1	OK	
05113200000546	7	0067	Urine	5	6	2.52	1	OK	
05113200000554	7	0069	Urine	-1	0	3.33	1	OK	
05113200000555	7	0069	Urine	0	1	2.07	1	OK	
05113200000556	7	0069	Urine	1	2	2.21	1	OK	
05113200000557	7	0069	Urine	2	3	3.31	1	OK	
05113200000558	7	0069	Urine	3	4	5.43	1	OK	
05113200000559	7	0069	Urine	4	5	6.87	1	OK	
05113200000560	7	0069	Urine	5	6	6.13	1	OK	
05113200000568	7	0071	Urine	-1	0	12.9	1	OK	
05113200000569	7	0071	Urine	0	1	19.1	1	OK	
05113200000570	7	0071	Urine	1	2	15.7	1	OK	
05113200000571	7	0071	Urine	2	3	12.5	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000572	7	0071	Urine	3	4	20.9	1	OK	
05113200000573	15	0071	Urine	4	5	31.8	1	OK	
05113200000574	7	0071	Urine	5	6	21.2	1	OK	
05113200000582	21	0072	Urine	-1	0	3.61	1	OK	
05113200000583	21	0072	Urine	0	1	3.97	1	OK	
05113200000584	21	0072	Urine	1	2	1.61	1	OK	
05113200000585	21	0072	Urine	2	3	3.76	1	OK	
05113200000586	21	0072	Urine	3	4	4.35	1	OK	
05113200000587	21	0072	Urine	4	5	2.45	1	OK	
05113200000588	21	0072	Urine	5	6	4.61	1	OK	
05113200000596	7	0074	Urine	-1	0	11.0	1	OK	
05113200000597	7	0074	Urine	0	1	13.0	1	OK	
05113200000598	7	0074	Urine	1	2	9.25	1	OK	
05113200000599	7	0074	Urine	2	3	7.07	1	OK	
05113200000600	7	0074	Urine	3	4	11.4	1	OK	
05113200000601	7	0074	Urine	4	5	5.47	1	OK	
05113200000602	7	0074	Urine	5	6	12.3	1	OK	
05113200000610	7	0076	Urine	-1	0	1.99	1	OK	
05113200000611	7	0076	Urine	0	1	2.00	1	OK	
05113200000612	7	0076	Urine	1	2	4.51	1	OK	
05113200000613	7	0076	Urine	2	3	3.60	1	OK	
05113200000614	7	0076	Urine	3	4	11.3	1	OK	
05113200000615	7	0076	Urine	4	5	3.93	1	OK	
05113200000616	7	0076	Urine	5	6	6.71	1	OK	
05113200000624	7	0080	Urine	-1	0	2.13	1	OK	
05113200000625	7	0080	Urine	0	1	3.20	1	OK	
05113200000626	7	0080	Urine	1	2	2.49	1	OK	
05113200000627	7	0080	Urine	2	3	2.31	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000628	7	0080	Urine	3	4	3.67	1	OK	
05113200000629	7	0080	Urine	4	5	1.42	1	OK	
05113200000630	7	0080	Urine	5	6	2.17	1	OK	
05113200000638	5	0083	Urine	-1	0	3.16	1	OK	
05113200000639	5	0083	Urine	0	1	5.67	1	OK	
05113200000640	5	0083	Urine	1	2	5.11	1	OK	
05113200000641	5	0083	Urine	2	3	2.74	1	OK	
05113200000642	5	0083	Urine	3	4	8.63	1	OK	
05113200000643	5	0083	Urine	4	5	5.78	1	OK	
05113200000644	5	0083	Urine	5	6	10.3	1	OK	
05113200000652	21	0085	Urine	-1	0	1.90	1	OK	
05113200000653	21	0085	Urine	0	1	3.37	1	OK	
05113200000654	21	0085	Urine	1	2	1.92	1	OK	
05113200000655	21	0085	Urine	2	3	1.56	1	OK	
05113200000666	5	0086	Urine	-1	0	3.97	1	OK	
05113200000667	5	0086	Urine	0	1	5.72	1	OK	
05113200000668	5	0086	Urine	1	2	5.15	1	OK	
05113200000669	5	0086	Urine	2	3	3.28	1	OK	
05113200000670	5	0086	Urine	3	4	5.41	1	OK	
05113200000671	5	0086	Urine	4	5	5.05	1	OK	
05113200000672	5	0086	Urine	5	6	9.36	1	OK	
05113200000680	5	0087	Urine	-1	0	7.38	1	OK	
05113200000681	5	0087	Urine	0	1	7.10	1	OK	
05113200000682	5	0087	Urine	1	2	6.44	1	OK	
05113200000683	5	0087	Urine	2	3	5.73	1	OK	
05113200000684	5	0087	Urine	3	4	9.47	1	OK	
05113200000685	5	0087	Urine	4	5	4.65	1	OK	
05113200000686	5	0087	Urine	5	6	3.20	1	OK	





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000694	5	0088	Urine	-1	0	10.5	1	OK	
05113200000695	5	0088	Urine	0	1	8.49	1	OK	
05113200000696	5	0088	Urine	1	2	10.7	1	OK	
05113200000697	5	0088	Urine	2	3	8.44	1	OK	
05113200000698	5	0088	Urine	3	4	13.2	1	OK	
05113200000699	5	0088	Urine	4	5	8.72	1	OK	
05113200000700	5	0088	Urine	5	6	11.2	1	OK	
05113200000708	5	0090	Urine	-1	0	2.53	1	OK	
05113200000709	5	0090	Urine	0	1	5.44	1	OK	
05113200000710	5	0090	Urine	1	2	4.20	1	OK	
05113200000711	5	0090	Urine	2	3	2.81	1	OK	
05113200000712	5	0090	Urine	3	4	4.97	1	OK	
05113200000713	5	0090	Urine	4	5	2.78	1	OK	
05113200000714	5	0090	Urine	5	6	12.9	1	OK	
05113200000722	6	0093	Urine	-1	0	2.23	1	OK	
05113200000723	6	0093	Urine	0	1	4.02	1	OK	
05113200000724	6	0093	Urine	1	2	3.86	1	OK	
05113200000725	6	0093	Urine	2	3	4.56	1	OK	
05113200000726	6	0093	Urine	3	4	3.47	1	OK	
05113200000727	6	0093	Urine	4	5	2.64	1	OK	
05113200000728	6	0093	Urine	5	6	11.4	1	OK	
05113200000736	5	0104	Urine	-1	0	5.69	1	OK	
05113200000737	5	0104	Urine	0	1	8.56	1	OK	
05113200000738	5	0104	Urine	1	2	4.40	1	OK	
05113200000739	5	0104	Urine	2	3	4.66	1	OK	
05113200000740	5	0104	Urine	3	4	4.25	1	OK	
05113200000741	5	0104	Urine	4	5	2.39	1	OK	
05113200000742	5	0104	Urine	5	6	4.59	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000750	5	0105	Urine	-1	0	3.74	1	OK	
05113200000751	5	0105	Urine	0	1	4.88	1	OK	
05113200000752	5	0105	Urine	1	2	4.46	1	OK	
05113200000753	5	0105	Urine	2	3	3.26	1	OK	
05113200000754	5	0105	Urine	3	4	8.78	1	OK	
05113200000755	5	0105	Urine	4	5	3.77	1	OK	
05113200000756	5	0105	Urine	5	6	2.89	1	OK	
05113200000764	5	0106	Urine	-1	0	3.42	1	OK	
05113200000765	5	0106	Urine	0	1	5.71	1	OK	
05113200000766	5	0106	Urine	1	2	2.14	1	OK	
05113200000767	5	0106	Urine	2	3	2.61	1	OK	
05113200000768	5	0106	Urine	3	4	3.53	1	OK	
05113200000769	5	0106	Urine	4	5	2.04	1	OK	
05113200000770	5	0106	Urine	5	6	2.41	1	OK	
05113200000778	5	0107	Urine	-1	0	8.28	1	OK	
05113200000779	5	0107	Urine	0	1	5.77	1	OK	
05113200000780	5	0107	Urine	1	2	4.47	1	OK	
05113200000781	5	0107	Urine	2	3	3.78	1	OK	
05113200000782	5	0107	Urine	3	4	2.36	1	OK	
05113200000783	5	0107	Urine	4	5	3.44	1	OK	
05113200000784	5	0107	Urine	5	6	2.96	1	OK	
05113200000792	5	0110	Urine	-1	0	3.08	1	OK	
05113200000793	5	0110	Urine	0	1	4.08	1	OK	
05113200000794	5	0110	Urine	1	2	2.73	1	OK	
05113200000795	5	0110	Urine	2	3	2.98	1	OK	
05113200000796	5	0110	Urine	3	4	2.90	1	OK	
05113200000797	5	0110	Urine	4	5	2.24	1	OK	
05113200000798	5	0110	Urine	5	6	5.99	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000806	7	0112	Urine	-1	0	3.42	1	OK	
05113200000807	7	0112	Urine	0	1	4.82	1	OK	
05113200000808	7	0112	Urine	1	2	2.83	1	OK	
05113200000809	7	0112	Urine	2	3	2.29	1	OK	
05113200000810	7	0112	Urine	3	4	2.80	1	OK	
05113200000811	7	0112	Urine	4	5	3.13	1	OK	
05113200000812	7	0112	Urine	5	6	3.05	1	OK	
05113200000820	6	0114	Urine	-1	0	6.74	1	OK	
05113200000821	6	0114	Urine	0	1	13.1	1	OK	
05113200000822	6	0114	Urine	1	2	9.16	1	OK	
05113200000823	6	0114	Urine	2	3	6.68	1	OK	
05113200000824	6	0114	Urine	3	4	6.62	1	OK	
05113200000825	6	0114	Urine	4	5	5.22	1	OK	
05113200000826	6	0114	Urine	5	6	9.39	1	OK	
05113200000834	10	0117	Urine	-1	0	3.57	1	OK	
05113200000835	10	0117	Urine	0	1	5.74	1	OK	
05113200000836	10	0117	Urine	1	2	4.88	1	OK	
05113200000837	10	0117	Urine	2	3	5.04	1	OK	
05113200000838	10	0117	Urine	3	4	4.48	1	OK	
05113200000839	10	0117	Urine	4	5	2.91	1	OK	
05113200000840	10	0117	Urine	5	6	2.36	1	OK	
05113200000848	10	0118	Urine	-1	0	3.27	1	OK	
05113200000849	10	0118	Urine	0	1	4.36	1	OK	
05113200000850	10	0118	Urine	1	2	3.51	1	OK	
05113200000851	10	0118	Urine	2	3	2.54	1	OK	
05113200000852	10	0118	Urine	3	4	3.85	1	OK	
05113200000853	10	0118	Urine	4	5	6.20	1	OK	
05113200000854	10	0118	Urine	5	6	4.92	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000862	6	0121	Urine	-1	0	4.85	1	OK	
05113200000863	6	0121	Urine	0	1	7.71	1	OK	
05113200000864	6	0121	Urine	1	2	3.54	1	OK	
05113200000865	6	0121	Urine	2	3	3.39	1	OK	
05113200000866	6	0121	Urine	3	4	4.61	1	OK	
05113200000867	6	0121	Urine	4	5	3.04	1	OK	
05113200000868	6	0121	Urine	5	6	6.47	1	OK	
05113200000876	6	0122	Urine	-1	0	3.88	1	OK	
05113200000877	6	0122	Urine	0	1	4.54	1	OK	
05113200000878	6	0122	Urine	1	2	2.74	1	OK	
05113200000879	6	0122	Urine	2	3	1.52	1	OK	
05113200000880	6	0122	Urine	3	4	3.57	1	OK	
05113200000881	6	0122	Urine	4	5	2.31	1	OK	
05113200000882	6	0122	Urine	5	6	3.17	1	OK	
05113200000890	6	0123	Urine	-1	0	2.16	1	OK	
05113200000891	6	0123	Urine	0	1	2.56	1	OK	
05113200000892	6	0123	Urine	1	2	2.06	1	OK	
05113200000893	6	0123	Urine	2	3	1.28	1	OK	
05113200000894	6	0123	Urine	3	4	3.31	1	OK	
05113200000895	6	0123	Urine	4	5	1.75	1	OK	
05113200000896	6	0123	Urine	5	6	3.19	1	OK	
05113200000904	6	0126	Urine	-1	0	2.77	1	OK	
05113200000905	6	0126	Urine	0	1	3.91	1	OK	
05113200000906	6	0126	Urine	1	2	3.67	1	OK	
05113200000907	6	0126	Urine	2	3	1.89	1	OK	
05113200000908	6	0126	Urine	3	4	2.45	1	OK	
05113200000909	6	0126	Urine	4	5	2.28	1	OK	
05113200000910	6	0126	Urine	5	6	3.36	1	OK	





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000918	15	0127	Urine	-1	0	30.8	1	OK	
05113200000919	6	0127	Urine	0	1	3.43	1	OK	
05113200000920	6	0127	Urine	1	2	1.89	1	OK	
05113200000921	6	0127	Urine	2	3	1.79	1	OK	
05113200000922	6	0127	Urine	3	4	1.70	1	OK	
05113200000923	6	0127	Urine	4	5	2.58	1	OK	
05113200000924	6	0127	Urine	5	6	4.46	1	OK	
05113200000932	6	0128	Urine	-1	0	15.3	1	OK	
05113200000933	6	0128	Urine	0	1	16.8	1	OK	
05113200000934	6	0128	Urine	1	2	9.19	1	OK	
05113200000935	6	0128	Urine	2	3	4.86	1	OK	
05113200000936	6	0128	Urine	3	4	5.90	1	OK	
05113200000937	6	0128	Urine	4	5	8.19	1	OK	
05113200000938	6	0128	Urine	5	6	15.2	1	OK	
05113200000946	6	0129	Urine	-1	0	1.52	1	OK	
05113200000947	6	0129	Urine	0	1	2.46	1	OK	
05113200000948	6	0129	Urine	1	2	2.19	1	OK	
05113200000949	6	0129	Urine	2	3	1.42	1	OK	
05113200000950	6	0129	Urine	3	4	1.55	1	OK	
05113200000951	6	0129	Urine	4	5	2.01	1	OK	
05113200000952	6	0129	Urine	5	6	1.02	1	OK	
05113200000960	8	0130	Urine	-1	0	8.32	1	OK	
05113200000961	8	0130	Urine	0	1	8.95	1	OK	
05113200000962	8	0130	Urine	1	2	3.94	1	OK	
05113200000963	8	0130	Urine	2	3	2.98	1	OK	
05113200000964	8	0130	Urine	3	4	4.92	1	OK	
05113200000965	8	0130	Urine	4	5	9.41	1	OK	
05113200000966	8	0130	Urine	5	6	7.83	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000974	8	0133	Urine	-1	0	2.75	1	OK	
05113200000975	8	0133	Urine	0	1	12.6	1	OK	
05113200000976	8	0133	Urine	1	2	11.9	1	OK	
05113200000977	8	0133	Urine	2	3	2.33	1	OK	
05113200000978	8	0133	Urine	3	4	5.31	1	OK	
05113200000979	8	0133	Urine	4	5	3.92	1	OK	
05113200000980	8	0133	Urine	5	6	6.09	1	OK	
05113200000988	8	0134	Urine	-1	0	3.93	1	OK	
05113200000989	8	0134	Urine	0	1	3.88	1	OK	
05113200000990	8	0134	Urine	1	2	3.05	1	OK	
05113200000991	8	0134	Urine	2	3	1.62	1	OK	
05113200000992	8	0134	Urine	3	4	2.76	1	OK	
05113200000993	8	0134	Urine	4	5	2.54	1	OK	
05113200000994	8	0134	Urine	5	6	3.31	1	OK	
05113200001002	8	0136	Urine	-1	0	5.06	1	OK	
05113200001003	8	0136	Urine	0	1	7.07	1	OK	
05113200001004	8	0136	Urine	1	2	6.89	1	OK	
05113200001005	8	0136	Urine	2	3	5.18	1	OK	
05113200001006	8	0136	Urine	3	4	6.07	1	OK	
05113200001007	8	0136	Urine	4	5	3.77	1	OK	
05113200001008	8	0136	Urine	5	6	5.01	1	OK	
05113200001016	8	0137	Urine	-1	0	5.84	1	OK	
05113200001017	8	0137	Urine	0	1	4.65	1	OK	
05113200001018	8	0137	Urine	1	2	4.67	1	OK	
05113200001019	8	0137	Urine	2	3	3.11	1	OK	
05113200001020	8	0137	Urine	3	4	3.90	1	OK	
05113200001021	8	0137	Urine	4	5	3.47	1	OK	
05113200001022	8	0137	Urine	5	6	4.45	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001030	8	0139	Urine	-1	0	10.9	1	OK	
05113200001031	8	0139	Urine	0	1	12.9	1	OK	
05113200001032	8	0139	Urine	1	2	8.47	1	OK	
05113200001033	8	0139	Urine	2	3	7.23	1	OK	
05113200001034	8	0139	Urine	3	4	10.6	1	OK	
05113200001035	8	0139	Urine	4	5	11.0	1	OK	
05113200001036	8	0139	Urine	5	6	11.2	1	OK	
05113200001044	8	0140	Urine	-1	0	3.00	1	OK	
05113200001045	8	0140	Urine	0	1	3.93	1	OK	
05113200001046	8	0140	Urine	1	2	2.82	1	OK	
05113200001047	8	0140	Urine	2	3	2.84	1	OK	
05113200001048	8	0140	Urine	3	4	3.38	1	OK	
05113200001049	8	0140	Urine	4	5	3.79	1	OK	
05113200001050	8	0140	Urine	5	6	2.17	1	OK	
05113200001058	8	0145	Urine	-1	0	4.44	1	OK	
05113200001059	8	0145	Urine	0	1	3.65	1	OK	
05113200001060	8	0145	Urine	1	2	3.07	1	OK	
05113200001061	8	0145	Urine	2	3	2.34	1	OK	
05113200001062	8	0145	Urine	3	4	1.84	1	OK	
05113200001063	8	0145	Urine	4	5	2.07	1	OK	
05113200001064	8	0145	Urine	5	6	3.09	1	OK	
05113200001072	8	0147	Urine	-1	0	9.03	1	OK	
05113200001073	8	0147	Urine	0	1	4.59	1	OK	
05113200001074	8	0147	Urine	1	2	3.70	1	OK	
05113200001075	8	0147	Urine	2	3	2.80	1	OK	
05113200001076	8	0147	Urine	3	4	2.31	1	OK	
05113200001077	8	0147	Urine	4	5	3.60	1	OK	
05113200001078	8	0147	Urine	5	6	7.81	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001086	8	0148	Urine	-1	0	12.0	1	OK	
05113200001087	8	0148	Urine	0	1	15.8	1	OK	
05113200001088	8	0148	Urine	1	2	10.4	1	OK	
05113200001089	8	0148	Urine	2	3	8.23	1	OK	
05113200001090	8	0148	Urine	3	4	7.66	1	OK	
05113200001091	8	0148	Urine	4	5	5.52	1	OK	
05113200001092	8	0148	Urine	5	6	8.34	1	OK	
05113200001100	9	0149	Urine	-1	0	9.61	1	OK	
05113200001101	9	0149	Urine	0	1	5.74	1	OK	
05113200001102	9	0149	Urine	1	2	3.95	1	OK	
05113200001103	9	0149	Urine	2	3	3.55	1	OK	
05113200001104	9	0149	Urine	3	4	4.32	1	OK	
05113200001105	9	0149	Urine	4	5	3.42	1	OK	
05113200001106	9	0149	Urine	5	6	5.42	1	OK	
05113200001114	9	0150	Urine	-1	0	5.62	1	OK	
05113200001115	9	0150	Urine	0	1	4.68	1	OK	
05113200001116	9	0150	Urine	1	2	5.85	1	OK	
05113200001117	9	0150	Urine	2	3	3.62	1	OK	
05113200001118	9	0150	Urine	3	4	3.66	1	OK	
05113200001119	9	0150	Urine	4	5	3.80	1	OK	
05113200001120	9	0150	Urine	5	6	6.64	1	OK	
05113200001128	9	0152	Urine	-1	0	4.82	1	OK	
05113200001129	9	0152	Urine	0	1	3.72	1	OK	
05113200001130	9	0152	Urine	1	2	2.25	1	OK	
05113200001131	9	0152	Urine	2	3	2.18	1	OK	
05113200001132	9	0152	Urine	3	4	2.49	1	OK	
05113200001133	9	0152	Urine	4	5	1.59	1	OK	
05113200001134	9	0152	Urine	5	6	1.30	1	OK	





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001142	9	0153	Urine	-1	0	2.73	1	OK	
05113200001143	9	0153	Urine	0	1	2.70	1	OK	
05113200001144	9	0153	Urine	1	2	2.50	1	OK	
05113200001145	9	0153	Urine	2	3	1.77	1	OK	
05113200001146	9	0153	Urine	3	4	2.58	1	OK	
05113200001147	9	0153	Urine	4	5	4.55	1	OK	
05113200001148	9	0153	Urine	5	6	5.04	1	OK	
05113200001156	9	0155	Urine	-1	0	4.89	1	OK	
05113200001157	9	0155	Urine	0	1	4.78	1	OK	
05113200001158	9	0155	Urine	1	2	4.05	1	OK	
05113200001159	9	0155	Urine	2	3	3.27	1	OK	
05113200001160	9	0155	Urine	3	4	2.62	1	OK	
05113200001161	9	0155	Urine	4	5	2.78	1	OK	
05113200001162	9	0155	Urine	5	6	3.47	1	OK	
05113200001170	9	0156	Urine	-1	0	4.24	1	OK	
05113200001171	9	0156	Urine	0	1	4.41	1	OK	
05113200001172	9	0156	Urine	1	2	3.01	1	OK	
05113200001173	9	0156	Urine	2	3	3.32	1	OK	
05113200001174	9	0156	Urine	3	4	2.81	1	OK	
05113200001175	9	0156	Urine	4	5	4.07	1	OK	
05113200001176	9	0156	Urine	5	6	4.49	1	OK	
05113200001184	9	0160	Urine	-1	0	2.07	1	OK	
05113200001185	9	0160	Urine	0	1	3.08	1	OK	
05113200001186	9	0160	Urine	1	2	2.28	1	OK	
05113200001187	9	0160	Urine	2	3	1.62	1	OK	
05113200001188	9	0160	Urine	3	4	2.06	1	OK	
05113200001189	9	0160	Urine	4	5	1.78	1	OK	
05113200001190	9	0160	Urine	5	6	1.92	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001198	9	0162	Urine	-1	0	9.94	1	OK	
05113200001199	9	0162	Urine	0	1	8.84	1	OK	
05113200001200	9	0162	Urine	1	2	4.51	1	OK	
05113200001201	9	0162	Urine	2	3	3.86	1	OK	
05113200001202	9	0162	Urine	3	4	4.79	1	OK	
05113200001203	9	0162	Urine	4	5	4.05	1	OK	
05113200001204	9	0162	Urine	5	6	8.35	1	OK	
05113200001212	9	0167	Urine	-1	0	6.20	1	OK	
05113200001213	9	0167	Urine	0	1	8.35	1	OK	
05113200001214	9	0167	Urine	1	2	4.30	1	OK	
05113200001215	9	0167	Urine	2	3	4.53	1	OK	
05113200001216	9	0167	Urine	3	4	5.05	1	OK	
05113200001217	9	0167	Urine	4	5	4.78	1	OK	
05113200001218	9	0167	Urine	5	6	5.06	1	OK	
05113200001226	9	0169	Urine	-1	0	4.73	1	OK	
05113200001227	9	0169	Urine	0	1	5.59	1	OK	
05113200001228	9	0169	Urine	1	2	7.35	1	OK	
05113200001229	9	0169	Urine	2	3	2.90	1	OK	
05113200001230	9	0169	Urine	3	4	3.91	1	OK	
05113200001231	9	0169	Urine	4	5	1.56	1	OK	
05113200001232	9	0169	Urine	5	6	4.66	1	OK	
05113200001240	10	0170	Urine	-1	0	10.9	1	OK	
05113200001241	10	0170	Urine	0	1	7.73	1	OK	
05113200001242	10	0170	Urine	1	2	5.79	1	OK	
05113200001243	10	0170	Urine	2	3	5.04	1	OK	
05113200001244	10	0170	Urine	3	4	4.33	1	OK	
05113200001245	10	0170	Urine	4	5	3.64	1	OK	
05113200001246	10	0170	Urine	5	6	5.69	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001254	10	0177	Urine	-1	0	1.10	1	OK	
05113200001255	10	0177	Urine	0	1	1.73	1	OK	
05113200001256	10	0177	Urine	1	2	1.18	1	OK	
05113200001257	10	0177	Urine	2	3	0.938	1	OK	
05113200001258	10	0177	Urine	3	4	1.11	1	OK	
05113200001259	10	0177	Urine	4	5	0.890	1	OK	
05113200001260	10	0177	Urine	5	6	2.21	1	OK	
05113200001366	18	0181	Urine	-1	0	4.36	1	OK	
05113200001367	18	0181	Urine	0	1	5.79	1	OK	
05113200001368	18	0181	Urine	1	2	3.36	1	OK	
05113200001369	18	0181	Urine	2	3	1.48	1	OK	
05113200001370	18	0181	Urine	3	4	2.52	1	OK	
05113200001371	18	0181	Urine	4	5	2.14	1	OK	
05113200001372	18	0181	Urine	5	6	2.79	1	OK	
05113200001268	10	0183	Urine	-1	0	6.20	1	OK	
05113200001269	10	0183	Urine	0	1	4.90	1	OK	
05113200001270	10	0183	Urine	1	2	2.49	1	OK	
05113200001271	10	0183	Urine	2	3	2.74	1	OK	
05113200001272	10	0183	Urine	3	4	2.13	1	OK	
05113200001273	10	0183	Urine	4	5	2.03	1	OK	
05113200001274	10	0183	Urine	5	6	2.66	1	OK	
05113200001282	10	0185	Urine	-1	0	3.63	1	OK	
05113200001283	10	0185	Urine	0	1	1.86	1	OK	
05113200001284	10	0185	Urine	1	2	1.85	1	OK	
05113200001285	10	0185	Urine	2	3	1.47	1	OK	
05113200001286	10	0185	Urine	3	4	1.77	1	OK	
05113200001287	10	0185	Urine	4	5	1.91	1	OK	
05113200001288	10	0185	Urine	5	6	2.27	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001296	10	0187	Urine	-1	0	6.48	1	OK	
05113200001297	10	0187	Urine	0	1	7.51	1	OK	
05113200001298	10	0187	Urine	1	2	4.15	1	OK	
05113200001299	10	0187	Urine	2	3	5.59	1	OK	
05113200001300	10	0187	Urine	3	4	7.81	1	OK	
05113200001301	10	0187	Urine	4	5	6.99	1	OK	
05113200001302	10	0187	Urine	5	6	4.33	1	OK	
05113200001352	18	0189	Urine	-1	0	1.90	1	OK	
05113200001353	18	0189	Urine	0	1	2.05	1	OK	
05113200001354	18	0189	Urine	1	2	1.74	1	OK	
05113200001355	18	0189	Urine	2	3	1.47	1	OK	
05113200001356	18	0189	Urine	3	4	1.44	1	OK	
05113200001357	18	0189	Urine	4	5	2.26	1	OK	
05113200001358	18	0189	Urine	5	6	3.67	1	OK	
05113200001310	10	0190	Urine	-1	0	5.77	1	OK	
05113200001311	10	0190	Urine	0	1	6.44	1	OK	
05113200001312	10	0190	Urine	1	2	4.19	1	OK	
05113200001313	10	0190	Urine	2	3	3.20	1	OK	
05113200001314	10	0190	Urine	3	4	2.84	1	OK	
05113200001315	10	0190	Urine	4	5	3.33	1	OK	
05113200001316	10	0190	Urine	5	6	5.11	1	OK	
05113200001324	10	0191	Urine	-1	0	2.67	1	OK	
05113200001325	10	0191	Urine	0	1	2.73	1	OK	
05113200001326	10	0191	Urine	1	2	3.11	1	OK	
05113200001327	10	0191	Urine	2	3	2.61	1	OK	
05113200001328	10	0191	Urine	3	4	2.82	1	OK	
05113200001329	10	0191	Urine	4	5	2.71	1	OK	
05113200001330	10	0191	Urine	5	6	1.81	1	OK	





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001338	10	0192	Urine	-1	0	6.28	1	OK	
05113200001339	10	0192	Urine	0	1	8.06	1	OK	
05113200001340	10	0192	Urine	1	2	3.40	1	OK	
05113200001341	10	0192	Urine	2	3	3.40	1	OK	
05113200001342	10	0192	Urine	3	4	4.49	1	OK	
05113200001343	10	0192	Urine	4	5	4.12	1	OK	
05113200001344	10	0192	Urine	5	6	8.03	1	OK	
05113200001380	18	0193	Urine	-1	0	3.08	1	OK	
05113200001381	18	0193	Urine	0	1	5.12	1	OK	
05113200001382	18	0193	Urine	1	2	2.27	1	OK	
05113200001383	18	0193	Urine	2	3	1.67	1	OK	
05113200001384	18	0193	Urine	3	4	2.08	1	OK	
05113200001385	18	0193	Urine	4	5	1.92	1	OK	
05113200001386	18	0193	Urine	5	6	1.37	1	OK	
05113200001394	18	0195	Urine	-1	0	2.05	1	OK	
05113200001395	18	0195	Urine	0	1	2.98	1	OK	
05113200001396	18	0195	Urine	1	2	2.35	1	OK	
05113200001397	18	0195	Urine	2	3	1.91	1	OK	
05113200001398	18	0195	Urine	3	4	2.05	1	OK	
05113200001399	18	0195	Urine	4	5	2.09	1	OK	
05113200001400	18	0195	Urine	5	6	0.416	1	OK	
05113200001408	18	0196	Urine	-1	0	3.57	1	OK	
05113200001409	18	0196	Urine	0	1	3.53	1	OK	
05113200001410	18	0196	Urine	1	2	3.29	1	OK	
05113200001411	18	0196	Urine	2	3	1.86	1	OK	
05113200001412	18	0196	Urine	3	4	2.85	1	OK	
05113200001413	18	0196	Urine	4	5	3.39	1	OK	
05113200001414	18	0196	Urine	5	6	1.36	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001422	18	0197	Urine	-1	0	2.06	1	OK	
05113200001423	18	0197	Urine	0	1	4.59	1	OK	
05113200001424	18	0197	Urine	1	2	2.88	1	OK	
05113200001425	18	0197	Urine	2	3	2.12	1	OK	
05113200001426	18	0197	Urine	3	4	1.78	1	OK	
05113200001427	18	0197	Urine	4	5	2.14	1	OK	
05113200001428	18	0197	Urine	5	6	2.10	1	OK	
05113200001436	18	0198	Urine	-1	0	4.59	1	OK	
05113200001437	18	0198	Urine	0	1	13.4	1	OK	
05113200001438	18	0198	Urine	1	2	8.41	1	OK	
05113200001439	18	0198	Urine	2	3	10.8	1	OK	
05113200001440	18	0198	Urine	3	4	9.33	1	OK	
05113200001441	18	0198	Urine	4	5	10.6	1	OK	
05113200001442	18	0198	Urine	5	6	6.65	1	OK	
05113200001450	18	0200	Urine	-1	0	3.04	1	OK	
05113200001451	18	0200	Urine	0	1	5.17	1	OK	
05113200001452	18	0200	Urine	1	2	3.33	1	OK	
05113200001453	18	0200	Urine	2	3	3.17	1	OK	
05113200001454	18	0200	Urine	3	4	3.88	1	OK	
05113200001455	18	0200	Urine	4	5	4.78	1	OK	
05113200001456	18	0200	Urine	5	6	1.80	1	OK	
05113200001464	18	0202	Urine	-1	0	2.21	1	OK	
05113200001465	18	0202	Urine	0	1	4.30	1	OK	
05113200001466	18	0202	Urine	1	2	4.16	1	OK	
05113200001467	18	0202	Urine	2	3	3.50	1	OK	
05113200001468	18	0202	Urine	3	4	3.28	1	OK	
05113200001469	18	0202	Urine	4	5	2.88	1	OK	
05113200001470	18	0202	Urine	5	6	1.44	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001478	18	0203	Urine	-1	0	9.05	1	OK	
05113200001479	18	0203	Urine	0	1	9.10	1	OK	
05113200001480	18	0203	Urine	1	2	5.48	1	OK	
05113200001481	18	0203	Urine	2	3	4.47	1	OK	
05113200001482	18	0203	Urine	3	4	4.61	1	OK	
05113200001483	18	0203	Urine	4	5	4.85	1	OK	
05113200001484	18	0203	Urine	5	6	4.91	1	OK	
05113200001492	22	0204	Urine	-1	0	1.77	1	OK	
05113200001493	22	0204	Urine	0	1	2.47	1	OK	
05113200001494	22	0204	Urine	1	2	1.90	1	OK	
05113200001495	22	0204	Urine	2	3	1.68	1	OK	
05113200001496	22	0204	Urine	3	4	2.11	1	OK	
05113200001497	22	0204	Urine	4	5	1.80	1	OK	
05113200001498	22	0204	Urine	5	6	2.08	1	OK	
05113200001506	22	0206	Urine	-1	0	2.10	1	OK	
05113200001507	22	0206	Urine	0	1	6.57	1	OK	
05113200001508	22	0206	Urine	1	2	3.98	1	OK	
05113200001509	22	0206	Urine	2	3	3.56	1	OK	
05113200001510	22	0206	Urine	3	4	3.32	1	OK	
05113200001511	22	0206	Urine	4	5	3.47	1	OK	
05113200001512	22	0206	Urine	5	6	2.35	1	OK	
05113200001520	22	0210	Urine	-1	0	3.08	1	OK	
05113200001521	22	0210	Urine	0	1	3.56	1	OK	
05113200001522	22	0210	Urine	1	2	3.00	1	OK	
05113200001523	22	0210	Urine	2	3	2.54	1	OK	
05113200001524	22	0210	Urine	3	4	3.13	1	OK	
05113200001525	22	0210	Urine	4	5	3.84	1	OK	
05113200001526	22	0210	Urine	5	6	2.95	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001548	22	0216	Urine	-1	0	4.38	1	OK	
05113200001549	22	0216	Urine	0	1	6.63	1	OK	
05113200001550	22	0216	Urine	1	2	4.53	1	OK	
05113200001551	22	0216	Urine	2	3	3.38	1	OK	
05113200001552	22	0216	Urine	3	4	5.31	1	OK	
05113200001553	22	0216	Urine	4	5	4.72	1	OK	
05113200001554	22	0216	Urine	5	6	2.10	1	OK	
05113200001562	22	0218	Urine	-1	0	3.33	1	OK	
05113200001563	22	0218	Urine	0	1	11.2	1	OK	
05113200001564	22	0218	Urine	1	2	4.15	1	OK	
05113200001565	22	0218	Urine	2	3	5.43	1	OK	
05113200001566	22	0218	Urine	3	4	6.41	1	OK	
05113200001567	22	0218	Urine	4	5	5.94	1	OK	
05113200001568	22	0218	Urine	5	6	6.85	1	OK	
05113200001576	22	0220	Urine	-1	0	8.54	1	OK	
05113200001577	22	0220	Urine	0	1	11.1	1	OK	
05113200001578	22	0220	Urine	1	2	5.34	1	OK	
05113200001579	22	0220	Urine	2	3	6.58	1	OK	
05113200001580	22	0220	Urine	3	4	7.15	1	OK	
05113200001581	22	0220	Urine	4	5	5.07	1	OK	
05113200001582	22	0220	Urine	5	6	1.66	1	OK	
05113200001590	22	0224	Urine	-1	0	4.21	1	OK	
05113200001591	22	0224	Urine	0	1	8.37	1	OK	
05113200001592	22	0224	Urine	1	2	4.05	1	OK	
05113200001593	22	0224	Urine	2	3	2.79	1	OK	
05113200001594	22	0224	Urine	3	4	4.88	1	OK	
05113200001595	22	0224	Urine	4	5	3.95	1	OK	
05113200001596	22	0224	Urine	5	6	2.82	1	OK	





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001604	22	0228	Urine	-1	0	4.24	1	OK	
05113200001605	22	0228	Urine	0	1	10.3	1	OK	
05113200001606	22	0228	Urine	1	2	5.61	1	OK	
05113200001607	22	0228	Urine	2	3	2.54	1	OK	
05113200001608	22	0228	Urine	3	4	4.86	1	OK	
05113200001609	22	0228	Urine	4	5	3.26	1	OK	
05113200001610	22	0228	Urine	5	6	5.06	1	OK	
05113200001618	22	0229	Urine	-1	0	7.77	1	OK	
05113200001619	22	0229	Urine	0	1	6.52	1	OK	
05113200001620	22	0229	Urine	1	2	10.7	1	OK	
05113200001621	22	0229	Urine	2	3	6.08	1	OK	
05113200001622	22	0229	Urine	3	4	8.98	1	OK	
05113200001623	22	0229	Urine	4	5	3.64	1	OK	
05113200001624	22	0229	Urine	5	6	5.82	1	OK	
05113200001632	22	0230	Urine	-1	0	1.22	1	OK	
05113200001633	22	0230	Urine	0	1	4.87	1	OK	
05113200001634	22	0230	Urine	1	2	2.50	1	OK	
05113200001635	22	0230	Urine	2	3	1.85	1	OK	
05113200001636	22	0230	Urine	3	4	1.92	1	OK	
05113200001637	22	0230	Urine	4	5	2.26	1	OK	
05113200001638	22	0230	Urine	5	6	1.45	1	OK	
05113200001646	20	0232	Urine	-1	0	3.33	1	OK	
05113200001647	20	0232	Urine	0	1	3.78	1	OK	
05113200001648	20	0232	Urine	1	2	1.76	1	OK	
05113200001649	20	0232	Urine	2	3	1.31	1	OK	
05113200001650	20	0232	Urine	3	4	1.83	1	OK	
05113200001651	20	0232	Urine	4	5	1.84	1	OK	
05113200001652	20	0232	Urine	5	6	0.710	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001660	20	0234	Urine	-1	0	3.86	1	OK	
05113200001661	20	0234	Urine	0	1	8.04	1	OK	
05113200001662	20	0234	Urine	1	2	4.85	1	OK	
05113200001663	20	0234	Urine	2	3	3.34	1	OK	
05113200001664	20	0234	Urine	3	4	4.71	1	OK	
05113200001665	20	0234	Urine	4	5	4.16	1	OK	
05113200001666	20	0234	Urine	5	6	4.84	1	OK	
05113200001674	20	0240	Urine	-1	0	2.91	1	OK	
05113200001675	20	0240	Urine	0	1	2.95	1	OK	
05113200001676	20	0240	Urine	1	2	1.66	1	OK	
05113200001677	20	0240	Urine	2	3	1.26	1	OK	
05113200001678	20	0240	Urine	3	4	1.71	1	OK	
05113200001679	20	0240	Urine	4	5	2.11	1	OK	
05113200001680	20	0240	Urine	5	6	1.97	1	OK	
05113200001688	20	0241	Urine	-1	0	6.45	1	OK	
05113200001689	20	0241	Urine	0	1	10.0	1	OK	
05113200001690	20	0241	Urine	1	2	5.35	1	OK	
05113200001691	20	0241	Urine	2	3	7.89	1	OK	
05113200001692	20	0241	Urine	3	4	3.64	1	OK	
05113200001693	20	0241	Urine	4	5	6.64	1	OK	
05113200001694	20	0241	Urine	5	6	4.06	1	OK	
05113200001716	20	0244	Urine	-1	0	3.16	1	OK	
05113200001717	20	0244	Urine	0	1	4.74	1	OK	
05113200001718	20	0244	Urine	1	2	2.93	1	OK	
05113200001719	20	0244	Urine	2	3	2.85	1	OK	
05113200001720	20	0244	Urine	3	4	2.55	1	OK	
05113200001721	20	0244	Urine	4	5	3.18	1	OK	
05113200001722	20	0244	Urine	5	6	2.51	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001758	20	0249	Urine	-1	0	3.61	1	OK	
05113200001759	20	0249	Urine	0	1	3.88	1	OK	
05113200001760	20	0249	Urine	1	2	2.24	1	OK	
05113200001761	20	0249	Urine	2	3	1.95	1	OK	
05113200001762	20	0249	Urine	3	4	4.04	1	OK	
05113200001763	20	0249	Urine	4	5	2.17	1	OK	
05113200001764	20	0249	Urine	5	6	2.87	1	OK	
05113200001772	20	0251	Urine	-1	0	3.00	1	OK	
05113200001773	20	0251	Urine	0	1	3.26	1	OK	
05113200001774	20	0251	Urine	1	2	3.60	1	OK	
05113200001775	20	0251	Urine	2	3	2.97	1	OK	
05113200001776	20	0251	Urine	3	4	2.85	1	OK	
05113200001777	20	0251	Urine	4	5	3.76	1	OK	
05113200001778	20	0251	Urine	5	6	4.17	1	OK	
05113200001786	20	0252	Urine	-1	0	4.33	1	OK	
05113200001787	20	0252	Urine	0	1	6.02	1	OK	
05113200001788	20	0252	Urine	1	2	3.46	1	OK	
05113200001789	20	0252	Urine	2	3	4.08	1	OK	
05113200001790	20	0252	Urine	3	4	3.47	1	OK	
05113200001791	20	0252	Urine	4	5	4.00	1	OK	
05113200001792	20	0252	Urine	5	6	4.64	1	OK	
05113200001856	20	0255	Urine	-1	0	3.87	1	OK	
05113200001857	20	0255	Urine	0	1	6.16	1	OK	
05113200001858	20	0255	Urine	1	2	3.60	1	OK	
05113200001859	20	0255	Urine	2	3	4.21	1	OK	
05113200001860	20	0255	Urine	3	4	4.06	1	OK	
05113200001861	20	0255	Urine	4	5	5.54	1	OK	
05113200001862	20	0255	Urine	5	6	5.43	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001800	20	0256	Urine	-1	0	4.34	1	OK	
05113200001801	20	0256	Urine	0	1	9.89	1	OK	
05113200001802	20	0256	Urine	1	2	6.23	1	OK	
05113200001803	20	0256	Urine	2	3	5.24	1	OK	
05113200001804	20	0256	Urine	3	4	7.93	1	OK	
05113200001805	20	0256	Urine	4	5	6.39	1	OK	
05113200001806	20	0256	Urine	5	6	13.1	1	OK	
05113200001814	21	0262	Urine	-1	0	3.08	1	OK	
05113200001815	21	0262	Urine	0	1	6.02	1	OK	
05113200001816	21	0262	Urine	1	2	3.66	1	OK	
05113200001817	21	0262	Urine	2	3	2.82	1	OK	
05113200001818	21	0262	Urine	3	4	3.98	1	OK	
05113200001819	21	0262	Urine	4	5	4.74	1	OK	
05113200001820	21	0262	Urine	5	6	2.42	1	OK	
05113200001828	21	0264	Urine	-1	0	2.14	1	OK	
05113200001829	21	0264	Urine	0	1	5.44	1	OK	
05113200001830	21	0264	Urine	1	2	5.12	1	OK	
05113200001831	21	0264	Urine	2	3	2.94	1	OK	
05113200001832	21	0264	Urine	3	4	4.73	1	OK	
05113200001833	21	0264	Urine	4	5	3.09	1	OK	
05113200001834	21	0264	Urine	5	6	3.41	1	OK	
05113200001842	21	0265	Urine	-1	0	2.64	1	OK	
05113200001843	21	0265	Urine	0	1	8.20	1	OK	
05113200001844	21	0265	Urine	1	2	7.19	1	OK	
05113200001845	21	0265	Urine	2	3	4.11	1	OK	
05113200001846	21	0265	Urine	3	4	4.84	1	OK	
05113200001847	21	0265	Urine	4	5	4.39	1	OK	
05113200001848	21	0265	Urine	5	6	6.66	1	OK	





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001870	21	0266	Urine	-1	0	2.46	1	OK	
05113200001871	21	0266	Urine	0	1	4.13	1	OK	
05113200001872	21	0266	Urine	1	2	2.44	1	OK	
05113200001873	21	0266	Urine	2	3	1.75	1	OK	
05113200001874	21	0266	Urine	3	4	1.70	1	OK	
05113200001875	21	0266	Urine	4	5	1.93	1	OK	
05113200001876	21	0266	Urine	5	6	2.23	1	OK	
05113200001898	23	0272	Urine	-1	0	6.96	1	OK	
05113200001899	23	0272	Urine	0	1	10.9	1	OK	
05113200001900	23	0272	Urine	1	2	7.19	1	OK	
05113200001901	23	0272	Urine	2	3	10.1	1	OK	
05113200001902	23	0272	Urine	3	4	15.7	1	OK	
05113200001903	23	0272	Urine	4	5	6.83	1	OK	
05113200001904	23	0272	Urine	5	6	11.5	1	OK	
05113200001912	23	0273	Urine	-1	0	4.71	1	OK	
05113200001913	23	0273	Urine	0	1	2.88	1	OK	
05113200001914	23	0273	Urine	1	2	2.63	1	OK	
05113200001915	23	0273	Urine	2	3	2.63	1	OK	
05113200001916	23	0273	Urine	3	4	4.18	1	OK	
05113200001917	23	0273	Urine	4	5	1.80	1	OK	
05113200001918	23	0273	Urine	5	6	3.37	1	OK	
05113200001926	23	0276	Urine	-1	0	2.31	1	OK	
05113200001927	23	0276	Urine	0	1	5.38	1	OK	
05113200001928	23	0276	Urine	1	2	4.84	1	OK	
05113200001929	23	0276	Urine	2	3	2.74	1	OK	
05113200001930	23	0276	Urine	3	4	4.50	1	OK	
05113200001931	23	0276	Urine	4	5	4.29	1	OK	
05113200001932	23	0276	Urine	5	6	3.57	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001940	23	0277	Urine	-1	0	1.67	1	OK	
05113200001941	23	0277	Urine	0	1	2.95	1	OK	
05113200001942	23	0277	Urine	1	2	4.58	1	OK	
05113200001943	23	0277	Urine	2	3	3.46	1	OK	
05113200001944	23	0277	Urine	3	4	4.60	1	OK	
05113200001945	23	0277	Urine	4	5	1.90	1	OK	
05113200001946	23	0277	Urine	5	6	1.62	1	OK	
05113200001954	23	0278	Urine	-1	0	1.75	1	OK	
05113200001955	23	0278	Urine	0	1	2.23	1	OK	
05113200001956	23	0278	Urine	1	2	3.80	1	OK	
05113200001957	23	0278	Urine	2	3	2.05	1	OK	
05113200001958	23	0278	Urine	3	4	3.27	1	OK	
05113200001959	23	0278	Urine	4	5	1.37	1	OK	
05113200001960	23	0278	Urine	5	6	1.72	1	OK	
05113200001968	23	0279	Urine	-1	0	10.7	1	OK	
05113200001969	23	0279	Urine	0	1	7.36	1	OK	
05113200001970	23	0279	Urine	1	2	7.72	1	OK	
05113200001971	23	0279	Urine	2	3	3.95	1	OK	
05113200001972	23	0279	Urine	3	4	9.46	1	OK	
05113200001973	23	0279	Urine	4	5	4.53	1	OK	
05113200001974	23	0279	Urine	5	6	5.30	1	OK	
05113200001982	23	0281	Urine	-1	0	5.85	1	OK	
05113200001983	23	0281	Urine	0	1	5.21	1	OK	
05113200001984	23	0281	Urine	1	2	6.85	1	OK	
05113200001985	23	0281	Urine	2	3	4.28	1	OK	
05113200001986	23	0281	Urine	3	4	7.73	1	OK	
05113200001987	23	0281	Urine	4	5	3.61	1	OK	
05113200001988	23	0281	Urine	5	6	5.94	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001996	23	0282	Urine	-1	0	2.14	1	OK	
05113200001997	23	0282	Urine	0	1	2.92	1	OK	
05113200001998	23	0282	Urine	1	2	2.08	1	OK	
05113200001999	23	0282	Urine	2	3	1.86	1	OK	
05113200002000	23	0282	Urine	3	4	2.32	1	OK	
05113200002001	23	0282	Urine	4	5	1.35	1	OK	
05113200002002	23	0282	Urine	5	6	1.05	1	OK	
05113200002010	23	0283	Urine	-1	0	2.12	1	OK	
05113200002011	23	0283	Urine	0	1	2.47	1	OK	
05113200002012	23	0283	Urine	1	2	2.56	1	OK	
05113200002013	23	0283	Urine	2	3	1.58	1	OK	
05113200002014	23	0283	Urine	3	4	2.26	1	OK	
05113200002015	23	0283	Urine	4	5	1.69	1	OK	
05113200002016	23	0283	Urine	5	6	1.06	1	OK	
05113200002024	23	0285	Urine	-1	0	1.99	1	OK	
05113200002025	23	0285	Urine	0	1	8.04	1	OK	
05113200002026	23	0285	Urine	1	2	4.93	1	OK	
05113200002027	23	0285	Urine	2	3	4.03	1	OK	
05113200002028	23	0285	Urine	3	4	5.83	1	OK	
05113200002029	23	0285	Urine	4	5	1.80	1	OK	
05113200002030	23	0285	Urine	5	6	3.13	1	OK	
05113200002038	24	0287	Urine	-1	0	2.93	1	OK	
05113200002039	24	0287	Urine	0	1	3.89	1	OK	
05113200002040	24	0287	Urine	1	2	4.56	1	OK	
05113200002041	24	0287	Urine	2	3	1.97	1	OK	
05113200002042	24	0287	Urine	3	4	4.22	1	OK	
05113200002043	24	0287	Urine	4	5	2.76	1	OK	
05113200002044	24	0287	Urine	5	6	2.79	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200002066	24	0289	Urine	-1	0	5.12	1	OK	
05113200002067	24	0289	Urine	0	1	4.79	1	OK	
05113200002068	24	0289	Urine	1	2	5.78	1	OK	
05113200002069	24	0289	Urine	2	3	4.21	1	OK	
05113200002070	24	0289	Urine	3	4	4.63	1	OK	
05113200002071	24	0289	Urine	4	5	2.82	1	OK	
05113200002072	24	0289	Urine	5	6	4.14	1	OK	
05113200002080	24	0291	Urine	-1	0	4.93	1	OK	
05113200002081	24	0291	Urine	0	1	6.11	1	OK	
05113200002082	24	0291	Urine	1	2	4.41	1	OK	
05113200002083	24	0291	Urine	2	3	3.94	1	OK	
05113200002084	24	0291	Urine	3	4	5.14	1	OK	
05113200002085	24	0291	Urine	4	5	4.83	1	OK	
05113200002086	24	0291	Urine	5	6	3.31	1	OK	
05113200002094	24	0292	Urine	-1	0	4.92	1	OK	
05113200002095	24	0292	Urine	0	1	8.97	1	OK	
05113200002096	24	0292	Urine	1	2	14.8	1	OK	
05113200002097	24	0292	Urine	2	3	8.68	1	OK	
05113200002098	24	0292	Urine	3	4	10.2	1	OK	
05113200002099	24	0292	Urine	4	5	3.90	1	OK	
05113200002100	24	0292	Urine	5	6	6.26	1	OK	
05113200002108	24	0296	Urine	-1	0	4.37	1	OK	
05113200002109	24	0296	Urine	0	1	6.36	1	OK	
05113200002110	24	0296	Urine	1	2	5.52	1	OK	
05113200002111	24	0296	Urine	2	3	6.14	1	OK	
05113200002112	24	0296	Urine	3	4	7.93	1	OK	
05113200002113	24	0296	Urine	4	5	7.11	1	OK	
05113200002114	24	0296	Urine	5	6	9.42	1	OK	





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200002122	24	0298	Urine	-1	0	7.09	1	OK	
05113200002123	24	0298	Urine	0	1	9.31	1	OK	
05113200002124	24	0298	Urine	1	2	13.3	1	OK	
05113200002125	24	0298	Urine	2	3	7.67	1	OK	
05113200002126	24	0298	Urine	3	4	9.09	1	OK	
05113200002127	24	0298	Urine	4	5	3.68	1	OK	
05113200002128	24	0298	Urine	5	6	10.3	1	OK	
05113200002150	24	0300	Urine	-1	0	10.2	1	OK	
05113200002151	24	0300	Urine	0	1	8.38	1	OK	
05113200002152	24	0300	Urine	1	2	6.52	1	OK	
05113200002153	24	0300	Urine	2	3	3.85	1	OK	
05113200002154	24	0300	Urine	3	4	5.62	1	OK	
05113200002155	24	0300	Urine	4	5	3.68	1	OK	
05113200002156	24	0300	Urine	5	6	3.36	1	OK	
05113200002164	24	0301	Urine	-1	0	3.41	1	OK	
05113200002165	24	0301	Urine	0	1	5.90	1	OK	
05113200002166	24	0301	Urine	1	2	3.39	1	OK	
05113200002167	24	0301	Urine	2	3	3.06	1	OK	
05113200002168	24	0301	Urine	3	4	6.43	1	OK	
05113200002169	24	0301	Urine	4	5	4.74	1	OK	
05113200002170	24	0301	Urine	5	6	2.93	1	OK	
05113200002178	24	0306	Urine	-1	0	5.47	1	OK	
05113200002179	24	0306	Urine	0	1	12.1	1	OK	
05113200002180	24	0306	Urine	1	2	9.11	1	OK	
05113200002181	24	0306	Urine	2	3	4.80	1	OK	
05113200002182	24	0306	Urine	3	4	8.57	1	OK	
05113200002183	24	0306	Urine	4	5	5.52	1	OK	
05113200002184	24	0306	Urine	5	6	12.1	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200002192	24	0307	Urine	-1	0	2.92	1	OK	
05113200002193	24	0307	Urine	0	1	5.94	1	OK	
05113200002194	24	0307	Urine	1	2	5.47	1	OK	
05113200002195	24	0307	Urine	2	3	3.89	1	OK	
05113200002196	24	0307	Urine	3	4	6.61	1	OK	
05113200002197	24	0307	Urine	4	5	3.58	1	OK	
05113200002198	24	0307	Urine	5	6	2.50	1	OK	
05113200002206	25	0308	Urine	-1	0	3.37	1	OK	
05113200002207	25	0308	Urine	0	1	6.81	1	OK	
05113200002208	25	0308	Urine	1	2	5.46	1	OK	
05113200002209	25	0308	Urine	2	3	3.33	1	OK	
05113200002210	25	0308	Urine	3	4	7.85	1	OK	
05113200002211	25	0308	Urine	4	5	3.53	1	OK	
05113200002212	25	0308	Urine	5	6	5.23	1	OK	
05113200002248	25	0313	Urine	-1	0	3.41	1	OK	
05113200002249	25	0313	Urine	0	1	5.80	1	OK	
05113200002250	25	0313	Urine	1	2	5.65	1	OK	
05113200002251	25	0313	Urine	2	3	2.89	1	OK	
05113200002252	25	0313	Urine	3	4	4.90	1	OK	
05113200002253	25	0313	Urine	4	5	3.72	1	OK	
05113200002254	25	0313	Urine	5	6	5.09	1	OK	
05113200002262	25	0315	Urine	-1	0	4.85	1	OK	
05113200002263	25	0315	Urine	0	1	4.98	1	OK	
05113200002264	25	0315	Urine	1	2	2.99	1	OK	
05113200002265	25	0315	Urine	2	3	2.74	1	OK	
05113200002266	25	0315	Urine	3	4	4.16	1	OK	
05113200002267	25	0315	Urine	4	5	1.72	1	OK	
05113200002268	25	0315	Urine	5	6	2.33	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200002276	25	0316	Urine	-1	0	2.74	1	OK	
05113200002277	25	0316	Urine	0	1	3.04	1	OK	
05113200002278	25	0316	Urine	1	2	4.32	1	OK	
05113200002279	25	0316	Urine	2	3	2.64	1	OK	
05113200002280	25	0316	Urine	3	4	3.34	1	OK	
05113200002281	25	0316	Urine	4	5	1.73	1	OK	
05113200002282	25	0316	Urine	5	6	1.76	1	OK	
05113200002290	25	0317	Urine	-1	0	3.99	1	OK	
05113200002291	25	0317	Urine	0	1	3.53	1	OK	
05113200002292	25	0317	Urine	1	2	5.14	1	OK	
05113200002293	25	0317	Urine	2	3	3.54	1	OK	
05113200002294	25	0317	Urine	3	4	3.68	1	OK	
05113200002295	25	0317	Urine	4	5	2.76	1	OK	
05113200002296	25	0317	Urine	5	6	3.68	1	OK	
05113200002304	25	0318	Urine	-1	0	3.10	1	OK	
05113200002305	25	0318	Urine	0	1	2.87	1	OK	
05113200002306	25	0318	Urine	1	2	4.71	1	OK	
05113200002307	25	0318	Urine	2	3	3.46	1	OK	
05113200002308	25	0318	Urine	3	4	5.02	1	OK	
05113200002309	25	0318	Urine	4	5	4.23	1	OK	
05113200002310	25	0318	Urine	5	6	18.5	1	OK	
05113200002318	25	0320	Urine	-1	0	4.86	1	OK	
05113200002319	25	0320	Urine	0	1	7.19	1	OK	
05113200002320	25	0320	Urine	1	2	5.31	1	OK	
05113200002321	25	0320	Urine	2	3	5.63	1	OK	
05113200002322	25	0320	Urine	3	4	9.59	1	OK	
05113200002323	25	0320	Urine	4	5	5.49	1	OK	
05113200002324	25	0320	Urine	5	6	5.39	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200002332	25	0321	Urine	-1	0	2.34	1	OK	
05113200002333	25	0321	Urine	0	1	3.61	1	OK	
05113200002334	25	0321	Urine	1	2	2.76	1	OK	
05113200002335	25	0321	Urine	2	3	2.74	1	OK	
05113200002336	25	0321	Urine	3	4	4.05	1	OK	
05113200002337	25	0321	Urine	4	5	3.06	1	OK	
05113200002338	25	0321	Urine	5	6	6.50	1	OK	
05113200002346	25	0322	Urine	-1	0	1.84	1	OK	
05113200002347	25	0322	Urine	0	1	5.13	1	OK	
05113200002348	25	0322	Urine	1	2	2.44	1	OK	
05113200002349	25	0322	Urine	2	3	1.30	1	OK	
05113200002350	25	0322	Urine	3	4	1.88	1	OK	
05113200002351	25	0322	Urine	4	5	1.25	1	OK	
05113200002352	25	0322	Urine	5	6	1.17	1	OK	
05113200002360	25	0325	Urine	-1	0	6.25	1	OK	
05113200002361	25	0325	Urine	0	1	5.66	1	OK	
05113200002362	25	0325	Urine	1	2	12.8	1	OK	
05113200002363	25	0325	Urine	2	3	6.22	1	OK	
05113200002364	25	0325	Urine	3	4	11.0	1	OK	
05113200002365	25	0325	Urine	4	5	4.35	1	OK	
05113200002366	25	0325	Urine	5	6	4.46	1	OK	
05113200002374	26	0328	Urine	-1	0	4.28	1	OK	
05113200002375	26	0328	Urine	0	1	5.45	1	OK	
05113200002376	26	0328	Urine	1	2	3.81	1	OK	
05113200002377	26	0328	Urine	2	3	3.00	1	OK	
05113200002378	26	0328	Urine	3	4	3.37	1	OK	
05113200002379	26	0328	Urine	4	5	2.02	1	OK	
05113200002380	26	0328	Urine	5	6	1.82	1	OK	





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Table 9 Study Sample Concentrations for SPMA

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000414	1	0001	Urine	-1	0	0.392	1	OK	
05113200000415	1	0001	Urine	0	1	0.640	1	OK	
05113200000416	1	0001	Urine	1	2	0.341	1	OK	
05113200000417	1	0001	Urine	2	3	0.162	1	OK	
05113200000418	1	0001	Urine	3	4	0.0637	1	OK	
05113200000419	1	0001	Urine	4	5	0.0430	1	OK	
05113200000420	1	0001	Urine	5	6	0.0528	1	OK	
05113200000428	1	0004	Urine	-1	0	3.31	1	OK	
05113200000429	1	0004	Urine	0	1	3.29	1	OK	
05113200000430	1	0004	Urine	1	2	1.81	1	OK	
05113200000431	1	0004	Urine	2	3	0.541	1	OK	
05113200000432	1	0004	Urine	3	4	0.282	1	OK	
05113200000433	1	0004	Urine	4	5	0.180	1	OK	
05113200000434	1	0004	Urine	5	6	0.0744	1	OK	
05113200000001	15	0008	Urine	-1	0	11.4	1	OK	
05113200000002	1	0008	Urine	0	1	4.59	1	OK	
05113200000003	1	0008	Urine	1	2	1.61	1	OK	
05113200000004	1	0008	Urine	2	3	0.792	1	OK	
05113200000005	1	0008	Urine	3	4	0.781	1	OK	
05113200000006	15	0008	Urine	4	5	0.798	1	OK	Mean of VRC reported
05113200000007	1	0008	Urine	5	6	0.443	1	OK	
05113200000008	1	0010	Urine	-1	0	4.34	1	OK	
05113200000009	1	0010	Urine	0	1	1.66	1	OK	
05113200000010	1	0010	Urine	1	2	1.42	1	OK	
05113200000011	1	0010	Urine	2	3	0.329	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000012	1	0010	Urine	3	4	0.223	1	OK	
05113200000013	1	0010	Urine	4	5	0.211	1	OK	
05113200000014	1	0010	Urine	5	6	0.109	1	OK	
05113200000015	1	0011	Urine	-1	0	0.481	1	OK	
05113200000016	1	0011	Urine	0	1	0.811	1	OK	
05113200000017	1	0011	Urine	1	2	0.385	1	OK	
05113200000018	1	0011	Urine	2	3	0.0781	1	OK	
05113200000019	1	0011	Urine	3	4	0.0647	1	OK	
05113200000020	1	0011	Urine	4	5	0.0534	1	OK	
05113200000021	1	0011	Urine	5	6	0.0827	1	OK	
05113200000442	1	0013	Urine	-1	0	0.962	1	OK	
05113200000443	1	0013	Urine	0	1	1.32	1	OK	
05113200000444	1	0013	Urine	1	2	0.487	1	OK	
05113200000445	15	0013	Urine	2	3	0.198	1	OK	Mean of VRC reported
05113200000446	1	0013	Urine	3	4	0.0672	1	OK	
05113200000447	1	0013	Urine	4	5	0.0320	1	OK	
05113200000448	1	0013	Urine	5	6	0.0602	1	OK	
05113200000022	1	0014	Urine	-1	0	2.11	1	OK	
05113200000023	1	0014	Urine	0	1	3.02	1	OK	
05113200000024	1	0014	Urine	1	2	0.572	1	OK	
05113200000025	1	0014	Urine	2	3	0.177	1	OK	
05113200000026	1	0014	Urine	3	4	0.132	1	OK	
05113200000027	1	0014	Urine	4	5	0.0614	1	OK	
05113200000028	1	0014	Urine	5	6	0.0826	1	OK	
05113200000029	21	0015	Urine	-1	0	3.13	1	OK	
05113200000030	21	0015	Urine	0	1	2.39	1	OK	
05113200000031	21	0015	Urine	1	2	1.22	1	OK	
05113200000032	21	0015	Urine	2	3	0.352	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000033	21	0015	Urine	3	4	0 0785	1	OK	
05113200000034	21	0015	Urine	4	5	0 0585	1	OK	
05113200000035	21	0015	Urine	5	6	0 0679	1	OK	
05113200000036	1	0016	Urine	-1	0	3 37	1	OK	
05113200000037	1	0016	Urine	0	1	0 776	1	OK	
05113200000038	1	0016	Urine	1	2	0 657	1	OK	
05113200000039	1	0016	Urine	2	3	0 213	1	OK	
05113200000040	1	0016	Urine	3	4	0 142	1	OK	
05113200000041	1	0016	Urine	4	5	0 113	1	OK	
05113200000042	1	0016	Urine	5	6	0 0978	1	OK	
05113200000043	1	0017	Urine	-1	0	1 02	1	OK	
05113200000044	1	0017	Urine	0	1	0 761	1	OK	
05113200000045	1	0017	Urine	1	2	0 800	1	OK	
05113200000046	1	0017	Urine	2	3	0 233	1	OK	
05113200000047	1	0017	Urine	3	4	0 0750	1	OK	
05113200000048	1	0017	Urine	4	5	0 0668	1	OK	
05113200000049	1	0017	Urine	5	6	0 0634	1	OK	
05113200000050	1	0020	Urine	-1	0	2 61	1	OK	
05113200000051	1	0020	Urine	0	1	2 55	1	OK	
05113200000052	1	0020	Urine	1	2	0 815	1	OK	
05113200000053	1	0020	Urine	2	3	0 514	1	OK	
05113200000054	1	0020	Urine	3	4	0 282	1	OK	
05113200000055	1	0020	Urine	4	5	0 166	1	OK	
05113200000056	1	0020	Urine	5	6	0 0675	1	OK	
05113200000456	2	0021	Urine	-1	0	3 54	1	OK	
05113200000457	2	0021	Urine	0	1	4 03	1	OK	
05113200000458	2	0021	Urine	1	2	1 39	1	OK	
05113200000459	2	0021	Urine	2	3	4 06	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000460	2	0021	Urine	3	4	0.277	1	OK	
05113200000461	2	0021	Urine	4	5	0.136	1	OK	
05113200000462	2	0021	Urine	5	6	0.131	1	OK	
05113200000057	26	0022	Urine	-1	0	6.10	1	OK	
05113200000058	28	0022	Urine	0	1	6.50	1	OK	
05113200000059	26	0022	Urine	1	2	1.58	1	OK	
05113200000060	26	0022	Urine	2	3	0.505	1	OK	
05113200000061	26	0022	Urine	3	4	0.478	1	OK	
05113200000062	28	0022	Urine	4	5	0.364	1	OK	
05113200000259	26	0022	Urine	5	6	0.222	2	OK	
05113200000064	2	0023	Urine	-1	0	1.12	1	OK	
05113200000065	2	0023	Urine	0	1	1.14	1	OK	
05113200000066	2	0023	Urine	1	2	0.593	1	OK	
05113200000067	2	0023	Urine	2	3	0.219	1	OK	
05113200000068	2	0023	Urine	3	4	0.127	1	OK	
05113200000069	2	0023	Urine	4	5	0.0600	1	OK	
05113200000070	2	0023	Urine	5	6	0.0533	1	OK	
05113200000071	2	0025	Urine	-1	0	1.19	1	OK	
05113200000072	2	0025	Urine	0	1	2.34	1	OK	
05113200000073	2	0025	Urine	1	2	2.49	1	OK	
05113200000074	2	0025	Urine	2	3	2.58	1	OK	
05113200000075	2	0025	Urine	3	4	2.06	1	OK	
05113200000076	2	0025	Urine	4	5	2.01	1	OK	
05113200000077	2	0025	Urine	5	6	1.24	1	OK	
05113200000078	2	0028	Urine	-1	0	3.84	1	OK	
05113200000079	2	0028	Urine	0	1	2.75	1	OK	
05113200000080	2	0028	Urine	1	2	1.65	1	OK	
05113200000081	2	0028	Urine	2	3	0.847	1	OK	





SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000082	2	0028	Urine	3	4	0.248	1	OK	
05113200000083	2	0028	Urine	4	5	0.348	1	OK	
05113200000084	2	0028	Urine	5	6	0.147	1	OK	
05113200000085	2	0029	Urine	-1	0	3.67	1	OK	
05113200000086	2	0029	Urine	0	1	1.29	1	OK	
05113200000087	2	0029	Urine	1	2	1.74	1	OK	
05113200000088	2	0029	Urine	2	3	2.08	1	OK	
05113200000089	2	0029	Urine	3	4	1.29	1	OK	
05113200000090	2	0029	Urine	4	5	1.36	1	OK	
05113200000091	2	0029	Urine	5	6	1.79	1	OK	
05113200000092	2	0030	Urine	-1	0	1.98	1	OK	
05113200000093	2	0030	Urine	0	1	1.36	1	OK	
05113200000094	2	0030	Urine	1	2	0.684	1	OK	
05113200000095	2	0030	Urine	2	3	0.117	1	OK	
05113200000096	2	0030	Urine	3	4	0.0806	1	OK	
05113200000097	2	0030	Urine	4	5	0.105	1	OK	
05113200000098	2	0030	Urine	5	6	0.0615	1	OK	
05113200000099	2	0031	Urine	-1	0	0.768	1	OK	
05113200000100	2	0031	Urine	0	1	1.16	1	OK	
05113200000101	2	0031	Urine	1	2	0.234	1	OK	
05113200000102	2	0031	Urine	2	3	0.101	1	OK	
05113200000103	2	0031	Urine	3	4	0.0755	1	OK	
05113200000104	2	0031	Urine	4	5	0.0271	1	OK	
05113200000105	2	0031	Urine	5	6	0.0393	1	OK	
05113200000106	2	0034	Urine	-1	0	1.07	1	OK	
05113200000107	2	0034	Urine	0	1	0.866	1	OK	
05113200000108	2	0034	Urine	1	2	0.592	1	OK	
05113200000109	2	0034	Urine	2	3	0.121	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000110	2	0034	Urine	3	4	0.127	1	OK	
05113200000111	2	0034	Urine	4	5	0.119	1	OK	
05113200000112	2	0034	Urine	5	6	0.0432	1	OK	
05113200000113	2	0035	Urine	-1	0	2.80	1	OK	
05113200000114	2	0035	Urine	0	1	3.28	1	OK	
05113200000115	2	0035	Urine	1	2	2.29	1	OK	
05113200000116	2	0035	Urine	2	3	1.92	1	OK	
05113200000117	2	0035	Urine	3	4	2.02	1	OK	
05113200000118	2	0035	Urine	4	5	2.60	1	OK	
05113200000119	2	0035	Urine	5	6	3.59	1	OK	
05113200000470	2	0037	Urine	-1	0	3.03	1	OK	
05113200000471	2	0037	Urine	0	1	3.06	1	OK	
05113200000472	2	0037	Urine	1	2	2.62	1	OK	
05113200000473	2	0037	Urine	2	3	1.77	1	OK	
05113200000474	2	0037	Urine	3	4	2.52	1	OK	
05113200000475	2	0037	Urine	4	5	2.63	1	OK	
05113200000476	2	0037	Urine	5	6	2.89	1	OK	
05113200000120	3	0038	Urine	-1	0	4.35	1	OK	
05113200000121	3	0038	Urine	0	1	4.06	1	OK	
05113200000122	3	0038	Urine	1	2	1.56	1	OK	
05113200000123	3	0038	Urine	2	3	0.321	1	OK	
05113200000124	3	0038	Urine	3	4	0.208	1	OK	
05113200000125	3	0038	Urine	4	5	0.146	1	OK	
05113200000126	3	0038	Urine	5	6	0.123	1	OK	
05113200000127	3	0039	Urine	-1	0	0.261	1	OK	
05113200000128	3	0039	Urine	0	1	0.303	1	OK	
05113200000129	3	0039	Urine	1	2	0.175	1	OK	
05113200000130	3	0039	Urine	2	3	0.0693	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000131	3	0039	Urine	3	4	0.0556	1	OK	
05113200000132	3	0039	Urine	4	5	0.0584	1	OK	
05113200000133	3	0039	Urine	5	6	0.0433	1	OK	
05113200000484	3	0042	Urine	-1	0	2.47	1	OK	
05113200000485	3	0042	Urine	0	1	3.18	1	OK	
05113200000486	3	0042	Urine	1	2	2.77	1	OK	
05113200000487	3	0042	Urine	2	3	0.386	1	OK	
05113200000488	3	0042	Urine	3	4	5.19	1	OK	
05113200000489	3	0042	Urine	4	5	2.32	1	OK	
05113200000490	3	0042	Urine	5	6	2.57	1	OK	
05113200000134	3	0044	Urine	-1	0	1.54	1	OK	
05113200000135	3	0044	Urine	0	1	2.26	1	OK	
05113200000136	3	0044	Urine	1	2	1.51	1	OK	
05113200000137	3	0044	Urine	2	3	0.752	1	OK	
05113200000138	3	0044	Urine	3	4	0.337	1	OK	
05113200000139	3	0044	Urine	4	5	0.208	1	OK	
05113200000140	3	0044	Urine	5	6	0.111	1	OK	
05113200000141	3	0049	Urine	-1	0	2.48	1	OK	
05113200000142	3	0049	Urine	0	1	0.832	1	OK	
05113200000143	3	0049	Urine	1	2	1.70	1	OK	
05113200000144	3	0049	Urine	2	3	0.316	1	OK	
05113200000145	3	0049	Urine	3	4	0.150	1	OK	
05113200000146	3	0049	Urine	4	5	0.101	1	OK	
05113200000147	3	0049	Urine	5	6	0.0582	1	OK	
05113200000498	3	0051	Urine	-1	0	0.185	1	OK	
05113200000499	3	0051	Urine	0	1	0.190	1	OK	
05113200000500	3	0051	Urine	1	2	0.0671	1	OK	
05113200000501	3	0051	Urine	2	3	0.0701	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000502	3	0051	Urine	3	4	0.0369	1	OK	
05113200000503	3	0051	Urine	4	5	0.0307	1	OK	
05113200000504	3	0051	Urine	5	6	0.0424	1	OK	
05113200000148	3	0052	Urine	-1	0	0.451	1	OK	
05113200000149	3	0052	Urine	0	1	0.611	1	OK	
05113200000150	3	0052	Urine	1	2	0.186	1	OK	
05113200000151	3	0052	Urine	2	3	0.144	1	OK	
05113200000152	3	0052	Urine	3	4	0.0505	1	OK	
05113200000153	3	0052	Urine	4	5	0.0655	1	OK	
05113200000154	3	0052	Urine	5	6	0.0700	1	OK	
05113200000155	3	0053	Urine	-1	0	4.28	1	OK	
05113200000156	3	0053	Urine	0	1	4.71	1	OK	
05113200000353	11	0053	Urine	1	2	5.06	2	OK	
05113200000158	3	0053	Urine	2	3	3.78	1	OK	
05113200000159	3	0053	Urine	3	4	4.37	1	OK	
05113200000160	3	0053	Urine	4	5	3.45	1	OK	
05113200000161	3	0053	Urine	5	6	4.31	1	OK	
05113200000162	3	0055	Urine	-1	0	1.15	1	OK	
05113200000163	3	0055	Urine	0	1	1.10	1	OK	
05113200000164	3	0055	Urine	1	2	1.12	1	OK	
05113200000165	3	0055	Urine	2	3	1.05	1	OK	
05113200000166	3	0055	Urine	3	4	0.732	1	OK	
05113200000167	3	0055	Urine	4	5	1.06	1	OK	
05113200000168	3	0055	Urine	5	6	1.04	1	OK	
05113200000169	21	0057	Urine	-1	0	0.649	1	OK	
05113200000170	21	0057	Urine	0	1	0.965	1	OK	
05113200000171	21	0057	Urine	1	2	0.362	1	OK	
05113200000172	21	0057	Urine	2	3	0.0868	1	OK	





SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000173	21	0057	Urine	3	4	0.109	1	OK	
05113200000174	21	0057	Urine	4	5	0.0736	1	OK	
05113200000175	21	0057	Urine	5	6	0.0314	1	OK	
05113200000176	3	0060	Urine	-1	0	1.69	1	OK	
05113200000177	3	0060	Urine	0	1	0.747	1	OK	
05113200000178	3	0060	Urine	1	2	0.449	1	OK	
05113200000179	3	0060	Urine	2	3	0.137	1	OK	
05113200000180	3	0060	Urine	3	4	0.111	1	OK	
05113200000181	3	0060	Urine	4	5	0.136	1	OK	
05113200000182	3	0060	Urine	5	6	0.0857	1	OK	
05113200000183	6	0062	Urine	-1	0	0.643	1	OK	
05113200000184	6	0062	Urine	0	1	0.826	1	OK	
05113200000185	6	0062	Urine	1	2	0.344	1	OK	
05113200000186	6	0062	Urine	2	3	0.161	1	OK	
05113200000187	6	0062	Urine	3	4	0.0830	1	OK	
05113200000188	6	0062	Urine	4	5	0.107	1	OK	
05113200000189	6	0062	Urine	5	6	0.0706	1	OK	
05113200000512	7	0063	Urine	-1	0	4.25	1	OK	
05113200000513	7	0063	Urine	0	1	4.45	1	OK	
05113200000514	7	0063	Urine	1	2	2.55	1	OK	
05113200000515	7	0063	Urine	2	3	0.610	1	OK	
05113200000516	7	0063	Urine	3	4	0.442	1	OK	
05113200000517	7	0063	Urine	4	5	0.234	1	OK	
05113200000518	7	0063	Urine	5	6	0.175	1	OK	
05113200000190	7	0064	Urine	-1	0	1.04	1	OK	
05113200000191	7	0064	Urine	0	1	2.01	1	OK	
05113200000192	7	0064	Urine	1	2	0.854	1	OK	
05113200000193	7	0064	Urine	2	3	0.690	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000194	7	0064	Urine	3	4	1.07	1	OK	
05113200000195	7	0064	Urine	4	5	0.899	1	OK	
05113200000196	7	0064	Urine	5	6	1.28	1	OK	
05113200000526	7	0066	Urine	-1	0	1.01	1	OK	
05113200000527	7	0066	Urine	0	1	1.45	1	OK	
05113200000528	7	0066	Urine	1	2	0.438	1	OK	
05113200000529	7	0066	Urine	2	3	0.289	1	OK	
05113200000530	7	0066	Urine	3	4	0.117	1	OK	
05113200000531	7	0066	Urine	4	5	0.0562	1	OK	
05113200000532	7	0066	Urine	5	6	0.0430	1	OK	
05113200000540	7	0067	Urine	-1	0	2.14	1	OK	
05113200000541	7	0067	Urine	0	1	3.18	1	OK	
05113200000542	7	0067	Urine	1	2	2.20	1	OK	
05113200000543	7	0067	Urine	2	3	1.82	1	OK	
05113200000544	7	0067	Urine	3	4	1.64	1	OK	
05113200000545	7	0067	Urine	4	5	1.56	1	OK	
05113200000546	7	0067	Urine	5	6	1.64	1	OK	
05113200000554	7	0069	Urine	-1	0	2.16	1	OK	
05113200000555	7	0069	Urine	0	1	1.26	1	OK	
05113200000556	7	0069	Urine	1	2	0.324	1	OK	
05113200000557	7	0069	Urine	2	3	1.25	1	OK	
05113200000558	7	0069	Urine	3	4	0.177	1	OK	
05113200000559	7	0069	Urine	4	5	0.113	1	OK	
05113200000560	7	0069	Urine	5	6	0.0920	1	OK	
05113200000568	7	0071	Urine	-1	0	1.64	1	OK	
05113200000569	7	0071	Urine	0	1	1.34	1	OK	
05113200000570	7	0071	Urine	1	2	0.675	1	OK	
05113200000571	7	0071	Urine	2	3	0.210	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000572	7	0071	Urine	3	4	0.0826	1	OK	
05113200000573	7	0071	Urine	4	5	0.0572	1	OK	
05113200000574	7	0071	Urine	5	6	0.0934	1	OK	
05113200000582	21	0072	Urine	-1	0	2.57	1	OK	
05113200000583	21	0072	Urine	0	1	1.98	1	OK	
05113200000584	21	0072	Urine	1	2	1.78	1	OK	
05113200000585	21	0072	Urine	2	3	3.14	1	OK	
05113200000586	21	0072	Urine	3	4	4.23	1	OK	
05113200000587	21	0072	Urine	4	5	3.01	1	OK	
05113200000588	21	0072	Urine	5	6	3.08	1	OK	
05113200000596	15	0074	Urine	-1	0	7.32	1	OK	
05113200000597	15	0074	Urine	0	1	6.88	1	OK	
05113200000598	7	0074	Urine	1	2	2.31	1	OK	
05113200000599	7	0074	Urine	2	3	0.804	1	OK	
05113200000600	7	0074	Urine	3	4	0.408	1	OK	
05113200000601	7	0074	Urine	4	5	0.186	1	OK	
05113200000602	7	0074	Urine	5	6	0.149	1	OK	
05113200000610	7	0076	Urine	-1	0	2.04	1	OK	
05113200000611	7	0076	Urine	0	1	1.58	1	OK	
05113200000612	7	0076	Urine	1	2	1.39	1	OK	
05113200000613	7	0076	Urine	2	3	0.337	1	OK	
05113200000614	7	0076	Urine	3	4	0.231	1	OK	
05113200000615	7	0076	Urine	4	5	0.0400	1	OK	
05113200000616	7	0076	Urine	5	6	0.103	1	OK	
05113200000624	7	0080	Urine	-1	0	4.96	1	OK	
05113200000625	7	0080	Urine	0	1	4.17	1	OK	
05113200000626	7	0080	Urine	1	2	4.39	1	OK	
05113200000627	7	0080	Urine	2	3	5.60	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000628	7	0080	Urine	3	4	0.335	1	OK	
05113200000629	7	0080	Urine	4	5	2.87	1	OK	
05113200000630	7	0080	Urine	5	6	3.05	1	OK	
05113200000638	5	0083	Urine	-1	0	2.08	1	OK	
05113200000639	5	0083	Urine	0	1	2.57	1	OK	
05113200000640	5	0083	Urine	1	2	0.887	1	OK	
05113200000641	5	0083	Urine	2	3	0.345	1	OK	
05113200000642	5	0083	Urine	3	4	0.192	1	OK	
05113200000643	5	0083	Urine	4	5	0.0755	1	OK	
05113200000644	5	0083	Urine	5	6	0.0715	1	OK	
05113200000652	21	0085	Urine	-1	0	0.477	1	OK	
05113200000653	21	0085	Urine	0	1	0.578	1	OK	
05113200000654	21	0085	Urine	1	2	0.317	1	OK	
05113200000655	21	0085	Urine	2	3	0.155	1	OK	
05113200000666	5	0086	Urine	-1	0	2.49	1	OK	
05113200000667	5	0086	Urine	0	1	2.30	1	OK	
05113200000668	5	0086	Urine	1	2	1.31	1	OK	
05113200000669	5	0086	Urine	2	3	0.421	1	OK	
05113200000670	5	0086	Urine	3	4	0.272	1	OK	
05113200000671	5	0086	Urine	4	5	0.206	1	OK	
05113200000672	5	0086	Urine	5	6	0.213	1	OK	
05113200000680	5	0087	Urine	-1	0	5.67	1	OK	
05113200000681	5	0087	Urine	0	1	4.32	1	OK	
05113200000682	5	0087	Urine	1	2	4.80	1	OK	
05113200000683	5	0087	Urine	2	3	4.46	1	OK	
05113200000684	5	0087	Urine	3	4	4.30	1	OK	
05113200000685	5	0087	Urine	4	5	2.45	1	OK	
05113200000686	5	0087	Urine	5	6	1.50	1	OK	





SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000694	5	0088	Urine	-1	0	0.203	1	OK	
05113200000695	5	0088	Urine	0	1	0.251	1	OK	
05113200000696	5	0088	Urine	1	2	0.141	1	OK	
05113200000697	5	0088	Urine	2	3	0.0689	1	OK	
05113200000698	5	0088	Urine	3	4	0.0493	1	OK	
05113200000699	5	0088	Urine	4	5	0.0280	1	OK	
05113200000700	5	0088	Urine	5	6	0.0435	1	OK	
05113200000708	5	0090	Urine	-1	0	0.387	1	OK	
05113200000709	5	0090	Urine	0	1	0.419	1	OK	
05113200000710	5	0090	Urine	1	2	0.179	1	OK	
05113200000711	5	0090	Urine	2	3	0.101	1	OK	
05113200000712	5	0090	Urine	3	4	0.0605	1	OK	
05113200000713	5	0090	Urine	4	5	0.0479	1	OK	
05113200000714	5	0090	Urine	5	6	0.0456	1	OK	
05113200000722	6	0093	Urine	-1	0	2.99	1	OK	
05113200000723	6	0093	Urine	0	1	3.52	1	OK	
05113200000724	6	0093	Urine	1	2	1.80	1	OK	
05113200000725	6	0093	Urine	2	3	0.775	1	OK	
05113200000726	6	0093	Urine	3	4	0.294	1	OK	
05113200000727	6	0093	Urine	4	5	0.120	1	OK	
05113200000728	6	0093	Urine	5	6	0.0757	1	OK	
05113200000736	5	0104	Urine	-1	0	0.857	1	OK	
05113200000737	5	0104	Urine	0	1	1.25	1	OK	
05113200000738	5	0104	Urine	1	2	0.695	1	OK	
05113200000739	5	0104	Urine	2	3	0.372	1	OK	
05113200000740	5	0104	Urine	3	4	0.135	1	OK	
05113200000741	5	0104	Urine	4	5	0.0700	1	OK	
05113200000742	5	0104	Urine	5	6	0.0794	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000750	5	0105	Urine	-1	0	1.64	1	OK	
05113200000751	5	0105	Urine	0	1	2.05	1	OK	
05113200000752	5	0105	Urine	1	2	2.78	1	OK	
05113200000753	5	0105	Urine	2	3	2.31	1	OK	
05113200000754	5	0105	Urine	3	4	1.72	1	OK	
05113200000755	5	0105	Urine	4	5	1.37	1	OK	
05113200000756	5	0105	Urine	5	6	0.897	1	OK	
05113200000764	5	0106	Urine	-1	0	1.64	1	OK	
05113200000765	5	0106	Urine	0	1	2.23	1	OK	
05113200000766	5	0106	Urine	1	2	0.878	1	OK	
05113200000767	5	0106	Urine	2	3	0.494	1	OK	
05113200000768	5	0106	Urine	3	4	0.262	1	OK	
05113200000769	5	0106	Urine	4	5	0.103	1	OK	
05113200000770	5	0106	Urine	5	6	0.0928	1	OK	
05113200000778	5	0107	Urine	-1	0	5.65	1	OK	
05113200000779	5	0107	Urine	0	1	3.51	1	OK	
05113200000780	5	0107	Urine	1	2	2.20	1	OK	
05113200000781	5	0107	Urine	2	3	0.905	1	OK	
05113200000782	5	0107	Urine	3	4	4.54	1	OK	
05113200000783	5	0107	Urine	4	5	0.198	1	OK	
05113200000784	5	0107	Urine	5	6	0.0886	1	OK	
05113200000792	5	0110	Urine	-1	0	3.95	1	OK	
05113200000793	5	0110	Urine	0	1	4.55	1	OK	
05113200000794	5	0110	Urine	1	2	1.89	1	OK	
05113200000795	5	0110	Urine	2	3	0.777	1	OK	
05113200000796	5	0110	Urine	3	4	0.373	1	OK	
05113200000797	5	0110	Urine	4	5	0.157	1	OK	
05113200000798	5	0110	Urine	5	6	0.120	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000806	7	0112	Urine	-1	0	1.74	1	OK	
05113200000807	7	0112	Urine	0	1	1.79	1	OK	
05113200000808	7	0112	Urine	1	2	0.562	1	OK	
05113200000809	7	0112	Urine	2	3	0.238	1	OK	
05113200000810	7	0112	Urine	3	4	0.166	1	OK	
05113200000811	7	0112	Urine	4	5	0.0978	1	OK	
05113200000812	7	0112	Urine	5	6	0.105	1	OK	
05113200000820	6	0114	Urine	-1	0	1.47	1	OK	
05113200000821	6	0114	Urine	0	1	2.27	1	OK	
05113200000822	6	0114	Urine	1	2	0.905	1	OK	
05113200000823	6	0114	Urine	2	3	0.216	1	OK	
05113200000824	6	0114	Urine	3	4	0.109	1	OK	
05113200000825	6	0114	Urine	4	5	0.0662	1	OK	
05113200000826	6	0114	Urine	5	6	0.0761	1	OK	
05113200000834	10	0117	Urine	-1	0	1.26	1	OK	
05113200000835	10	0117	Urine	0	1	1.30	1	OK	
05113200000836	10	0117	Urine	1	2	2.52	1	OK	
05113200000837	10	0117	Urine	2	3	2.55	1	OK	
05113200000838	10	0117	Urine	3	4	2.51	1	OK	
05113200000839	10	0117	Urine	4	5	1.79	1	OK	
05113200000840	10	0117	Urine	5	6	1.13	1	OK	
05113200000848	10	0118	Urine	-1	0	0.539	1	OK	
05113200000849	10	0118	Urine	0	1	0.653	1	OK	
05113200000850	10	0118	Urine	1	2	0.484	1	OK	
05113200000851	10	0118	Urine	2	3	0.468	1	OK	
05113200000852	10	0118	Urine	3	4	0.732	1	OK	
05113200000853	10	0118	Urine	4	5	0.489	1	OK	
05113200000854	10	0118	Urine	5	6	0.494	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000862	6	0121	Urine	-1	0	2.30	1	OK	
05113200000863	6	0121	Urine	0	1	2.88	1	OK	
05113200000864	6	0121	Urine	1	2	1.91	1	OK	
05113200000865	6	0121	Urine	2	3	2.08	1	OK	
05113200000866	6	0121	Urine	3	4	1.92	1	OK	
05113200000867	6	0121	Urine	4	5	1.55	1	OK	
05113200000868	6	0121	Urine	5	6	1.48	1	OK	
05113200000876	6	0122	Urine	-1	0	0.206	1	OK	
05113200000877	6	0122	Urine	0	1	0.174	1	OK	
05113200000878	6	0122	Urine	1	2	0.0475	1	OK	
05113200000879	6	0122	Urine	2	3	0.0437	1	OK	
05113200000880	6	0122	Urine	3	4	BLQ<(0.0250)	1	OK	
05113200000881	6	0122	Urine	4	5	BLQ<(0.0250)	1	OK	
05113200000882	6	0122	Urine	5	6	BLQ<(0.0250)	1	OK	
05113200000890	6	0123	Urine	-1	0	0.304	1	OK	
05113200000891	6	0123	Urine	0	1	0.385	1	OK	
05113200000892	6	0123	Urine	1	2	0.216	1	OK	
05113200000893	6	0123	Urine	2	3	0.128	1	OK	
05113200000894	6	0123	Urine	3	4	0.0906	1	OK	
05113200000895	6	0123	Urine	4	5	0.0377	1	OK	
05113200000896	6	0123	Urine	5	6	0.0534	1	OK	
05113200000904	6	0126	Urine	-1	0	0.788	1	OK	
05113200000905	6	0126	Urine	0	1	1.21	1	OK	
05113200000906	6	0126	Urine	1	2	1.39	1	OK	
05113200000907	6	0126	Urine	2	3	1.09	1	OK	
05113200000908	6	0126	Urine	3	4	1.42	1	OK	
05113200000909	6	0126	Urine	4	5	1.24	1	OK	
05113200000910	6	0126	Urine	5	6	0.905	1	OK	





SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000918	6	0127	Urine	-1	0	5.95	1	OK	
05113200000919	6	0127	Urine	0	1	3.07	1	OK	
05113200000920	6	0127	Urine	1	2	0.773	1	OK	
05113200000921	6	0127	Urine	2	3	0.312	1	OK	
05113200000922	6	0127	Urine	3	4	0.144	1	OK	
05113200000923	6	0127	Urine	4	5	0.0980	1	OK	
05113200000924	6	0127	Urine	5	6	0.113	1	OK	
05113200000932	6	0128	Urine	-1	0	0.474	1	OK	
05113200000933	6	0128	Urine	0	1	0.523	1	OK	
05113200000934	6	0128	Urine	1	2	0.198	1	OK	
05113200000935	6	0128	Urine	2	3	0.105	1	OK	
05113200000936	6	0128	Urine	3	4	0.0956	1	OK	
05113200000937	6	0128	Urine	4	5	0.0574	1	OK	
05113200000938	6	0128	Urine	5	6	0.0807	1	OK	
05113200000946	6	0129	Urine	-1	0	0.380	1	OK	
05113200000947	6	0129	Urine	0	1	0.432	1	OK	
05113200000948	6	0129	Urine	1	2	0.116	1	OK	
05113200000949	6	0129	Urine	2	3	0.125	1	OK	
05113200000950	6	0129	Urine	3	4	0.0682	1	OK	
05113200000951	6	0129	Urine	4	5	0.0856	1	OK	
05113200000952	6	0129	Urine	5	6	0.0605	1	OK	
05113200000960	8	0130	Urine	-1	0	1.61	1	OK	
05113200000961	8	0130	Urine	0	1	1.37	1	OK	
05113200000962	8	0130	Urine	1	2	0.604	1	OK	
05113200000963	8	0130	Urine	2	3	0.295	1	OK	
05113200000964	8	0130	Urine	3	4	0.256	1	OK	
05113200000965	8	0130	Urine	4	5	0.173	1	OK	
05113200000966	8	0130	Urine	5	6	0.0795	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200000974	8	0133	Urine	-1	0	3.96	1	OK	
05113200000975	8	0133	Urine	0	1	5.44	1	OK	
05113200000976	8	0133	Urine	1	2	2.14	1	OK	
05113200000977	8	0133	Urine	2	3	0.205	1	OK	
05113200000978	8	0133	Urine	3	4	0.164	1	OK	
05113200000979	8	0133	Urine	4	5	0.101	1	OK	
05113200000980	8	0133	Urine	5	6	0.111	1	OK	
05113200000988	8	0134	Urine	-1	0	1.39	1	OK	
05113200000989	8	0134	Urine	0	1	1.83	1	OK	
05113200000990	8	0134	Urine	1	2	0.615	1	OK	
05113200000991	8	0134	Urine	2	3	0.213	1	OK	
05113200000992	8	0134	Urine	3	4	0.172	1	OK	
05113200000993	8	0134	Urine	4	5	0.122	1	OK	
05113200000994	8	0134	Urine	5	6	0.129	1	OK	
05113200001002	8	0136	Urine	-1	0	4.02	1	OK	
05113200001003	8	0136	Urine	0	1	3.60	1	OK	
05113200001004	8	0136	Urine	1	2	2.02	1	OK	
05113200001005	8	0136	Urine	2	3	0.753	1	OK	
05113200001006	8	0136	Urine	3	4	0.676	1	OK	
05113200001007	8	0136	Urine	4	5	0.253	1	OK	
05113200001008	8	0136	Urine	5	6	0.195	1	OK	
05113200001016	8	0137	Urine	-1	0	3.80	1	OK	
05113200001017	8	0137	Urine	0	1	2.78	1	OK	
05113200001018	8	0137	Urine	1	2	1.31	1	OK	
05113200001019	8	0137	Urine	2	3	0.540	1	OK	
05113200001020	8	0137	Urine	3	4	0.381	1	OK	
05113200001021	8	0137	Urine	4	5	0.204	1	OK	
05113200001022	8	0137	Urine	5	6	0.145	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001030	8	0139	Urine	-1	0	2.47	1	OK	
05113200001031	8	0139	Urine	0	1	2.92	1	OK	
05113200001032	8	0139	Urine	1	2	2.23	1	OK	
05113200001033	8	0139	Urine	2	3	2.17	1	OK	
05113200001034	8	0139	Urine	3	4	2.88	1	OK	
05113200001035	8	0139	Urine	4	5	2.58	1	OK	
05113200001036	8	0139	Urine	5	6	2.16	1	OK	
05113200001044	8	0140	Urine	-1	0	1.24	1	OK	
05113200001045	8	0140	Urine	0	1	1.42	1	OK	
05113200001046	8	0140	Urine	1	2	1.40	1	OK	
05113200001047	8	0140	Urine	2	3	1.73	1	OK	
05113200001048	8	0140	Urine	3	4	1.86	1	OK	
05113200001049	8	0140	Urine	4	5	1.33	1	OK	
05113200001050	8	0140	Urine	5	6	1.09	1	OK	
05113200001058	8	0145	Urine	-1	0	2.53	1	OK	
05113200001059	8	0145	Urine	0	1	2.51	1	OK	
05113200001060	8	0145	Urine	1	2	1.86	1	OK	
05113200001061	8	0145	Urine	2	3	0.721	1	OK	
05113200001062	8	0145	Urine	3	4	0.262	1	OK	
05113200001063	8	0145	Urine	4	5	0.166	1	OK	
05113200001064	8	0145	Urine	5	6	0.112	1	OK	
05113200001072	8	0147	Urine	-1	0	3.86	1	OK	
05113200001073	8	0147	Urine	0	1	4.52	1	OK	
05113200001074	8	0147	Urine	1	2	1.44	1	OK	
05113200001075	8	0147	Urine	2	3	0.523	1	OK	
05113200001076	8	0147	Urine	3	4	0.355	1	OK	
05113200001077	8	0147	Urine	4	5	0.323	1	OK	
05113200001078	8	0147	Urine	5	6	0.166	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001086	8	0148	Urine	-1	0	2.07	1	OK	
05113200001087	8	0148	Urine	0	1	1.85	1	OK	
05113200001088	8	0148	Urine	1	2	1.69	1	OK	
05113200001089	8	0148	Urine	2	3	1.30	1	OK	
05113200001090	8	0148	Urine	3	4	1.53	1	OK	
05113200001091	8	0148	Urine	4	5	1.29	1	OK	
05113200001092	8	0148	Urine	5	6	1.17	1	OK	
05113200001100	9	0149	Urine	-1	0	0.260	1	OK	
05113200001101	9	0149	Urine	0	1	0.247	1	OK	
05113200001102	9	0149	Urine	1	2	0.101	1	OK	
05113200001103	9	0149	Urine	2	3	0.0966	1	OK	
05113200001104	9	0149	Urine	3	4	0.0545	1	OK	
05113200001105	9	0149	Urine	4	5	0.0345	1	OK	
05113200001106	9	0149	Urine	5	6	0.0335	1	OK	
05113200001114	9	0150	Urine	-1	0	0.469	1	OK	
05113200001115	9	0150	Urine	0	1	0.404	1	OK	
05113200001116	9	0150	Urine	1	2	0.213	1	OK	
05113200001117	9	0150	Urine	2	3	0.145	1	OK	
05113200001118	9	0150	Urine	3	4	0.0696	1	OK	
05113200001119	9	0150	Urine	4	5	0.0539	1	OK	
05113200001120	9	0150	Urine	5	6	0.0928	1	OK	
05113200001128	9	0152	Urine	-1	0	1.26	1	OK	
05113200001129	9	0152	Urine	0	1	1.51	1	OK	
05113200001130	9	0152	Urine	1	2	1.97	1	OK	
05113200001131	9	0152	Urine	2	3	1.83	1	OK	
05113200001132	9	0152	Urine	3	4	2.03	1	OK	
05113200001133	9	0152	Urine	4	5	1.45	1	OK	
05113200001134	9	0152	Urine	5	6	1.57	1	OK	





SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001142	9	0153	Urine	-1	0	0.201	1	OK	
05113200001143	9	0153	Urine	0	1	0.276	1	OK	
05113200001144	9	0153	Urine	1	2	0.0816	1	OK	
05113200001145	9	0153	Urine	2	3	0.0555	1	OK	
05113200001146	9	0153	Urine	3	4	0.0370	1	OK	
05113200001147	9	0153	Urine	4	5	0.0278	1	OK	
05113200001148	9	0153	Urine	5	6	BLQ<(0.0250)	1	OK	
05113200001156	9	0155	Urine	-1	0	1.73	1	OK	
05113200001157	9	0155	Urine	0	1	1.86	1	OK	
05113200001158	9	0155	Urine	1	2	1.12	1	OK	
05113200001159	9	0155	Urine	2	3	0.477	1	OK	
05113200001160	9	0155	Urine	3	4	0.249	1	OK	
05113200001161	9	0155	Urine	4	5	0.171	1	OK	
05113200001162	9	0155	Urine	5	6	0.126	1	OK	
05113200001170	9	0156	Urine	-1	0	5.14	1	OK	
05113200001171	15	0156	Urine	0	1	6.87	1	OK	
05113200001172	9	0156	Urine	1	2	6.08	1	OK	
05113200001173	9	0156	Urine	2	3	6.23	1	OK	
05113200001174	9	0156	Urine	3	4	6.19	1	OK	
05113200001175	15	0156	Urine	4	5	7.63	1	OK	
05113200001176	9	0156	Urine	5	6	5.14	1	OK	
05113200001184	9	0160	Urine	-1	0	3.65	1	OK	
05113200001185	9	0160	Urine	0	1	4.88	1	OK	
05113200001186	9	0160	Urine	1	2	4.47	1	OK	
05113200001187	9	0160	Urine	2	3	3.41	1	OK	
05113200001188	9	0160	Urine	3	4	4.53	1	OK	
05113200001189	9	0160	Urine	4	5	3.91	1	OK	
05113200001190	9	0160	Urine	5	6	3.59	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001198	9	0162	Urine	-1	0	1.54	1	OK	
05113200001199	9	0162	Urine	0	1	2.14	1	OK	
05113200001200	9	0162	Urine	1	2	0.687	1	OK	
05113200001201	9	0162	Urine	2	3	0.361	1	OK	
05113200001202	9	0162	Urine	3	4	0.287	1	OK	
05113200001203	9	0162	Urine	4	5	0.156	1	OK	
05113200001204	9	0162	Urine	5	6	0.133	1	OK	
05113200001212	9	0167	Urine	-1	0	1.49	1	OK	
05113200001213	9	0167	Urine	0	1	1.93	1	OK	
05113200001214	9	0167	Urine	1	2	0.783	1	OK	
05113200001215	9	0167	Urine	2	3	0.276	1	OK	
05113200001216	9	0167	Urine	3	4	0.149	1	OK	
05113200001217	9	0167	Urine	4	5	0.0967	1	OK	
05113200001218	9	0167	Urine	5	6	0.0868	1	OK	
05113200001226	9	0169	Urine	-1	0	1.11	1	OK	
05113200001227	9	0169	Urine	0	1	0.944	1	OK	
05113200001228	9	0169	Urine	1	2	0.656	1	OK	
05113200001229	9	0169	Urine	2	3	0.181	1	OK	
05113200001230	9	0169	Urine	3	4	0.120	1	OK	
05113200001231	9	0169	Urine	4	5	0.0445	1	OK	
05113200001232	9	0169	Urine	5	6	0.0692	1	OK	
05113200001240	10	0170	Urine	-1	0	3.18	1	OK	
05113200001241	10	0170	Urine	0	1	2.39	1	OK	
05113200001242	10	0170	Urine	1	2	0.872	1	OK	
05113200001243	10	0170	Urine	2	3	0.390	1	OK	
05113200001244	10	0170	Urine	3	4	0.160	1	OK	
05113200001245	10	0170	Urine	4	5	0.122	1	OK	
05113200001246	10	0170	Urine	5	6	0.100	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001254	10	0177	Urine	-1	0	4.93	1	OK	
05113200001255	10	0177	Urine	0	1	5.14	1	OK	
05113200001256	10	0177	Urine	1	2	2.03	1	OK	
05113200001257	10	0177	Urine	2	3	0.590	1	OK	
05113200001258	10	0177	Urine	3	4	0.334	1	OK	
05113200001259	10	0177	Urine	4	5	0.160	1	OK	
05113200001260	10	0177	Urine	5	6	0.159	1	OK	
05113200001366	18	0181	Urine	-1	0	5.03	1	OK	
05113200001367	18	0181	Urine	0	1	3.88	1	OK	
05113200001368	18	0181	Urine	1	2	1.55	1	OK	
05113200001369	18	0181	Urine	2	3	0.430	1	OK	
05113200001370	18	0181	Urine	3	4	0.313	1	OK	
05113200001371	18	0181	Urine	4	5	0.179	1	OK	
05113200001372	18	0181	Urine	5	6	0.106	1	OK	
05113200001268	10	0183	Urine	-1	0	4.19	1	OK	
05113200001269	10	0183	Urine	0	1	3.50	1	OK	
05113200001270	10	0183	Urine	1	2	1.48	1	OK	
05113200001271	10	0183	Urine	2	3	0.585	1	OK	
05113200001272	10	0183	Urine	3	4	0.217	1	OK	
05113200001273	10	0183	Urine	4	5	0.125	1	OK	
05113200001274	10	0183	Urine	5	6	0.109	1	OK	
05113200001282	10	0185	Urine	-1	0	6.00	1	OK	
05113200001283	10	0185	Urine	0	1	3.38	1	OK	
05113200001284	10	0185	Urine	1	2	1.60	1	OK	
05113200001285	10	0185	Urine	2	3	0.594	1	OK	
05113200001286	10	0185	Urine	3	4	0.303	1	OK	
05113200001287	10	0185	Urine	4	5	0.208	1	OK	
05113200001288	10	0185	Urine	5	6	0.146	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001296	10	0187	Urine	-1	0	1.58	1	OK	
05113200001297	10	0187	Urine	0	1	1.52	1	OK	
05113200001298	10	0187	Urine	1	2	1.41	1	OK	
05113200001299	10	0187	Urine	2	3	2.26	1	OK	
05113200001300	10	0187	Urine	3	4	3.53	1	OK	
05113200001301	10	0187	Urine	4	5	2.19	1	OK	
05113200001302	10	0187	Urine	5	6	1.24	1	OK	
05113200001352	18	0189	Urine	-1	0	2.75	1	OK	
05113200001353	18	0189	Urine	0	1	2.45	1	OK	
05113200001354	18	0189	Urine	1	2	0.915	1	OK	
05113200001355	18	0189	Urine	2	3	0.379	1	OK	
05113200001356	18	0189	Urine	3	4	0.180	1	OK	
05113200001357	18	0189	Urine	4	5	0.146	1	OK	
05113200001358	18	0189	Urine	5	6	0.114	1	OK	
05113200001310	10	0190	Urine	-1	0	0.549	1	OK	
05113200001311	10	0190	Urine	0	1	0.560	1	OK	
05113200001312	10	0190	Urine	1	2	0.236	1	OK	
05113200001313	10	0190	Urine	2	3	0.138	1	OK	
05113200001314	10	0190	Urine	3	4	0.0690	1	OK	
05113200001315	10	0190	Urine	4	5	0.0506	1	OK	
05113200001316	10	0190	Urine	5	6	0.0718	1	OK	
05113200001324	10	0191	Urine	-1	0	1.65	1	OK	
05113200001325	10	0191	Urine	0	1	1.66	1	OK	
05113200001326	10	0191	Urine	1	2	1.94	1	OK	
05113200001327	10	0191	Urine	2	3	1.84	1	OK	
05113200001328	10	0191	Urine	3	4	2.22	1	OK	
05113200001329	10	0191	Urine	4	5	1.74	1	OK	
05113200001330	10	0191	Urine	5	6	1.23	1	OK	





SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001338	10	0192	Urine	-1	0	4.63	1	OK	
05113200001339	10	0192	Urine	0	1	4.21	1	OK	
05113200001340	10	0192	Urine	1	2	1.20	1	OK	
05113200001341	10	0192	Urine	2	3	0.650	1	OK	
05113200001342	10	0192	Urine	3	4	0.365	1	OK	
05113200001343	10	0192	Urine	4	5	0.167	1	OK	
05113200001344	10	0192	Urine	5	6	0.154	1	OK	
05113200001380	18	0193	Urine	-1	0	2.12	1	OK	
05113200001381	18	0193	Urine	0	1	4.29	1	OK	
05113200001382	18	0193	Urine	1	2	1.45	1	OK	
05113200001383	18	0193	Urine	2	3	0.680	1	OK	
05113200001384	18	0193	Urine	3	4	0.487	1	OK	
05113200001385	18	0193	Urine	4	5	0.270	1	OK	
05113200001386	18	0193	Urine	5	6	0.180	1	OK	
05113200001394	18	0195	Urine	-1	0	0.753	1	OK	
05113200001395	18	0195	Urine	0	1	1.12	1	OK	
05113200001396	18	0195	Urine	1	2	0.529	1	OK	
05113200001397	18	0195	Urine	2	3	0.302	1	OK	
05113200001398	18	0195	Urine	3	4	0.131	1	OK	
05113200001399	18	0195	Urine	4	5	0.105	1	OK	
05113200001400	18	0195	Urine	5	6	0.0277	1	OK	
05113200001408	18	0196	Urine	-1	0	0.483	1	OK	
05113200001409	18	0196	Urine	0	1	0.619	1	OK	
05113200001410	18	0196	Urine	1	2	0.294	1	OK	
05113200001411	18	0196	Urine	2	3	0.0814	1	OK	
05113200001412	18	0196	Urine	3	4	0.0585	1	OK	
05113200001413	18	0196	Urine	4	5	0.0663	1	OK	
05113200001414	18	0196	Urine	5	6	0.0319	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001422	18	0197	Urine	-1	0	3.07	1	OK	
05113200001423	18	0197	Urine	0	1	6.03	1	OK	
05113200001424	18	0197	Urine	1	2	1.44	1	OK	
05113200001425	18	0197	Urine	2	3	0.610	1	OK	
05113200001426	18	0197	Urine	3	4	0.244	1	OK	
05113200001427	18	0197	Urine	4	5	0.200	1	OK	
05113200001428	18	0197	Urine	5	6	0.115	1	OK	
05113200001436	18	0198	Urine	-1	0	2.47	1	OK	
05113200001437	18	0198	Urine	0	1	4.99	1	OK	
05113200001438	18	0198	Urine	1	2	3.51	1	OK	
05113200001439	18	0198	Urine	2	3	5.20	1	OK	
05113200001440	18	0198	Urine	3	4	5.13	1	OK	
05113200001441	18	0198	Urine	4	5	5.45	1	OK	
05113200001442	18	0198	Urine	5	6	3.94	1	OK	
05113200001450	18	0200	Urine	-1	0	0.828	1	OK	
05113200001451	18	0200	Urine	0	1	1.37	1	OK	
05113200001452	18	0200	Urine	1	2	1.04	1	OK	
05113200001453	18	0200	Urine	2	3	0.881	1	OK	
05113200001454	18	0200	Urine	3	4	1.07	1	OK	
05113200001455	18	0200	Urine	4	5	1.08	1	OK	
05113200001456	18	0200	Urine	5	6	0.521	1	OK	
05113200001464	18	0202	Urine	-1	0	1.16	1	OK	
05113200001465	18	0202	Urine	0	1	1.47	1	OK	
05113200001466	18	0202	Urine	1	2	1.26	1	OK	
05113200001467	18	0202	Urine	2	3	0.474	1	OK	
05113200001468	18	0202	Urine	3	4	0.157	1	OK	
05113200001469	18	0202	Urine	4	5	0.0706	1	OK	
05113200001470	18	0202	Urine	5	6	BLQ<(0.0250)	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001478	18	0203	Urine	-1	0	1.66	1	OK	
05113200001479	18	0203	Urine	0	1	1.90	1	OK	
05113200001480	18	0203	Urine	1	2	0.726	1	OK	
05113200001481	18	0203	Urine	2	3	0.339	1	OK	
05113200001482	18	0203	Urine	3	4	0.181	1	OK	
05113200001483	18	0203	Urine	4	5	0.116	1	OK	
05113200001484	18	0203	Urine	5	6	0.0647	1	OK	
05113200001492	22	0204	Urine	-1	0	0.452	1	OK	
05113200001493	22	0204	Urine	0	1	1.12	1	OK	
05113200001494	22	0204	Urine	1	2	1.21	1	OK	
05113200001495	22	0204	Urine	2	3	0.948	1	OK	
05113200001496	22	0204	Urine	3	4	1.22	1	OK	
05113200001497	22	0204	Urine	4	5	1.12	1	OK	
05113200001498	22	0204	Urine	5	6	1.08	1	OK	
05113200001506	22	0206	Urine	-1	0	1.41	1	OK	
05113200001507	22	0206	Urine	0	1	2.88	1	OK	
05113200001508	22	0206	Urine	1	2	1.14	1	OK	
05113200001509	22	0206	Urine	2	3	0.339	1	OK	
05113200001510	22	0206	Urine	3	4	0.150	1	OK	
05113200001511	22	0206	Urine	4	5	0.0917	1	OK	
05113200001512	22	0206	Urine	5	6	0.0673	1	OK	
05113200001520	22	0210	Urine	-1	0	2.62	1	OK	
05113200001521	22	0210	Urine	0	1	2.35	1	OK	
05113200001522	22	0210	Urine	1	2	1.01	1	OK	
05113200001523	22	0210	Urine	2	3	0.368	1	OK	
05113200001524	22	0210	Urine	3	4	0.193	1	OK	
05113200001525	22	0210	Urine	4	5	0.153	1	OK	
05113200001526	22	0210	Urine	5	6	0.0364	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001548	22	0216	Urine	-1	0	2.94	1	OK	
05113200001549	22	0216	Urine	0	1	3.34	1	OK	
05113200001550	22	0216	Urine	1	2	1.36	1	OK	
05113200001551	22	0216	Urine	2	3	0.448	1	OK	
05113200001552	22	0216	Urine	3	4	0.257	1	OK	
05113200001553	22	0216	Urine	4	5	0.145	1	OK	
05113200001554	22	0216	Urine	5	6	0.0770	1	OK	
05113200001562	22	0218	Urine	-1	0	0.611	1	OK	
05113200001563	22	0218	Urine	0	1	0.774	1	OK	
05113200001564	22	0218	Urine	1	2	0.123	1	OK	
05113200001565	22	0218	Urine	2	3	0.112	1	OK	
05113200001566	22	0218	Urine	3	4	0.0665	1	OK	
05113200001567	22	0218	Urine	4	5	0.0513	1	OK	
05113200001568	22	0218	Urine	5	6	0.0498	1	OK	
05113200001576	22	0220	Urine	-1	0	1.45	1	OK	
05113200001577	22	0220	Urine	0	1	1.84	1	OK	
05113200001578	22	0220	Urine	1	2	0.617	1	OK	
05113200001579	22	0220	Urine	2	3	0.381	1	OK	
05113200001580	22	0220	Urine	3	4	0.183	1	OK	
05113200001581	22	0220	Urine	4	5	0.0999	1	OK	
05113200001582	22	0220	Urine	5	6	0.0300	1	OK	
05113200001590	22	0224	Urine	-1	0	1.45	1	OK	
05113200001591	22	0224	Urine	0	1	2.56	1	OK	
05113200001592	22	0224	Urine	1	2	1.57	1	OK	
05113200001593	22	0224	Urine	2	3	1.66	1	OK	
05113200001594	22	0224	Urine	3	4	2.23	1	OK	
05113200001595	22	0224	Urine	4	5	2.06	1	OK	
05113200001596	22	0224	Urine	5	6	1.36	1	OK	





SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001604	22	0228	Urine	-1	0	0.351	1	OK	
05113200001605	22	0228	Urine	0	1	0.737	1	OK	
05113200001606	22	0228	Urine	1	2	0.139	1	OK	
05113200001607	22	0228	Urine	2	3	0.0584	1	OK	
05113200001608	22	0228	Urine	3	4	0.0484	1	OK	
05113200001609	22	0228	Urine	4	5	0.0401	1	OK	
05113200001610	22	0228	Urine	5	6	0.0270	1	OK	
05113200001618	22	0229	Urine	-1	0	1.16	1	OK	
05113200001619	22	0229	Urine	0	1	1.13	1	OK	
05113200001620	22	0229	Urine	1	2	1.60	1	OK	
05113200001621	22	0229	Urine	2	3	1.54	1	OK	
05113200001622	22	0229	Urine	3	4	2.04	1	OK	
05113200001623	22	0229	Urine	4	5	1.21	1	OK	
05113200001624	22	0229	Urine	5	6	1.02	1	OK	
05113200001632	22	0230	Urine	-1	0	1.05	1	OK	
05113200001633	22	0230	Urine	0	1	2.59	1	OK	
05113200001634	22	0230	Urine	1	2	1.73	1	OK	
05113200001635	22	0230	Urine	2	3	1.52	1	OK	
05113200001636	22	0230	Urine	3	4	1.68	1	OK	
05113200001637	22	0230	Urine	4	5	1.67	1	OK	
05113200001638	22	0230	Urine	5	6	1.22	1	OK	
05113200001646	20	0232	Urine	-1	0	1.80	1	OK	
05113200001647	20	0232	Urine	0	1	1.96	1	OK	
05113200001648	20	0232	Urine	1	2	0.592	1	OK	
05113200001649	20	0232	Urine	2	3	0.316	1	OK	
05113200001650	20	0232	Urine	3	4	0.195	1	OK	
05113200001651	20	0232	Urine	4	5	0.117	1	OK	
05113200001652	20	0232	Urine	5	6	0.0715	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001660	20	0234	Urine	-1	0	1.42	1	OK	
05113200001661	20	0234	Urine	0	1	2.48	1	OK	
05113200001662	20	0234	Urine	1	2	0.613	1	OK	
05113200001663	20	0234	Urine	2	3	0.300	1	OK	
05113200001664	20	0234	Urine	3	4	0.175	1	OK	
05113200001665	20	0234	Urine	4	5	0.103	1	OK	
05113200001666	20	0234	Urine	5	6	0.0633	1	OK	
05113200001674	20	0240	Urine	-1	0	2.35	1	OK	
05113200001675	20	0240	Urine	0	1	2.50	1	OK	
05113200001676	20	0240	Urine	1	2	0.936	1	OK	
05113200001677	20	0240	Urine	2	3	0.279	1	OK	
05113200001678	20	0240	Urine	3	4	0.142	1	OK	
05113200001679	20	0240	Urine	4	5	0.111	1	OK	
05113200001680	20	0240	Urine	5	6	0.0657	1	OK	
05113200001688	20	0241	Urine	-1	0	1.37	1	OK	
05113200001689	20	0241	Urine	0	1	1.75	1	OK	
05113200001690	20	0241	Urine	1	2	0.489	1	OK	
05113200001691	20	0241	Urine	2	3	0.218	1	OK	
05113200001692	20	0241	Urine	3	4	0.0757	1	OK	
05113200001693	20	0241	Urine	4	5	0.0918	1	OK	
05113200001694	20	0241	Urine	5	6	0.0643	1	OK	
05113200001716	20	0244	Urine	-1	0	2.70	1	OK	
05113200001717	20	0244	Urine	0	1	2.04	1	OK	
05113200001718	20	0244	Urine	1	2	0.767	1	OK	
05113200001719	20	0244	Urine	2	3	0.377	1	OK	
05113200001720	20	0244	Urine	3	4	0.189	1	OK	
05113200001721	20	0244	Urine	4	5	0.156	1	OK	
05113200001722	20	0244	Urine	5	6	0.0837	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001758	27	0249	Urine	-1	0	7.73	1	OK	
05113200001759	27	0249	Urine	0	1	6.22	1	OK	
05113200001760	20	0249	Urine	1	2	2.45	1	OK	
05113200001761	20	0249	Urine	2	3	0.960	1	OK	
05113200001762	20	0249	Urine	3	4	0.795	1	OK	
05113200001763	20	0249	Urine	4	5	0.313	1	OK	
05113200001764	20	0249	Urine	5	6	0.262	1	OK	
05113200001772	20	0251	Urine	-1	0	1.03	1	OK	
05113200001773	20	0251	Urine	0	1	1.07	1	OK	
05113200001774	20	0251	Urine	1	2	0.557	1	OK	
05113200001775	20	0251	Urine	2	3	0.212	1	OK	
05113200001776	20	0251	Urine	3	4	0.115	1	OK	
05113200001777	20	0251	Urine	4	5	0.0864	1	OK	
05113200001778	20	0251	Urine	5	6	0.0402	1	OK	
05113200001786	20	0252	Urine	-1	0	2.22	1	OK	
05113200001787	20	0252	Urine	0	1	2.23	1	OK	
05113200001788	20	0252	Urine	1	2	0.861	1	OK	
05113200001789	20	0252	Urine	2	3	0.358	1	OK	
05113200001790	20	0252	Urine	3	4	0.165	1	OK	
05113200001791	20	0252	Urine	4	5	0.0979	1	OK	
05113200001792	20	0252	Urine	5	6	0.0775	1	OK	
05113200001856	20	0255	Urine	-1	0	2.85	1	OK	
05113200001857	20	0255	Urine	0	1	3.09	1	OK	
05113200001858	20	0255	Urine	1	2	0.887	1	OK	
05113200001859	20	0255	Urine	2	3	0.457	1	OK	
05113200001860	20	0255	Urine	3	4	0.229	1	OK	
05113200001861	20	0255	Urine	4	5	0.212	1	OK	
05113200001862	20	0255	Urine	5	6	0.132	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001800	20	0256	Urine	-1	0	2.34	1	OK	
05113200001801	20	0256	Urine	0	1	2.73	1	OK	
05113200001802	20	0256	Urine	1	2	0.846	1	OK	
05113200001803	20	0256	Urine	2	3	0.314	1	OK	
05113200001804	20	0256	Urine	3	4	0.141	1	OK	
05113200001805	20	0256	Urine	4	5	0.0942	1	OK	
05113200001806	20	0256	Urine	5	6	0.0782	1	OK	
05113200001814	21	0262	Urine	-1	0	0.143	1	OK	
05113200001815	21	0262	Urine	0	1	0.220	1	OK	
05113200001816	21	0262	Urine	1	2	0.193	1	OK	
05113200001817	21	0262	Urine	2	3	0.167	1	OK	
05113200001818	21	0262	Urine	3	4	0.212	1	OK	
05113200001819	21	0262	Urine	4	5	0.239	1	OK	
05113200001820	21	0262	Urine	5	6	0.113	1	OK	
05113200001828	21	0264	Urine	-1	0	0.933	1	OK	
05113200001829	21	0264	Urine	0	1	1.04	1	OK	
05113200001830	21	0264	Urine	1	2	0.620	1	OK	
05113200001831	21	0264	Urine	2	3	0.196	1	OK	
05113200001832	21	0264	Urine	3	4	0.180	1	OK	
05113200001833	21	0264	Urine	4	5	0.0851	1	OK	
05113200001834	21	0264	Urine	5	6	0.0392	1	OK	
05113200001842	21	0265	Urine	-1	0	0.472	1	OK	
05113200001843	21	0265	Urine	0	1	0.850	1	OK	
05113200001844	21	0265	Urine	1	2	0.350	1	OK	
05113200001845	21	0265	Urine	2	3	0.120	1	OK	
05113200001846	21	0265	Urine	3	4	0.0737	1	OK	
05113200001847	21	0265	Urine	4	5	0.0686	1	OK	
05113200001848	21	0265	Urine	5	6	0.0553	1	OK	





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001870	21	0266	Urine	-1	0	0.424	1	OK	
05113200001871	21	0266	Urine	0	1	0.524	1	OK	
05113200001872	21	0266	Urine	1	2	0.170	1	OK	
05113200001873	21	0266	Urine	2	3	0.217	1	OK	
05113200001874	21	0266	Urine	3	4	0.0779	1	OK	
05113200001875	21	0266	Urine	4	5	0.0711	1	OK	
05113200001876	21	0266	Urine	5	6	0.0835	1	OK	
05113200001898	23	0272	Urine	-1	0	1.00	1	OK	
05113200001899	23	0272	Urine	0	1	1.24	1	OK	
05113200001900	23	0272	Urine	1	2	0.242	1	OK	
05113200001901	23	0272	Urine	2	3	0.426	1	OK	
05113200001902	23	0272	Urine	3	4	0.169	1	OK	
05113200001903	23	0272	Urine	4	5	0.0529	1	OK	
05113200001904	23	0272	Urine	5	6	0.0810	1	OK	
05113200001912	23	0273	Urine	-1	0	1.82	1	OK	
05113200001913	23	0273	Urine	0	1	1.37	1	OK	
05113200001914	23	0273	Urine	1	2	0.520	1	OK	
05113200001915	23	0273	Urine	2	3	0.248	1	OK	
05113200001916	23	0273	Urine	3	4	0.126	1	OK	
05113200001917	23	0273	Urine	4	5	0.0511	1	OK	
05113200001918	23	0273	Urine	5	6	0.0797	1	OK	
05113200001926	23	0276	Urine	-1	0	0.335	1	OK	
05113200001927	23	0276	Urine	0	1	0.499	1	OK	
05113200001928	23	0276	Urine	1	2	0.196	1	OK	
05113200001929	23	0276	Urine	2	3	0.141	1	OK	
05113200001930	23	0276	Urine	3	4	0.0839	1	OK	
05113200001931	23	0276	Urine	4	5	0.0914	1	OK	
05113200001932	23	0276	Urine	5	6	0.101	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001940	23	0277	Urine	-1	0	1.31	1	OK	
05113200001941	23	0277	Urine	0	1	2.12	1	OK	
05113200001942	23	0277	Urine	1	2	1.13	1	OK	
05113200001943	23	0277	Urine	2	3	0.675	1	OK	
05113200001944	23	0277	Urine	3	4	0.223	1	OK	
05113200001945	23	0277	Urine	4	5	0.0717	1	OK	
05113200001946	23	0277	Urine	5	6	0.0977	1	OK	
05113200001954	23	0278	Urine	-1	0	1.39	1	OK	
05113200001955	23	0278	Urine	0	1	1.18	1	OK	
05113200001956	23	0278	Urine	1	2	2.05	1	OK	
05113200001957	23	0278	Urine	2	3	1.81	1	OK	
05113200001958	23	0278	Urine	3	4	1.29	1	OK	
05113200001959	23	0278	Urine	4	5	1.01	1	OK	
05113200001960	23	0278	Urine	5	6	0.949	1	OK	
05113200001968	23	0279	Urine	-1	0	2.49	1	OK	
05113200001969	23	0279	Urine	0	1	2.07	1	OK	
05113200001970	23	0279	Urine	1	2	0.966	1	OK	
05113200001971	23	0279	Urine	2	3	0.495	1	OK	
05113200001972	23	0279	Urine	3	4	0.362	1	OK	
05113200001973	23	0279	Urine	4	5	0.135	1	OK	
05113200001974	23	0279	Urine	5	6	0.150	1	OK	
05113200001982	23	0281	Urine	-1	0	5.97	1	OK	
05113200001983	23	0281	Urine	0	1	4.98	1	OK	
05113200001984	23	0281	Urine	1	2	2.02	1	OK	
05113200001985	23	0281	Urine	2	3	0.675	1	OK	
05113200001986	23	0281	Urine	3	4	0.608	1	OK	
05113200001987	23	0281	Urine	4	5	0.290	1	OK	
05113200001988	23	0281	Urine	5	6	0.354	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200001996	23	0282	Urine	-1	0	3.11	1	OK	
05113200001997	23	0282	Urine	0	1	3.56	1	OK	
05113200001998	23	0282	Urine	1	2	1.09	1	OK	
05113200001999	23	0282	Urine	2	3	0.616	1	OK	
05113200002000	23	0282	Urine	3	4	0.424	1	OK	
05113200002001	23	0282	Urine	4	5	0.198	1	OK	
05113200002002	23	0282	Urine	5	6	0.114	1	OK	
05113200002010	23	0283	Urine	-1	0	2.17	1	OK	
05113200002011	23	0283	Urine	0	1	2.04	1	OK	
05113200002012	23	0283	Urine	1	2	1.52	1	OK	
05113200002013	23	0283	Urine	2	3	1.28	1	OK	
05113200002014	23	0283	Urine	3	4	1.20	1	OK	
05113200002015	23	0283	Urine	4	5	1.18	1	OK	
05113200002016	23	0283	Urine	5	6	0.860	1	OK	
05113200002024	23	0285	Urine	-1	0	1.65	1	OK	
05113200002025	23	0285	Urine	0	1	3.70	1	OK	
05113200002026	23	0285	Urine	1	2	3.32	1	OK	
05113200002027	23	0285	Urine	2	3	3.53	1	OK	
05113200002028	23	0285	Urine	3	4	3.47	1	OK	
05113200002029	23	0285	Urine	4	5	1.60	1	OK	
05113200002030	23	0285	Urine	5	6	3.42	1	OK	
05113200002038	24	0287	Urine	-1	0	3.52	1	OK	
05113200002039	24	0287	Urine	0	1	3.12	1	OK	
05113200002040	24	0287	Urine	1	2	2.31	1	OK	
05113200002041	24	0287	Urine	2	3	0.712	1	OK	
05113200002042	24	0287	Urine	3	4	0.529	1	OK	
05113200002043	24	0287	Urine	4	5	0.247	1	OK	
05113200002044	24	0287	Urine	5	6	0.215	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200002066	24	0289	Urine	-1	0	1.16	1	OK	
05113200002067	24	0289	Urine	0	1	1.16	1	OK	
05113200002068	24	0289	Urine	1	2	1.01	1	OK	
05113200002069	24	0289	Urine	2	3	0.615	1	OK	
05113200002070	24	0289	Urine	3	4	0.239	1	OK	
05113200002071	24	0289	Urine	4	5	0.125	1	OK	
05113200002072	24	0289	Urine	5	6	0.119	1	OK	
05113200002080	24	0291	Urine	-1	0	3.00	1	OK	
05113200002081	24	0291	Urine	0	1	2.15	1	OK	
05113200002082	24	0291	Urine	1	2	0.810	1	OK	
05113200002083	24	0291	Urine	2	3	0.523	1	OK	
05113200002084	24	0291	Urine	3	4	0.259	1	OK	
05113200002085	24	0291	Urine	4	5	0.171	1	OK	
05113200002086	24	0291	Urine	5	6	0.0585	1	OK	
05113200002094	24	0292	Urine	-1	0	0.577	1	OK	
05113200002095	24	0292	Urine	0	1	0.919	1	OK	
05113200002096	24	0292	Urine	1	2	0.722	1	OK	
05113200002097	24	0292	Urine	2	3	0.275	1	OK	
05113200002098	24	0292	Urine	3	4	0.140	1	OK	
05113200002099	24	0292	Urine	4	5	0.0509	1	OK	
05113200002100	24	0292	Urine	5	6	0.0617	1	OK	
05113200002108	24	0296	Urine	-1	0	2.32	1	OK	
05113200002109	24	0296	Urine	0	1	2.66	1	OK	
05113200002110	24	0296	Urine	1	2	1.09	1	OK	
05113200002111	24	0296	Urine	2	3	0.959	1	OK	
05113200002112	24	0296	Urine	3	4	0.261	1	OK	
05113200002113	24	0296	Urine	4	5	0.206	1	OK	
05113200002114	24	0296	Urine	5	6	0.179	1	OK	





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200002122	24	0298	Urine	-1	0	2.45	1	OK	
05113200002123	24	0298	Urine	0	1	3.44	1	OK	
05113200002124	24	0298	Urine	1	2	4.32	1	OK	
05113200002125	24	0298	Urine	2	3	2.96	1	OK	
05113200002126	24	0298	Urine	3	4	2.93	1	OK	
05113200002127	24	0298	Urine	4	5	2.18	1	OK	
05113200002128	24	0298	Urine	5	6	2.94	1	OK	
05113200002150	24	0300	Urine	-1	0	0.826	1	OK	
05113200002151	24	0300	Urine	0	1	0.728	1	OK	
05113200002152	24	0300	Urine	1	2	0.361	1	OK	
05113200002153	24	0300	Urine	2	3	0.401	1	OK	
05113200002154	24	0300	Urine	3	4	0.182	1	OK	
05113200002155	24	0300	Urine	4	5	0.101	1	OK	
05113200002156	24	0300	Urine	5	6	0.107	1	OK	
05113200002164	24	0301	Urine	-1	0	0.588	1	OK	
05113200002165	24	0301	Urine	0	1	0.856	1	OK	
05113200002166	24	0301	Urine	1	2	0.199	1	OK	
05113200002167	24	0301	Urine	2	3	0.217	1	OK	
05113200002168	24	0301	Urine	3	4	0.125	1	OK	
05113200002169	24	0301	Urine	4	5	0.0639	1	OK	
05113200002170	24	0301	Urine	5	6	0.0523	1	OK	
05113200002178	24	0306	Urine	-1	0	0.393	1	OK	
05113200002179	24	0306	Urine	0	1	0.526	1	OK	
05113200002180	24	0306	Urine	1	2	0.161	1	OK	
05113200002181	24	0306	Urine	2	3	0.221	1	OK	
05113200002182	24	0306	Urine	3	4	0.0954	1	OK	
05113200002183	24	0306	Urine	4	5	0.0440	1	OK	
05113200002184	24	0306	Urine	5	6	0.116	1	OK	



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200002192	24	0307	Urine	-1	0	2.50	1	OK	
05113200002193	24	0307	Urine	0	1	3.02	1	OK	
05113200002194	24	0307	Urine	1	2	1.13	1	OK	
05113200002195	24	0307	Urine	2	3	0.630	1	OK	
05113200002196	24	0307	Urine	3	4	0.318	1	OK	
05113200002197	24	0307	Urine	4	5	0.162	1	OK	
05113200002198	24	0307	Urine	5	6	0.192	1	OK	
05113200002206	25	0308	Urine	-1	0	0.270	1	OK	
05113200002207	25	0308	Urine	0	1	0.419	1	OK	
05113200002208	25	0308	Urine	1	2	0.130	1	OK	
05113200002209	25	0308	Urine	2	3	0.189	1	OK	
05113200002210	25	0308	Urine	3	4	0.0784	1	OK	
05113200002211	25	0308	Urine	4	5	0.0498	1	OK	
05113200002212	25	0308	Urine	5	6	0.102	1	OK	
05113200002248	25	0313	Urine	-1	0	0.947	1	OK	
05113200002249	25	0313	Urine	0	1	1.30	1	OK	
05113200002250	25	0313	Urine	1	2	1.44	1	OK	
05113200002251	25	0313	Urine	2	3	1.10	1	OK	
05113200002252	25	0313	Urine	3	4	1.32	1	OK	
05113200002253	25	0313	Urine	4	5	1.17	1	OK	
05113200002254	25	0313	Urine	5	6	0.911	1	OK	
05113200002262	25	0315	Urine	-1	0	2.29	1	OK	
05113200002263	25	0315	Urine	0	1	1.94	1	OK	
05113200002264	25	0315	Urine	1	2	1.25	1	OK	
05113200002265	25	0315	Urine	2	3	2.07	1	OK	
05113200002266	25	0315	Urine	3	4	1.79	1	OK	
05113200002267	25	0315	Urine	4	5	1.16	1	OK	
05113200002268	25	0315	Urine	5	6	1.35	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200002276	25	0316	Urine	-1	0	0.557	1	OK	
05113200002277	25	0316	Urine	0	1	0.638	1	OK	
05113200002278	25	0316	Urine	1	2	0.449	1	OK	
05113200002279	25	0316	Urine	2	3	0.319	1	OK	
05113200002280	25	0316	Urine	3	4	0.167	1	OK	
05113200002281	25	0316	Urine	4	5	0.0819	1	OK	
05113200002282	25	0316	Urine	5	6	0.0666	1	OK	
05113200002290	25	0317	Urine	-1	0	3.25	1	OK	
05113200002291	25	0317	Urine	0	1	2.16	1	OK	
05113200002292	25	0317	Urine	1	2	1.64	1	OK	
05113200002293	25	0317	Urine	2	3	0.810	1	OK	
05113200002294	25	0317	Urine	3	4	0.400	1	OK	
05113200002295	25	0317	Urine	4	5	0.187	1	OK	
05113200002296	25	0317	Urine	5	6	0.170	1	OK	
05113200002304	25	0318	Urine	-1	0	0.450	1	OK	
05113200002305	25	0318	Urine	0	1	0.410	1	OK	
05113200002306	25	0318	Urine	1	2	0.650	1	OK	
05113200002307	25	0318	Urine	2	3	0.762	1	OK	
05113200002308	25	0318	Urine	3	4	0.574	1	OK	
05113200002309	25	0318	Urine	4	5	0.764	1	OK	
05113200002310	25	0318	Urine	5	6	0.904	1	OK	
05113200002318	25	0320	Urine	-1	0	5.57	1	OK	
05113200002319	25	0320	Urine	0	1	6.08	1	OK	
05113200002320	25	0320	Urine	1	2	2.73	1	OK	
05113200002321	25	0320	Urine	2	3	1.34	1	OK	
05113200002322	25	0320	Urine	3	4	0.901	1	OK	
05113200002323	25	0320	Urine	4	5	0.501	1	OK	
05113200002324	25	0320	Urine	5	6	0.342	1	OK	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Custom ID	Watson Run ID	Subject	Biological Matrix	Start Day Nominal	Day Nominal	Concentration (ng/mL)	Split	Sample Condition	Sample Comments
05113200002332	25	0321	Urine	-1	0	1.95	1	OK	
05113200002333	25	0321	Urine	0	1	2.24	1	OK	
05113200002334	25	0321	Urine	1	2	0.659	1	OK	
05113200002335	25	0321	Urine	2	3	0.473	1	OK	
05113200002336	25	0321	Urine	3	4	0.267	1	OK	
05113200002337	25	0321	Urine	4	5	0.175	1	OK	
05113200002338	25	0321	Urine	5	6	0.183	1	OK	
05113200002346	25	0322	Urine	-1	0	1.60	1	OK	
05113200002347	25	0322	Urine	0	1	1.83	1	OK	
05113200002348	25	0322	Urine	1	2	1.25	1	OK	
05113200002349	25	0322	Urine	2	3	1.34	1	OK	
05113200002350	25	0322	Urine	3	4	1.29	1	OK	
05113200002351	25	0322	Urine	4	5	1.02	1	OK	
05113200002352	25	0322	Urine	5	6	0.977	1	OK	
05113200002360	25	0325	Urine	-1	0	1.29	1	OK	
05113200002361	25	0325	Urine	0	1	0.968	1	OK	
05113200002362	25	0325	Urine	1	2	0.897	1	OK	
05113200002363	25	0325	Urine	2	3	0.449	1	OK	
05113200002364	25	0325	Urine	3	4	0.192	1	OK	
05113200002365	25	0325	Urine	4	5	0.0606	1	OK	
05113200002366	25	0325	Urine	5	6	0.0747	1	OK	
05113200002374	26	0328	Urine	-1	0	0.865	1	OK	
05113200002375	26	0328	Urine	0	1	1.20	1	OK	
05113200002376	26	0328	Urine	1	2	0.792	1	OK	
05113200002377	26	0328	Urine	2	3	1.04	1	OK	
05113200002378	26	0328	Urine	3	4	0.961	1	OK	
05113200002379	26	0328	Urine	4	5	0.636	1	OK	
05113200002380	26	0328	Urine	5	6	0.731	1	OK	





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Table 10 Summary of Reassay for Analytical Reasons for SBMA

Watson Run ID	Reason*	Sample Name
		(Study number Custom ID Subject Treatment Period Nominal Time Matrix-Split)
3	AAR	AA99602-01 05113200000488 0042 N/A P1 Day 4 URN-1
3	AAR	AA99602-01 05113200000489 0042 N/A P1 Day 5 URN-1
3	ISA	AA99602-01 05113200000157 0053 N/A P1 Day 2 URN-1
4	ISP	AA99602-01 05113200000806 0112 N/A P1 Day 0 URN-1
4	ISP	AA99602-01 05113200000807 0112 N/A P1 Day 1 URN-1
4	ISP	AA99602-01 05113200000808 0112 N/A P1 Day 2 URN-1
4	ISP	AA99602-01 05113200000809 0112 N/A P1 Day 3 URN-1
4	ISP	AA99602-01 05113200000810 0112 N/A P1 Day 4 URN-1
4	ISP	AA99602-01 05113200000811 0112 N/A P1 Day 5 URN-1
4	ISP	AA99602-01 05113200000812 0112 N/A P1 Day 6 URN-1
4	ISP	AA99602-01 05113200000512 0063 N/A P1 Day 0 URN-1
4	ISP	AA99602-01 05113200000513 0063 N/A P1 Day 1 URN-1
4	ISP	AA99602-01 05113200000514 0063 N/A P1 Day 2 URN-1
4	ISP	AA99602-01 05113200000515 0063 N/A P1 Day 3 URN-1
4	ISP	AA99602-01 05113200000516 0063 N/A P1 Day 4 URN-1
4	ISP	AA99602-01 05113200000517 0063 N/A P1 Day 5 URN-1
4	ISP	AA99602-01 05113200000518 0063 N/A P1 Day 6 URN-1
4	ISP	AA99602-01 05113200000190 0064 N/A P1 Day 0 URN-1
4	ISP	AA99602-01 05113200000191 0064 N/A P1 Day 1 URN-1
4	ISP	AA99602-01 05113200000192 0064 N/A P1 Day 2 URN-1
4	ISP	AA99602-01 05113200000193 0064 N/A P1 Day 3 URN-1
4	ISP	AA99602-01 05113200000194 0064 N/A P1 Day 4 URN-1
4	ISP	AA99602-01 05113200000195 0064 N/A P1 Day 5 URN-1
4	ISP	AA99602-01 05113200000196 0064 N/A P1 Day 6 URN-1
4	ISP	AA99602-01 05113200000526 0066 N/A P1 Day 0 URN-1
4	ISP	AA99602-01 05113200000527 0066 N/A P1 Day 1 URN-1
4	ISP	AA99602-01 05113200000528 0066 N/A P1 Day 2 URN-1
4	ISP	AA99602-01 05113200000529 0066 N/A P1 Day 3 URN-1
4	ISP	AA99602-01 05113200000530 0066 N/A P1 Day 4 URN-1
4	ISP	AA99602-01 05113200000531 0066 N/A P1 Day 5 URN-1
4	ISP	AA99602-01 05113200000532 0066 N/A P1 Day 6 URN-1
4	ISP	AA99602-01 05113200000540 0067 N/A P1 Day 0 URN-1
4	ISP	AA99602-01 05113200000541 0067 N/A P1 Day 1 URN-1
4	ISP	AA99602-01 05113200000542 0067 N/A P1 Day 2 URN-1
4	ISP	AA99602-01 05113200000543 0067 N/A P1 Day 3 URN-1
4	ISP	AA99602-01 05113200000544 0067 N/A P1 Day 4 URN-1
4	ISP	AA99602-01 05113200000545 0067 N/A P1 Day 5 URN-1
4	ISP	AA99602-01 05113200000546 0067 N/A P1 Day 6 URN-1
4	ISP	AA99602-01 05113200000554 0069 N/A P1 Day 0 URN-1
4	ISP	AA99602-01 05113200000555 0069 N/A P1 Day 1 URN-1
4	ISP	AA99602-01 05113200000556 0069 N/A P1 Day 2 URN-1
4	ISP	AA99602-01 05113200000557 0069 N/A P1 Day 3 URN-1
4	ISP	AA99602-01 05113200000558 0069 N/A P1 Day 4 URN-1
4	ISP	AA99602-01 05113200000559 0069 N/A P1 Day 5 URN-1



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Watson Run ID	Reason*	Sample Name			
		(Study number	Custom ID	Subject Treatment Period	Nominal Time Matrix-Split)
4	ISP	AA99602-01	05113200000560	0069 N/A P1 Day 6	URN-1
4	ISP	AA99602-01	05113200000568	0071 N/A P1 Day 0	URN-1
4	ISP	AA99602-01	05113200000569	0071 N/A P1 Day 1	URN-1
4	ISP	AA99602-01	05113200000570	0071 N/A P1 Day 2	URN-1
4	ISP	AA99602-01	05113200000571	0071 N/A P1 Day 3	URN-1
4	ISP	AA99602-01	05113200000572	0071 N/A P1 Day 4	URN-1
4	ISP	AA99602-01	05113200000573	0071 N/A P1 Day 5	URN-1
4	ISP	AA99602-01	05113200000574	0071 N/A P1 Day 6	URN-1
4	ISP	AA99602-01	05113200000596	0074 N/A P1 Day 0	URN-1
4	ISP	AA99602-01	05113200000597	0074 N/A P1 Day 1	URN-1
4	ISP	AA99602-01	05113200000598	0074 N/A P1 Day 2	URN-1
4	ISP	AA99602-01	05113200000599	0074 N/A P1 Day 3	URN-1
4	ISP	AA99602-01	05113200000600	0074 N/A P1 Day 4	URN-1
4	ISP	AA99602-01	05113200000601	0074 N/A P1 Day 5	URN-1
4	ISP	AA99602-01	05113200000602	0074 N/A P1 Day 6	URN-1
4	ISP	AA99602-01	05113200000610	0076 N/A P1 Day 0	URN-1
4	ISP	AA99602-01	05113200000611	0076 N/A P1 Day 1	URN-1
4	ISP	AA99602-01	05113200000612	0076 N/A P1 Day 2	URN-1
4	ISP	AA99602-01	05113200000613	0076 N/A P1 Day 3	URN-1
4	ISP	AA99602-01	05113200000614	0076 N/A P1 Day 4	URN-1
4	ISP	AA99602-01	05113200000615	0076 N/A P1 Day 5	URN-1
4	ISP	AA99602-01	05113200000616	0076 N/A P1 Day 6	URN-1
4	ISP	AA99602-01	05113200000624	0080 N/A P1 Day 0	URN-1
4	ISP	AA99602-01	05113200000625	0080 N/A P1 Day 1	URN-1
4	ISP	AA99602-01	05113200000626	0080 N/A P1 Day 2	URN-1
4	ISP	AA99602-01	05113200000627	0080 N/A P1 Day 3	URN-1
4	ISP	AA99602-01	05113200000628	0080 N/A P1 Day 4	URN-1
4	ISP	AA99602-01	05113200000629	0080 N/A P1 Day 5	URN-1
4	ISP	AA99602-01	05113200000630	0080 N/A P1 Day 6	URN-1
6	AAR	AA99602-01	05113200000918	0127 N/A P1 Day 0	URN-1
7	AAR	AA99602-01	05113200000573	0071 N/A P1 Day 5	URN-1
19	ISP	AA99602-01	05113200001492	0204 N/A P1 Day 0	URN-1
19	ISP	AA99602-01	05113200001493	0204 N/A P1 Day 1	URN-1
19	ISP	AA99602-01	05113200001494	0204 N/A P1 Day 2	URN-1
19	ISP	AA99602-01	05113200001495	0204 N/A P1 Day 3	URN-1
19	ISP	AA99602-01	05113200001496	0204 N/A P1 Day 4	URN-1
19	ISP	AA99602-01	05113200001497	0204 N/A P1 Day 5	URN-1
19	ISP	AA99602-01	05113200001498	0204 N/A P1 Day 6	URN-1
19	ISP	AA99602-01	05113200001506	0206 N/A P1 Day 0	URN-1
19	ISP	AA99602-01	05113200001507	0206 N/A P1 Day 1	URN-1
19	ISP	AA99602-01	05113200001508	0206 N/A P1 Day 2	URN-1
19	ISP	AA99602-01	05113200001509	0206 N/A P1 Day 3	URN-1
19	ISP	AA99602-01	05113200001510	0206 N/A P1 Day 4	URN-1
19	ISP	AA99602-01	05113200001511	0206 N/A P1 Day 5	URN-1
19	ISP	AA99602-01	05113200001512	0206 N/A P1 Day 6	URN-1
19	ISP	AA99602-01	05113200001520	0210 N/A P1 Day 0	URN-1
19	ISP	AA99602-01	05113200001521	0210 N/A P1 Day 1	URN-1





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Watson Run ID	Reason*	Sample Name				
		(Study number	Custom ID	Subject	Treatment Period	Nominal Time Matrix-Split)
19	ISP	AA99602-01	05113200001522	0210	N/A P1	Day 2 URN-1
19	ISP	AA99602-01	05113200001523	0210	N/A P1	Day 3 URN-1
19	ISP	AA99602-01	05113200001524	0210	N/A P1	Day 4 URN-1
19	ISP	AA99602-01	05113200001525	0210	N/A P1	Day 5 URN-1
19	ISP	AA99602-01	05113200001526	0210	N/A P1	Day 6 URN-1
19	ISP	AA99602-01	05113200001548	0216	N/A P1	Day 0 URN-1
19	ISP	AA99602-01	05113200001549	0216	N/A P1	Day 1 URN-1
19	ISP	AA99602-01	05113200001550	0216	N/A P1	Day 2 URN-1
19	ISP	AA99602-01	05113200001551	0216	N/A P1	Day 3 URN-1
19	ISP	AA99602-01	05113200001552	0216	N/A P1	Day 4 URN-1
19	ISP	AA99602-01	05113200001553	0216	N/A P1	Day 5 URN-1
19	ISP	AA99602-01	05113200001554	0216	N/A P1	Day 6 URN-1
19	ISP	AA99602-01	05113200001562	0218	N/A P1	Day 0 URN-1
19	ISP	AA99602-01	05113200001563	0218	N/A P1	Day 1 URN-1
19	ISP	AA99602-01	05113200001564	0218	N/A P1	Day 2 URN-1
19	ISP	AA99602-01	05113200001565	0218	N/A P1	Day 3 URN-1
19	ISP	AA99602-01	05113200001566	0218	N/A P1	Day 4 URN-1
19	ISP	AA99602-01	05113200001567	0218	N/A P1	Day 5 URN-1
19	ISP	AA99602-01	05113200001568	0218	N/A P1	Day 6 URN-1
19	ISP	AA99602-01	05113200001576	0220	N/A P1	Day 0 URN-1
19	ISP	AA99602-01	05113200001577	0220	N/A P1	Day 1 URN-1
19	ISP	AA99602-01	05113200001578	0220	N/A P1	Day 2 URN-1
19	ISP	AA99602-01	05113200001579	0220	N/A P1	Day 3 URN-1
19	ISP	AA99602-01	05113200001580	0220	N/A P1	Day 4 URN-1
19	ISP	AA99602-01	05113200001581	0220	N/A P1	Day 5 URN-1
19	ISP	AA99602-01	05113200001582	0220	N/A P1	Day 6 URN-1
19	ISP	AA99602-01	05113200001590	0224	N/A P1	Day 0 URN-1
19	ISP	AA99602-01	05113200001591	0224	N/A P1	Day 1 URN-1
19	ISP	AA99602-01	05113200001592	0224	N/A P1	Day 2 URN-1
19	ISP	AA99602-01	05113200001593	0224	N/A P1	Day 3 URN-1
19	ISP	AA99602-01	05113200001594	0224	N/A P1	Day 4 URN-1
19	ISP	AA99602-01	05113200001595	0224	N/A P1	Day 5 URN-1
19	ISP	AA99602-01	05113200001596	0224	N/A P1	Day 6 URN-1
19	ISP	AA99602-01	05113200001604	0228	N/A P1	Day 0 URN-1
19	ISP	AA99602-01	05113200001605	0228	N/A P1	Day 1 URN-1
19	ISP	AA99602-01	05113200001606	0228	N/A P1	Day 2 URN-1
19	ISP	AA99602-01	05113200001607	0228	N/A P1	Day 3 URN-1
19	ISP	AA99602-01	05113200001608	0228	N/A P1	Day 4 URN-1
19	ISP	AA99602-01	05113200001609	0228	N/A P1	Day 5 URN-1
19	ISP	AA99602-01	05113200001610	0228	N/A P1	Day 6 URN-1
19	ISP	AA99602-01	05113200001618	0229	N/A P1	Day 0 URN-1
19	ISP	AA99602-01	05113200001619	0229	N/A P1	Day 1 URN-1
19	ISP	AA99602-01	05113200001620	0229	N/A P1	Day 2 URN-1
19	ISP	AA99602-01	05113200001621	0229	N/A P1	Day 3 URN-1
19	ISP	AA99602-01	05113200001622	0229	N/A P1	Day 4 URN-1
19	ISP	AA99602-01	05113200001623	0229	N/A P1	Day 5 URN-1
19	ISP	AA99602-01	05113200001624	0229	N/A P1	Day 6 URN-1



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Watson Run ID	Reason*	Sample Name
		(Study number Custom ID Subject Treatment Period Nominal Time Matrix-Split)
19	ISP	AA99602-01 05113200001632 0230 N/A P1 Day 0 URN-1
19	ISP	AA99602-01 05113200001633 0230 N/A P1 Day 1 URN-1
19	ISP	AA99602-01 05113200001634 0230 N/A P1 Day 2 URN-1
19	ISP	AA99602-01 05113200001635 0230 N/A P1 Day 3 URN-1
19	ISP	AA99602-01 05113200001636 0230 N/A P1 Day 4 URN-1
19	ISP	AA99602-01 05113200001637 0230 N/A P1 Day 5 URN-1
19	ISP	AA99602-01 05113200001638 0230 N/A P1 Day 6 URN-1
21	ISA	AA99602-01 05113200000157 0053 N/A P1 Day 2 URN-1

\*: See [Attachment 5](#) for reassay descriptions.





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Table 11 Summary of Reassay for Analytical Reasons for SPMA

Watson Run ID	Reason*	Sample Name
		(Study number Custom ID Subject Treatment Period Nominal Time Matrix-Split)
1	AAR	AA99602-01 05113200000001 0008 N/A P1 Day 0 URN-1
3	ISA	AA99602-01 05113200000157 0053 N/A P1 Day 2 URN-1
4	ISP	AA99602-01 05113200000806 0112 N/A P1 Day 0 URN-1
4	ISP	AA99602-01 05113200000807 0112 N/A P1 Day 1 URN-1
4	ISP	AA99602-01 05113200000808 0112 N/A P1 Day 2 URN-1
4	ISP	AA99602-01 05113200000809 0112 N/A P1 Day 3 URN-1
4	ISP	AA99602-01 05113200000810 0112 N/A P1 Day 4 URN-1
4	ISP	AA99602-01 05113200000811 0112 N/A P1 Day 5 URN-1
4	ISP	AA99602-01 05113200000812 0112 N/A P1 Day 6 URN-1
4	ISP	AA99602-01 05113200000512 0063 N/A P1 Day 0 URN-1
4	ISP	AA99602-01 05113200000513 0063 N/A P1 Day 1 URN-1
4	ISP	AA99602-01 05113200000514 0063 N/A P1 Day 2 URN-1
4	ISP	AA99602-01 05113200000515 0063 N/A P1 Day 3 URN-1
4	ISP	AA99602-01 05113200000516 0063 N/A P1 Day 4 URN-1
4	ISP	AA99602-01 05113200000517 0063 N/A P1 Day 5 URN-1
4	ISP	AA99602-01 05113200000518 0063 N/A P1 Day 6 URN-1
4	ISP	AA99602-01 05113200000190 0064 N/A P1 Day 0 URN-1
4	ISP	AA99602-01 05113200000191 0064 N/A P1 Day 1 URN-1
4	ISP	AA99602-01 05113200000192 0064 N/A P1 Day 2 URN-1
4	ISP	AA99602-01 05113200000193 0064 N/A P1 Day 3 URN-1
4	ISP	AA99602-01 05113200000194 0064 N/A P1 Day 4 URN-1
4	ISP	AA99602-01 05113200000195 0064 N/A P1 Day 5 URN-1
4	ISP	AA99602-01 05113200000196 0064 N/A P1 Day 6 URN-1
4	ISP	AA99602-01 05113200000526 0066 N/A P1 Day 0 URN-1
4	ISP	AA99602-01 05113200000527 0066 N/A P1 Day 1 URN-1
4	ISP	AA99602-01 05113200000528 0066 N/A P1 Day 2 URN-1
4	ISP	AA99602-01 05113200000529 0066 N/A P1 Day 3 URN-1
4	ISP	AA99602-01 05113200000530 0066 N/A P1 Day 4 URN-1
4	ISP	AA99602-01 05113200000531 0066 N/A P1 Day 5 URN-1
4	ISP	AA99602-01 05113200000532 0066 N/A P1 Day 6 URN-1
4	ISP	AA99602-01 05113200000540 0067 N/A P1 Day 0 URN-1
4	ISP	AA99602-01 05113200000541 0067 N/A P1 Day 1 URN-1
4	ISP	AA99602-01 05113200000542 0067 N/A P1 Day 2 URN-1
4	ISP	AA99602-01 05113200000543 0067 N/A P1 Day 3 URN-1
4	ISP	AA99602-01 05113200000544 0067 N/A P1 Day 4 URN-1
4	ISP	AA99602-01 05113200000545 0067 N/A P1 Day 5 URN-1
4	ISP	AA99602-01 05113200000546 0067 N/A P1 Day 6 URN-1
4	ISP	AA99602-01 05113200000554 0069 N/A P1 Day 0 URN-1
4	ISP	AA99602-01 05113200000555 0069 N/A P1 Day 1 URN-1
4	ISP	AA99602-01 05113200000556 0069 N/A P1 Day 2 URN-1
4	ISP	AA99602-01 05113200000557 0069 N/A P1 Day 3 URN-1
4	ISP	AA99602-01 05113200000558 0069 N/A P1 Day 4 URN-1
4	ISP	AA99602-01 05113200000559 0069 N/A P1 Day 5 URN-1
4	ISP	AA99602-01 05113200000560 0069 N/A P1 Day 6 URN-1



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Watson Run ID	Reason*	Sample Name				
		(Study number	Custom ID	Subject	Treatment Period	Nominal Time Matrix-Split)
4	ISP	AA99602-01	05113200000568	0071	N/A P1 Day 0	URN-1
4	ISP	AA99602-01	05113200000569	0071	N/A P1 Day 1	URN-1
4	ISP	AA99602-01	05113200000570	0071	N/A P1 Day 2	URN-1
4	ISP	AA99602-01	05113200000571	0071	N/A P1 Day 3	URN-1
4	ISP	AA99602-01	05113200000572	0071	N/A P1 Day 4	URN-1
4	ISP	AA99602-01	05113200000573	0071	N/A P1 Day 5	URN-1
4	ISP	AA99602-01	05113200000574	0071	N/A P1 Day 6	URN-1
4	ISP	AA99602-01	05113200000596	0074	N/A P1 Day 0	URN-1
4	ISP	AA99602-01	05113200000597	0074	N/A P1 Day 1	URN-1
4	ISP	AA99602-01	05113200000598	0074	N/A P1 Day 2	URN-1
4	ISP	AA99602-01	05113200000599	0074	N/A P1 Day 3	URN-1
4	ISP	AA99602-01	05113200000600	0074	N/A P1 Day 4	URN-1
4	ISP	AA99602-01	05113200000601	0074	N/A P1 Day 5	URN-1
4	ISP	AA99602-01	05113200000602	0074	N/A P1 Day 6	URN-1
4	ISP	AA99602-01	05113200000610	0076	N/A P1 Day 0	URN-1
4	ISP	AA99602-01	05113200000611	0076	N/A P1 Day 1	URN-1
4	ISP	AA99602-01	05113200000612	0076	N/A P1 Day 2	URN-1
4	ISP	AA99602-01	05113200000613	0076	N/A P1 Day 3	URN-1
4	ISP	AA99602-01	05113200000614	0076	N/A P1 Day 4	URN-1
4	ISP	AA99602-01	05113200000615	0076	N/A P1 Day 5	URN-1
4	ISP	AA99602-01	05113200000616	0076	N/A P1 Day 6	URN-1
4	ISP	AA99602-01	05113200000624	0080	N/A P1 Day 0	URN-1
4	ISP	AA99602-01	05113200000625	0080	N/A P1 Day 1	URN-1
4	ISP	AA99602-01	05113200000626	0080	N/A P1 Day 2	URN-1
4	ISP	AA99602-01	05113200000627	0080	N/A P1 Day 3	URN-1
4	ISP	AA99602-01	05113200000628	0080	N/A P1 Day 4	URN-1
4	ISP	AA99602-01	05113200000629	0080	N/A P1 Day 5	URN-1
4	ISP	AA99602-01	05113200000630	0080	N/A P1 Day 6	URN-1
7	AAR	AA99602-01	05113200000596	0074	N/A P1 Day 0	URN-1
7	AAR	AA99602-01	05113200000597	0074	N/A P1 Day 1	URN-1
9	AAR	AA99602-01	05113200001171	0156	N/A P1 Day 1	URN-1
9	AAR	AA99602-01	05113200001175	0156	N/A P1 Day 5	URN-1
19	ISP	AA99602-01	05113200001492	0204	N/A P1 Day 0	URN-1
19	ISP	AA99602-01	05113200001493	0204	N/A P1 Day 1	URN-1
19	ISP	AA99602-01	05113200001494	0204	N/A P1 Day 2	URN-1
19	ISP	AA99602-01	05113200001495	0204	N/A P1 Day 3	URN-1
19	ISP	AA99602-01	05113200001496	0204	N/A P1 Day 4	URN-1
19	ISP	AA99602-01	05113200001497	0204	N/A P1 Day 5	URN-1
19	ISP	AA99602-01	05113200001498	0204	N/A P1 Day 6	URN-1
19	ISP	AA99602-01	05113200001506	0206	N/A P1 Day 0	URN-1
19	ISP	AA99602-01	05113200001507	0206	N/A P1 Day 1	URN-1
19	ISP	AA99602-01	05113200001508	0206	N/A P1 Day 2	URN-1
19	ISP	AA99602-01	05113200001509	0206	N/A P1 Day 3	URN-1
19	ISP	AA99602-01	05113200001510	0206	N/A P1 Day 4	URN-1
19	ISP	AA99602-01	05113200001511	0206	N/A P1 Day 5	URN-1
19	ISP	AA99602-01	05113200001512	0206	N/A P1 Day 6	URN-1
19	ISP	AA99602-01	05113200001520	0210	N/A P1 Day 0	URN-1





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Watson Run ID	Reason*	Sample Name				
		(Study number	Custom ID	Subject	Treatment Period	Nominal Time Matrix-Split)
19	ISP	AA99602-01	05113200001521	0210	N/A P1 Day 1	URN-1
19	ISP	AA99602-01	05113200001522	0210	N/A P1 Day 2	URN-1
19	ISP	AA99602-01	05113200001523	0210	N/A P1 Day 3	URN-1
19	ISP	AA99602-01	05113200001524	0210	N/A P1 Day 4	URN-1
19	ISP	AA99602-01	05113200001525	0210	N/A P1 Day 5	URN-1
19	ISP	AA99602-01	05113200001526	0210	N/A P1 Day 6	URN-1
19	ISP	AA99602-01	05113200001548	0216	N/A P1 Day 0	URN-1
19	ISP	AA99602-01	05113200001549	0216	N/A P1 Day 1	URN-1
19	ISP	AA99602-01	05113200001550	0216	N/A P1 Day 2	URN-1
19	ISP	AA99602-01	05113200001551	0216	N/A P1 Day 3	URN-1
19	ISP	AA99602-01	05113200001552	0216	N/A P1 Day 4	URN-1
19	ISP	AA99602-01	05113200001553	0216	N/A P1 Day 5	URN-1
19	ISP	AA99602-01	05113200001554	0216	N/A P1 Day 6	URN-1
19	ISP	AA99602-01	05113200001562	0218	N/A P1 Day 0	URN-1
19	ISP	AA99602-01	05113200001563	0218	N/A P1 Day 1	URN-1
19	ISP	AA99602-01	05113200001564	0218	N/A P1 Day 2	URN-1
19	ISP	AA99602-01	05113200001565	0218	N/A P1 Day 3	URN-1
19	ISP	AA99602-01	05113200001566	0218	N/A P1 Day 4	URN-1
19	ISP	AA99602-01	05113200001567	0218	N/A P1 Day 5	URN-1
19	ISP	AA99602-01	05113200001568	0218	N/A P1 Day 6	URN-1
19	ISP	AA99602-01	05113200001576	0220	N/A P1 Day 0	URN-1
19	ISP	AA99602-01	05113200001577	0220	N/A P1 Day 1	URN-1
19	ISP	AA99602-01	05113200001578	0220	N/A P1 Day 2	URN-1
19	ISP	AA99602-01	05113200001579	0220	N/A P1 Day 3	URN-1
19	ISP	AA99602-01	05113200001580	0220	N/A P1 Day 4	URN-1
19	ISP	AA99602-01	05113200001581	0220	N/A P1 Day 5	URN-1
19	ISP	AA99602-01	05113200001582	0220	N/A P1 Day 6	URN-1
19	ISP	AA99602-01	05113200001590	0224	N/A P1 Day 0	URN-1
19	ISP	AA99602-01	05113200001591	0224	N/A P1 Day 1	URN-1
19	ISP	AA99602-01	05113200001592	0224	N/A P1 Day 2	URN-1
19	ISP	AA99602-01	05113200001593	0224	N/A P1 Day 3	URN-1
19	ISP	AA99602-01	05113200001594	0224	N/A P1 Day 4	URN-1
19	ISP	AA99602-01	05113200001595	0224	N/A P1 Day 5	URN-1
19	ISP	AA99602-01	05113200001596	0224	N/A P1 Day 6	URN-1
19	ISP	AA99602-01	05113200001604	0228	N/A P1 Day 0	URN-1
19	ISP	AA99602-01	05113200001605	0228	N/A P1 Day 1	URN-1
19	ISP	AA99602-01	05113200001606	0228	N/A P1 Day 2	URN-1
19	ISP	AA99602-01	05113200001607	0228	N/A P1 Day 3	URN-1
19	ISP	AA99602-01	05113200001608	0228	N/A P1 Day 4	URN-1
19	ISP	AA99602-01	05113200001609	0228	N/A P1 Day 5	URN-1
19	ISP	AA99602-01	05113200001610	0228	N/A P1 Day 6	URN-1
19	ISP	AA99602-01	05113200001618	0229	N/A P1 Day 0	URN-1
19	ISP	AA99602-01	05113200001619	0229	N/A P1 Day 1	URN-1
19	ISP	AA99602-01	05113200001620	0229	N/A P1 Day 2	URN-1
19	ISP	AA99602-01	05113200001621	0229	N/A P1 Day 3	URN-1
19	ISP	AA99602-01	05113200001622	0229	N/A P1 Day 4	URN-1
19	ISP	AA99602-01	05113200001623	0229	N/A P1 Day 5	URN-1



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Watson Run ID	Reason*	Sample Name
		(Study number Custom ID Subject Treatment Period Nominal Time Matrix-Split)
19	ISP	AA99602-01 05113200001624 0229 N/A P1 Day 6 URN-1
19	ISP	AA99602-01 05113200001632 0230 N/A P1 Day 0 URN-1
19	ISP	AA99602-01 05113200001633 0230 N/A P1 Day 1 URN-1
19	ISP	AA99602-01 05113200001634 0230 N/A P1 Day 2 URN-1
19	ISP	AA99602-01 05113200001635 0230 N/A P1 Day 3 URN-1
19	ISP	AA99602-01 05113200001636 0230 N/A P1 Day 4 URN-1
19	ISP	AA99602-01 05113200001637 0230 N/A P1 Day 5 URN-1
19	ISP	AA99602-01 05113200001638 0230 N/A P1 Day 6 URN-1
20	AAR	AA99602-01 05113200001758 0249 N/A P1 Day 0 URN-1
20	AAR	AA99602-01 05113200001759 0249 N/A P1 Day 1 URN-1
21	ISA	AA99602-01 05113200000157 0053 N/A P1 Day 2 URN-1
26	AAR	AA99602-01 05113200000058 0022 N/A P1 Day 1 URN-1
27	AAR	AA99602-01 05113200000058 0022 N/A P1 Day 1 URN-1

\*: See [Attachment 5](#) for reassay descriptions.





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Table 12 Summary of Reassay for Non-analytical Reasons (VRC, Value Requiring Confirmation) for SBMA

Subject	Period	Nominal time	Analyte	Reasons for Reassay	Units	Original Watson Run ID	Original Value	Reassay Watson Run ID	Reassay Value 1	Reassay Value 2	Reassay Value 3	Mean repeat	CV% of Reassays	% Diff from Original	Confirms Original	Reported Concentration
0008	1	Day 5	SBMA	VRC	ng/mL	11	8.26	15	5.65	5.78	5.92	5.78	2.3	-30.0	No	5.78
0013	1	Day 3	SBMA	VRC	ng/mL	11	0.759	15	2.76	2.74	2.87	2.79	2.5	267.6	No	2.79



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Table 13 Summary of Reassay for Non-analytical Reasons (VRC, Value Requiring Confirmation) for SPMA

Subject	Period	Nominal time	Analyte	Reasons for Reassay	Units	Original Watson Run ID	Original Value	Reassay Watson Run ID	Reassay Value 1	Reassay Value 2	Reassay Value 3	Mean repeat	CV% of Reassays	% Diff from Original	Confirms Original	Reported Concentration
0008	1	Day 5	SPMA	VRC	ng/mL	11	0.414	15	0.786	0.794	0.814	0.798	1.8	92.8	No	0.798
0013	1	Day 3	SPMA	VRC	ng/mL	11	0.0580	15	0.189	0.197	0.207	0.198	4.6	240.8	No	0.198



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Table 14 Incurred Sample Reproducibility Assessment for SBMA

Subject	Custom ID	Day Nominal	Original analysis		ISR analysis		%Diff	Match
			Result (ng/mL)	Watson Run ID	Result (ng/mL)	Watson Run ID		
0001	05113200000414	0	0.708	1	1.19	11	50.8	No
0008	05113200000006	5	8.26	1	4.64	11	56.1	No <sup>a</sup>
0008	05113200000007	6	8.42	1	7.90	11	6.4	Yes
0013	05113200000445	3	0.759	1	2.35	11	102.3	No <sup>a</sup>
0014	05113200000023	1	9.18	1	10.2	11	10.5	Yes
0015	05113200000033	4	1.19	21	1.84	27	42.9	No
0016	05113200000037	1	1.28	1	1.92	11	40.0	No
0017	05113200000049	6	9.52	1	10.6	11	10.7	Yes
0021	05113200000459	3	18.4	2	12.7	11	36.7	No
0022	05113200000058	1	13.3	26	12.3	27	7.8	Yes
0029	05113200000086	1	0.935	2	0.994	11	6.1	Yes
0029	05113200000089	4	0.545	2	0.937	11	52.9	No
0029	05113200000090	5	0.793	2	0.806	11	1.6	Yes
0034	05113200000111	5	8.29	2	9.64	11	15.1	Yes
0035	05113200000117	4	0.947	2	1.06	11	11.3	Yes
0037	05113200000476	6	7.91	2	10.7	11	30.0	No
0049	05113200000141	0	3.31	3	2.93	11	12.2	Yes
0049	05113200000142	1	1.46	3	1.22	11	17.9	Yes
0051	05113200000502	4	16.4	3	14.3	11	13.7	Yes
0051	05113200000503	5	18.3	3	15.6	11	15.9	Yes
0051	05113200000504	6	17.5	3	15.5	11	12.1	Yes
0053	05113200000158	3	1.51	3	1.37	11	9.7	Yes
0053	05113200000159	4	1.20	3	1.13	11	6.0	Yes
0053	05113200000160	5	1.34	3	1.19	11	11.9	Yes
0057	05113200000172	3	0.991	21	1.78	27	56.9	No
0066	05113200000528	2	1.64	7	1.63	11	0.6	Yes
0067	05113200000545	5	1.81	7	1.43	11	23.5	No



SPMA and SBMA in Human Urine  
Celeron Study AA99602-01

Subject	Custom ID	Day Nominal	Original analysis		ISR analysis		%Diff	Match
			Result (ng/mL)	Watson Run ID	Result (ng/mL)	Watson Run ID		
0071	05113200000569	1	19.1	7	17.5	11	8.7	Yes
0071	05113200000570	2	15.7	7	14.4	11	8.6	Yes
0071	05113200000572	4	20.9	7	20.2	11	3.4	Yes
0071	05113200000574	6	21.2	7	20.1	11	5.3	Yes
0080	05113200000629	5	14.2	7	11.9	11	17.6	Yes
0085	05113200000655	3	1.56	21	2.17	27	32.7	No
0088	05113200000696	2	10.7	5	10.2	11	4.8	Yes
0088	05113200000698	4	13.2	5	11.5	11	13.8	Yes
0088	05113200000700	6	11.2	5	10.2	11	9.3	Yes
0090	05113200000714	6	12.9	5	11.6	11	10.6	Yes
0106	05113200000766	2	2.14	5	1.71	11	22.3	No
0106	05113200000769	5	2.04	5	1.38	11	38.6	No
0110	05113200000797	5	2.24	5	1.99	11	11.8	Yes
0122	05113200000879	3	1.52	6	1.56	11	2.6	Yes
0123	05113200000893	3	1.28	6	1.10	11	15.1	Yes
0128	05113200000932	0	15.3	6	14.2	11	7.5	Yes
0128	05113200000933	1	16.8	6	15.2	11	10.0	Yes
0128	05113200000938	6	15.2	6	14.1	11	7.5	Yes
0129	05113200000949	3	1.42	6	1.15	11	21.0	No
0129	05113200000952	6	1.02	6	0.913	11	11.1	Yes
0133	05113200000975	1	12.6	8	11.2	11	11.8	Yes
0134	05113200000991	3	1.62	8	1.46	11	10.4	Yes
0139	05113200001031	1	12.9	8	12.3	11	4.8	Yes
0140	05113200001050	6	2.17	8	1.96	11	10.2	Yes
0145	05113200001062	4	1.84	8	1.72	11	6.7	Yes
0145	05113200001063	5	2.07	8	1.81	11	13.4	Yes
0148	05113200001087	1	15.8	8	14.4	11	9.3	Yes
0152	05113200001133	5	1.59	9	1.31	11	19.3	Yes
0152	05113200001134	6	1.30	9	1.10	11	16.7	Yes
0162	05113200001198	0	9.94	9	8.86	11	11.5	Yes





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Subject	Custom ID	Day Nominal	Original analysis		ISR analysis		%Diff	Match
			Result (ng/mL)	Watson Run ID	Result (ng/mL)	Watson Run ID		
0162	05113200001199	1	8.84	9	7.70	11	13.8	Yes
0167	05113200001213	1	8.35	9	6.89	11	19.2	Yes
0169	05113200001231	5	1.56	9	1.12	11	32.8	No
0170	05113200001240	0	10.9	10	11.2	27	2.7	Yes
0177	05113200001259	5	0.89	10	0.851	27	4.5	Yes
0181	05113200001367	1	5.79	18	5.77	27	0.3	Yes
0185	05113200001285	3	1.47	10	1.40	27	4.9	Yes
0187	05113200001300	4	7.81	10	7.92	27	1.4	Yes
0191	05113200001330	6	1.81	10	1.72	27	5.1	Yes
0192	05113200001339	1	8.06	10	7.87	27	2.4	Yes
0193	05113200001386	6	1.37	18	1.34	27	2.2	Yes
0195	05113200001400	6	0.416	18	0.432	27	3.8	Yes
0196	05113200001414	6	1.36	18	1.33	27	2.2	Yes
0198	05113200001437	1	13.4	18	13.1	27	2.3	Yes
0203	05113200001479	1	9.10	18	8.72	27	4.3	Yes
0204	05113200001495	3	1.68	22	1.58	27	6.1	Yes
0216	05113200001554	6	2.10	22	2.00	27	4.9	Yes
0218	05113200001563	1	11.2	22	10.8	27	3.6	Yes
0220	05113200001577	1	11.1	22	10.9	27	1.8	Yes
0229	05113200001620	2	10.7	22	9.93	27	7.5	Yes
0230	05113200001632	0	1.22	22	1.21	27	0.8	Yes
0232	05113200001652	6	0.710	20	0.674	27	5.2	Yes
0234	05113200001661	1	8.04	20	8.55	27	6.1	Yes
0240	05113200001677	3	1.26	20	1.24	27	1.6	Yes
0241	05113200001689	1	10.0	20	10.2	27	2.0	Yes
0249	05113200001761	3	1.95	20	1.98	27	1.5	Yes
0256	05113200001801	1	9.89	20	9.77	27	1.2	Yes
0262	05113200001815	1	6.02	21	6.29	27	4.4	Yes
0264	05113200001829	1	5.44	21	5.23	27	3.9	Yes
0265	05113200001843	1	8.20	21	9.09	27	10.3	Yes



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Subject	Custom ID	Day Nominal	Original analysis		ISR analysis		%Diff	Match
			Result (ng/mL)	Watson Run ID	Result (ng/mL)	Watson Run ID		
0272	05113200001902	4	15.7	23	18.6	27	16.9	Yes
0278	05113200001959	5	1.37	23	1.99	27	36.9	No
0279	05113200001968	0	10.7	23	11.3	27	5.5	Yes
0282	05113200002002	6	1.05	23	1.45	27	32.0	No
0283	05113200002016	6	1.06	23	1.08	27	1.9	Yes
0285	05113200002025	1	8.04	23	7.47	27	7.4	Yes
0287	05113200002041	3	1.97	24	1.95	27	1.0	Yes
0289	05113200002071	5	2.82	24	2.70	27	4.3	Yes
0292	05113200002096	2	14.8	24	14.4	27	2.7	Yes
0298	05113200002124	2	13.3	24	13.4	27	0.7	Yes
0306	05113200002184	6	12.1	24	11.3	27	6.8	Yes
0307	05113200002198	6	2.50	24	2.36	27	5.8	Yes
0315	05113200002267	5	1.72	25	2.40	27	33.0	No
0316	05113200002281	5	1.73	25	2.08	27	18.4	Yes
0318	05113200002310	6	18.5	25	20.1	27	8.3	Yes
0320	05113200002322	4	9.59	25	9.94	27	3.6	Yes
0322	05113200002352	6	1.17	25	1.19	27	1.7	Yes
0325	05113200002362	2	12.8	25	13.0	27	1.6	Yes
0328	05113200002380	6	1.82	26	1.80	27	1.1	Yes
n							106	88
Matches (%)								83

<sup>a</sup> see also event resolution dated 04-Oct-2013 (section 7.1)



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Table 15 Incurred Sample Reproducibility Assessment for SPMA

Subject	Custom ID	Day Nominal	Original analysis		ISR analysis		%Diff	Match
			Result (ng/mL)	Watson Run ID	Result (ng/mL)	Watson Run ID		
0001	05113200000414	0	0.392	1	0.746	11	62.2	No
0008	05113200000006	5	0.414	1	0.764	11	59.4	No <sup>a</sup>
0008	05113200000007	6	0.443	1	0.422	11	4.9	Yes
0013	05113200000445	3	0.0580	1	0.203	11	111.1	No <sup>a</sup>
0014	05113200000023	1	3.02	1	3.50	11	14.7	Yes
0015	05113200000033	4	0.0785	21	0.110	27	33.4	No
0016	05113200000037	1	0.776	1	1.31	11	51.2	No
0017	05113200000049	6	0.0634	1	0.0684	11	7.6	Yes
0021	05113200000459	3	4.06	2	2.93	11	32.3	No
0022	05113200000059	2	1.58	26	1.61	28	1.9	Yes
0029	05113200000086	1	1.29	2	1.48	11	13.7	Yes
0029	05113200000089	4	1.29	2	2.25	11	54.2	No
0029	05113200000090	5	1.36	2	1.40	11	2.9	Yes
0034	05113200000111	5	0.119	2	0.163	11	31.2	No
0035	05113200000117	4	2.02	2	2.55	11	23.2	No
0037	05113200000476	6	2.89	2	4.24	11	37.9	No
0049	05113200000141	0	2.48	3	2.33	11	6.2	Yes
0049	05113200000142	1	0.832	3	0.713	11	15.4	Yes
0051	05113200000502	4	0.0369	3	0.0342	11	7.6	Yes
0051	05113200000503	5	0.0307	3	0.0294	11	4.3	Yes
0051	05113200000504	6	0.0424	3	0.0425	11	0.2	Yes
0053	05113200000158	3	3.78	3	3.52	11	7.1	Yes
0053	05113200000159	4	4.37	3	4.31	11	1.4	Yes
0053	05113200000160	5	3.45	3	3.44	11	0.3	Yes
0057	05113200000172	3	0.0868	21	0.169	27	64.3	No
0066	05113200000528	2	0.438	7	0.478	11	8.7	Yes
0067	05113200000545	5	1.56	7	1.44	11	8.0	Yes



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Subject	Custom ID	Day Nominal	Original analysis		ISR analysis		%Diff	Match
			Result (ng/mL)	Watson Run ID	Result (ng/mL)	Watson Run ID		
0071	05113200000569	1	1.34	7	1.27	11	5.4	Yes
0071	05113200000570	2	0.675	7	0.615	11	9.3	Yes
0071	05113200000572	4	0.0826	7	0.0788	11	4.7	Yes
0071	05113200000574	6	0.0934	7	0.0861	11	8.1	Yes
0080	05113200000629	5	2.87	7	2.73	11	5.0	Yes
0085	05113200000655	3	0.155	21	0.219	27	34.2	No
0088	05113200000696	2	0.141	5	0.139	11	1.4	Yes
0088	05113200000698	4	0.0493	5	0.0459	11	7.1	Yes
0088	05113200000700	6	0.0435	5	0.0346	11	22.8	No
0090	05113200000714	6	0.0456	5	0.0438	11	4.0	Yes
0106	05113200000766	2	0.878	5	0.747	11	16.1	Yes
0106	05113200000769	5	0.103	5	0.0951	11	8.0	Yes
0110	05113200000797	5	0.157	5	0.151	11	3.9	Yes
0122	05113200000879	3	0.0437	6	0.052	11	17.3	Yes
0123	05113200000893	3	0.128	6	0.110	11	15.1	Yes
0128	05113200000932	0	0.474	6	0.447	11	5.9	Yes
0128	05113200000933	1	0.523	6	0.507	11	3.1	Yes
0128	05113200000938	6	0.0807	6	0.0844	11	4.5	Yes
0129	05113200000949	3	0.125	6	0.121	11	3.3	Yes
0129	05113200000952	6	0.0605	6	0.0594	11	1.8	Yes
0133	05113200000975	1	5.44	8	5.13	11	5.9	Yes
0134	05113200000991	3	0.213	8	0.198	11	7.3	Yes
0139	05113200001031	1	2.92	8	2.94	11	0.7	Yes
0140	05113200001050	6	1.09	8	1.09	11	0.0	Yes
0145	05113200001062	4	0.262	8	0.258	11	1.5	Yes
0145	05113200001063	5	0.166	8	0.151	11	9.5	Yes
0148	05113200001087	1	1.85	8	1.80	11	2.7	Yes
0152	05113200001133	5	1.45	9	1.23	11	16.4	Yes
0152	05113200001134	6	1.57	9	1.38	11	12.9	Yes
0162	05113200001198	0	1.54	9	1.44	11	6.7	Yes





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Subject	Custom ID	Day Nominal	Original analysis		ISR analysis		%Diff	Match
			Result (ng/mL)	Watson Run ID	Result (ng/mL)	Watson Run ID		
0162	05113200001199	1	2.14	9	2.03	11	5.3	Yes
0167	05113200001213	1	1.93	9	1.71	11	12.1	Yes
0169	05113200001231	5	0.0445	9	0.0372	11	17.9	Yes
0170	05113200001240	0	3.18	10	2.71	27	16.0	Yes
0177	05113200001259	5	0.160	10	0.146	27	9.2	Yes
0181	05113200001367	1	3.88	18	3.75	27	3.4	Yes
0185	05113200001285	3	0.594	10	0.540	27	9.5	Yes
0187	05113200001300	4	3.53	10	2.97	27	17.2	Yes
0191	05113200001330	6	1.23	10	1.12	27	9.4	Yes
0192	05113200001339	1	4.21	10	3.71	27	12.6	Yes
0193	05113200001386	6	0.180	18	0.172	27	4.5	Yes
0195	05113200001400	6	0.0277	18	0.0275	27	0.7	Yes
0196	05113200001414	6	0.0319	18	0.0255	27	22.3	No
0198	05113200001437	1	4.99	18	4.85	27	2.8	Yes
0203	05113200001479	1	1.90	18	1.81	27	4.9	Yes
0204	05113200001495	3	0.948	22	0.924	27	2.6	Yes
0216	05113200001554	6	0.077	22	0.0764	27	0.8	Yes
0218	05113200001563	1	0.774	22	0.719	27	7.4	Yes
0220	05113200001577	1	1.84	22	1.86	27	1.1	Yes
0229	05113200001620	2	1.60	22	1.54	27	3.8	Yes
0230	05113200001632	0	1.05	22	1.04	27	1.0	Yes
0232	05113200001652	6	0.0715	20	0.0610	27	15.8	Yes
0234	05113200001661	1	2.48	20	2.51	27	1.2	Yes
0240	05113200001677	3	0.279	20	0.283	27	1.4	Yes
0241	05113200001689	1	1.75	20	1.68	27	4.1	Yes
0249	05113200001761	3	0.960	20	1.02	27	6.1	Yes
0256	05113200001801	1	2.73	20	2.68	27	1.8	Yes
0262	05113200001815	1	0.220	21	0.227	27	3.1	Yes
0264	05113200001829	1	1.04	21	0.943	27	9.8	Yes
0265	05113200001843	1	0.850	21	0.926	27	8.6	Yes



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Subject	Custom ID	Day Nominal	Original analysis		ISR analysis		%Diff	Match
			Result (ng/mL)	Watson Run ID	Result (ng/mL)	Watson Run ID		
0272	05113200001902	4	0 169	23	0 208	27	20.7	No
0278	05113200001959	5	1 01	23	1 50	27	39.0	No
0279	05113200001968	0	2 49	23	2 72	27	8 8	Yes
0282	05113200002002	6	0 114	23	0 154	27	29.9	No
0283	05113200002016	6	0 860	23	0 988	27	13 9	Yes
0285	05113200002025	1	3 70	23	3 44	27	7 3	Yes
0287	05113200002041	3	0 712	24	0 724	27	1 7	Yes
0289	05113200002071	5	0 125	24	0 127	27	1 6	Yes
0292	05113200002096	2	0 722	24	0 727	27	0 7	Yes
0298	05113200002124	2	4 32	24	4 50	27	4 1	Yes
0306	05113200002184	6	0 116	24	0 126	27	8 3	Yes
0307	05113200002198	6	0 192	24	0 193	27	0 5	Yes
0315	05113200002267	5	1 16	25	1 56	27	29.4	No
0316	05113200002281	5	0 0819	25	0 0831	27	1 5	Yes
0318	05113200002310	6	0 904	25	0 986	27	8 7	Yes
0320	05113200002322	4	0 901	25	0 973	27	7 7	Yes
0322	05113200002352	6	0 977	25	1 02	27	4 3	Yes
0325	05113200002362	2	0 897	25	0 924	27	3 0	Yes
0328	05113200002380	6	0 731	26	0 734	27	0 4	Yes
n							106	88
Matches (%)								83


<sup>a</sup> see also event resolution dated 04-Oct-2013 (section 7 1)

SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

## FIGURES


Figure 1 Calibration Curve for SBMA in human urine, Watson Run ID 1

Analytical Run 1 analyzed on 24-Sep-2013 Calibration Standards for SBMA (ng/mL)  
Regression Method = LINEAR - Weighting Factor =  $1/X^2$   
Response = Slope \* Conc + Intercept  
Slope = 0.230128587 Intercept = 0.000234146404 R-Squared = 0.9973  
(Study ZRHR-REXC-03-EU; SBMA/SPMA)



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01**Figure 2 Calibration Curve for SPMA in human urine, Watson Run ID 1**

Analytical Run 1 analyzed on 24-Sep-2013 Calibration Standards for SPMA (ng/mL)  
Regression Method = LINEAR - Weighting Factor =  $1/X^2$   
Response = Slope \* Conc + Intercept  
Slope = 0.992562201 Intercept = 0.000215280954 R-Squared = 0.9987  
(Study ZRHR-REXC-03-EU; SBMA/SPMA)







SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

## ATTACHMENTS

### Attachment 1 General List of Abbreviations used at Celerion

Abbreviations are used in this document as applicable.

Abbreviation	Description
C	Degree Celsius (centigrade)
µg	Microgram
AAR	Above the acceptable range
AB	Applied Biosystems
API	Stmospheric pressure ionization
ASCII	American standard code for information interchange
BAM	Bioanalytical method
BLK	Blank
BLQ	Below limit of quantification
CC	Conventional Cigarette
CDER	Center for Drug Evaluation and Research
CFR	Code of Federal Regulations
CRO	Contract research organisation
CV	Coefficient of variation
Da	Dalton
DCU	Diluted concentration unreliable
DFNR	Dilution factor not reliable
DQC	Dilution quality control sample
EDTA	Ethylenediaminetetraacetic acid
ELISA	Enzyme-linked immunosorbent assay
EMA	European Medicines Agency
EQB	Exceeding quadratic bounds
EXT	Extraction
FDA	Food and Drug Administration (U.S. Department of Health and Human Services)
fg	Femtogram
g	Gram
GLP	Good laboratory practices
h	Hour
HDPE	High density polyethylene
HPLC	High performance liquid chromatography
HSR	High standard removed



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

ID	Identifier
INC	Incongruous
INS	Instrumentation
IS	Internal standard
ISA	Insufficient volume for full analysis
ISP	Incomplete sample processing
ISR	Incurred sample reproducibility
ISV	Insufficient volume
IVR	Insufficient volume to reassay
L	Litre, liter
LC-MS/MS	Liquid chromatography-tandem mass spectrometry
LLOQ	Lower limit of quantitation
LNK	Celerion, Lincoln site
M	Molar
mg	Milligram
mL	Millilitre, milliliter
mol	Mole
MS	Mass spectrometry
MW	Molecular weight
n	Number of data points
N/AP	Not applicable
N/AV	Not available
NFV	Not full volume
ng	Nanogram
No.	Number
NU	Not used
OECD	Organization for Economic Cooperation and Development
PD	Period
pg	Picogram
QC	Quality control
QCs	Quality control samples
R.E.	Relative error
REF	Reference
RI	Reinjection
RIA	Rarioimmunoassay
RT	Room temperature



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

RR	Reanalysis
RVL	Remaining volume low
S.A.	Smoking Abstinence
S.D.	Standard deviation
SOP	Standard operating procedure
SPE	Solid-phase extraction
SST	System suitability test
STD	Standard
Sub	Subject
SVD	Sample volume depleted
TBD	To be determined
Temp	Temperature
THS	Tobacco Heating System
UCR	Unacceptable chromatography
UISR	Unacceptable internal standard response
ULOQ	Upper limit of quantitation
USP	US pharmacopeia
$\bar{x}$	Mean



---

SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

---

#### Attachment 2 Temperature Definitions at Celerion

Values for temperatures are nominal temperatures representing the following temperature ranges:


Nominal temperature	Temperature Range
-80 C	-65 C to -90 C
-20 C	-10 C to -30 C
5 C	2 C to 8 C
Room temperature	15 C to 25 C
24 C	22 C to 26 C





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

### Attachment 3 Procedure for VCR and SSR Reassays and Reporting of Reassay Results



To compare reassays:

$$\frac{|\text{Reassay Value 1} - \text{Reassay Value 2}|}{\text{Mean of Reassay Value 1 and 2}} \times 100\%$$

To compare to original:

$$\frac{|\text{Mean of Reassays} - \text{Original Value}|}{\text{Original Value}} \times 100\%$$

An LC-MS/MS value as outlined in the decision tree is obtained from a single determination.

If BLQ is obtained for a value, the nominal concentration of the LLOQ is used when comparing reassays in this decision tree.

SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

## Attachment 4 General List of Calculation Formulae

Mean:

$$\bar{X} = \frac{1}{n} \sum_{i=1}^n X_i$$

Standard Deviation (SD):

$$s = \sqrt{\frac{1}{n-1} \sum_{i=1}^n (X_i - \bar{X})^2}$$

Precision (RSD, CV):

$$CV \% = (SD / X_{Mean}) * 100$$

Accuracy (% Theoretical):

$$Accuracy \% = (X / X_{Nominal}) * 100$$

$$Accuracy \text{ of Mean } \% = (X_{Mean} / X_{Nominal}) * 100$$

Inaccuracy (% Bias, % RE):

$$Bias \% = ((X - X_{nominal}) / X_{nominal}) * 100$$

$$Bias \text{ of Mean } \% = ((X_{Mean} - X_{nominal}) / X_{nominal}) * 100$$

X = value (e.g. analyte concentration, OD value, cpm value, peak signal)  
n = number of values X



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01



#### Attachment 5 Reassay Descriptions

Analytical Reason (Code)	Description
Above the Accepted Range (AAR)	Identifies a study sample whose calculated concentration is greater than the upper limit of quantitation (ULOQ). This study sample will be diluted before being reassayed.
Diluted Concentration Unreliable (DCU)	Identifies a study sample that has been diluted and determined to have a concentration below LLOQ (BLQ, below limit of quantification) before correction for the final dilution factor.
Dilution Factor Not Reliable (DFNR)	Identifies a study sample that has been diluted, and determined to have a measurable concentration, however >50% of the dilution QC samples (having the same dilution factor) did not meet their acceptance criteria. Identifies a dilution QC sample that does not fulfil the acceptance criterion and is excluded from the DQC statistics.
Highest / Lowest Standard Removed (HSR / LSR)	If the working range of the method is truncated as a result of - the ULOQ calibration standard being rejected or unavailable (e.g. incomplete sample processing or incomplete instrument analysis, unacceptable chromatography), all study samples with concentrations greater than the highest acceptable standard are identified as 'highest standard removed' (HSR). - the calibration standard at the LLOQ being rejected or unavailable (e.g. incomplete sample processing or incomplete instrument analysis, unacceptable chromatography), all study samples with concentrations below the lowest acceptable standard are identified as 'lowest standard removed' (LSR).
Incomplete Sample Processing (ISP)	Identifies a study sample, calibration standard, or QC sample for which data could not be obtained due to processing problems that occurred during the extraction or assay documented by the analyst prior to instrumental analysis.
Insufficient Volume for Reassay (TVR)	Identified a study sample that has insufficient sample volume for reanalysis (including all received splits)
Incomplete Instrument Analysis (IIA)	Identifies a study sample, calibration standard, or QC sample for which data could not be obtained due to processing problems that occurred during HPLC injection or instrumental analysis and were documented by the analyst.
Unacceptable Chromatography (UCR)	Identifies a study sample, calibration standard, or QC sample judged to demonstrate unacceptable chromatography according to the applicable Celerion procedures (e.g. split peak, poor peak symmetry, unseparated interference).



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

## Attachment 6 Statement of GLP Compliance (Swissmedic)

The Swiss GLP Monitoring Authorities		
	Schweizerische Eidgenossenschaft Confédération suisse Confederazione Svizzera Confederaziun svizra Swiss Confederation	Federal Department of Home Affairs DHA Federal Office of Public Health FOPH  Federal Department of the Environment, Transport, Energy and Communications DETEC Federal Office for the Environment FOEN
		 <b>swissmedic</b> Swiss Agency for Therapeutic Products

### Statement of GLP Compliance

According to Article 14 paragraph 3 Ordinance on Good Laboratory Practice [OGLP, SR 813.112.1]

The notification authority for chemicals confirms that the following test facility was inspected with respect to the compliance with the Swiss Ordinance on Good Laboratory Practice, adopted on 18th May 2005 [OGLP, SR 813.112.1]. This Ordinance is based on the OECD Principles of Good Laboratory Practice, as revised in 1997 and adopted on 28th November 1997 by decision of the OECD Council [C(97)186/Final].

Unequivocal name and address of the test facility:	Area of expertise according to article 3 paragraph 1 letter d OGLP:
Celerion Switzerland Ltd Allmendstrasse 32 8320 Fehraltorf, Switzerland	8. analytic and clinical chemistry testing.

Inspection authority: Swiss Agency for Therapeutic Products (Swissmedic)

Date of inspection: 13 to 14 May 2013

Date of decision: 27 June 2013

Based on the above mentioned decision it can be confirmed that the above mentioned test facility is able to conduct studies according to the aforementioned area of expertise in compliance with the principles of GLP. The above mentioned test facility is listed in the register and GLP list according to the Article 14 OGLP and is inspected on a regular basis according to Article 6 paragraph 2 OGLP.

Swiss Federal Office of Public Health  
Consumer protection directorate  
Notification authority for chemicals  
CH-3003 Bern



*Dag Kappes*

Bern, 14 August 2013, The Head, Dr. Dag Kappes.

The notification authority for chemicals is the coordination and decision authority for the good laboratory practice (GLP) for the FOEN, the FOPH and Swissmedic.

Swiss Federal Office of Public Health, Consumer protection directorate, Notification authority for chemicals, CH-3003 Bern.

[www.glp.admin.ch](http://www.glp.admin.ch), Phone: +41 (0)31 322 73 05, Fax: +41 (0)31 323 54 86





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Attachment 7 Certificates of Analysis

(b) (4)

A large rectangular area of the page is completely redacted with a solid grey fill, covering the majority of the lower half of the document.



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

(b) (4)

A large rectangular area of the page is completely redacted with a solid grey fill, covering the majority of the central content area.



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

(b) (4)

A large rectangular area of the page is completely redacted with a solid grey fill, covering the majority of the central content area.



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

(b) (4)

A large, solid grey rectangular box covers the majority of the page, indicating that the content has been redacted under FOIA exemption (b)(4). The text "(b) (4)" is printed in the top-left corner of this redacted area.





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Attachment 8 Summary of the Method Validation Data



PMI RESEARCH &amp; DEVELOPMENT

## BIOANALYTICAL METHOD SUMMARY (BMS)

Doc Ref: FGR\_QM000496 - 0125442

Version N°: 2.0

Page 1 of 1

Biomarker: S-Benzyl Mercapturic Acid (SBMA)		Matrix: Human urine
MVR/SOP no. & date: SM1-382B / 06-Sep-2013		CRO/Laboratory: Celerion Switzerland
LLOQ: 0.100 ng/mL		ULOQ: 25.0 ng/mL
Validation	<input type="checkbox"/> Full <input type="checkbox"/> Partial <input checked="" type="checkbox"/> Cross Comments (required for Partial/Cross): Validated parameters: Precision & Accuracy, Carry-over, Stress-test (pipetting robot), Comparison of cross-site quality control samples	
Assay:	<input checked="" type="checkbox"/> Chromatographic <input type="checkbox"/> Ligand binding <input type="checkbox"/> Enzymatic <input type="checkbox"/> Other describe: <input type="checkbox"/> LC/MS <input checked="" type="checkbox"/> LC/MS/MS <input type="checkbox"/> GC/MS <input type="checkbox"/> GC/MS/MS <input type="checkbox"/> ELISA	
Equipment and short description of extraction and analysis: An aliquot of human urine containing the analyte and internal standard (assay volume of 500 µL) was extracted using a solid phase extraction procedure. The extracted samples were analyzed by an HPLC equipped with an AB Sciex API 4000 <sup>TM</sup> mass spectrometer. Negative ions were monitored in the multiple reaction monitoring (MRM) mode. Quantification was performed using the peak area ratios of analyte versus IS for each pair of analyte and IS. The calibration curve fitting was done by 1/concentration <sup>2</sup> -weighted linear regression.		

Selectivity/Sensitivity/Matrix effect:	N/AP
Accuracy:	Intra-run: -4.9 – 5.7% R.E. Inter-run: -9.9 – 6.3% R.E.
Precision:	Intra-run: 0.8 – 2.7% C.V. Inter-run: 2.2 – 8.6% C.V.
Recovery:	N/AP
Freeze and thaw stability:	N/AP
Short-term temperature stability:	N/AP
Long-term stability:	N/AP
Stock solution stability:	N/AP
Post-preparative stability:	N/AP

Accreditation/ GLP compliance/ QA statements:	GLP Compliance as Assay Validation conforms to Celerion Standard Operating Procedures which were written in compliance with FDA: Guidance to Industry "Bioanalytical Method Validation"
---	---

BMS completed by:		
Name:	Date:	Signature:
Matthias Jecklin, PhD	23 OCT 2013	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

Doc No: FOR_QM000499 - CR201A2		Version 1: 2.0		Page 1 of 2	
		PMI RESEARCH & DEVELOPMENT			
BIOANALYTICAL METHOD SUMMARY (BMS)					
Biomarker: SBMA		Matrix: Urine			
MVR/SOP no. & date: AA98877-02 / 29-MAY-2013		CRO/Laboratory: Celerion-Lincoln			
LLOQ: 100 pg/mL		ULOQ: 25,000 pg/mL			
Validation	<input checked="" type="checkbox"/> Full <input type="checkbox"/> Partial	<input type="checkbox"/> Cross			
Comments (required for Partial/Cross):					
Assay:	<input checked="" type="checkbox"/> Chromatographic <input type="checkbox"/> Ligand binding <input type="checkbox"/> Enzymatic <input type="checkbox"/> Other	describe:			
	<input type="checkbox"/> LC/MS <input type="checkbox"/> LC/MS/MS <input type="checkbox"/> GC/MS <input type="checkbox"/> GC/MS/MS				
	<input type="checkbox"/> ELISA				
Equipment and short description of extraction and analysis: An aliquot of human urine containing the analyte and internal standard (IS) was extracted using a solid phase extraction procedure. The extracted samples will be analyzed using an HPLC equipped with an AB SCIEX API 4000™ triple quadrupole mass spectrometer using an ESI source. Negative ions will be monitored in the multiple reaction monitoring (MRM) mode. Quantitation was determined using a weighted linear regression analysis (1/x²) of peak area ratios of the analyte and internal standard.					
Selectivity/Sensitivity/Matrix effect:	No significant matrix effect was observed in any of the 10 human urine lots that were fortified with SBMA near the concentration of the LLOQ (100 pg/mL) samples, in any of the 10 human urine lots that were fortified with SBMA near the concentration of a middle standard (1000 pg/mL), or in any of the 10 human urine lots that were fortified with SBMA near the concentration of the high standard (8000 pg/mL) samples				
Accuracy:	Intra-batch: -12.6 to 6.3% R.E. Inter-batch: -8.0 to 0.0% R.E.				
Precision:	Intra-batch: 0.8 to 5.5% C.V. Inter-batch: 2.1 to 6.8% C.V.				
Recovery:	80% at 200 pg/mL in human urine 76% at 4000 pg/mL in human urine 84% at 21,000 pg/mL in human urine				
Freeze and thaw stability:	4 freeze (-20°C)-thaw (5°C) cycles in UV-shielded polypropylene tubes protected from light 4 freeze (-20°C)-thaw (ambient temperature) cycles in polypropylene tubes under yellow light				
Short-term temperature stability:	21 hours in UV-shielded polypropylene tubes at 5°C protected from light 5 hours in polypropylene tubes at ambient temperature under yellow light 21 hours in polypropylene tubes at 5°C protected from light				
Long-term stability:	76 days (LLOQ GC only) and 61 days in polypropylene tubes at -20°C				
Stock solution stability:	55 days at approximately 500 µg/mL in methanol in a polypropylene container at -20°C				



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01



PMI RESEARCH &amp; DEVELOPMENT

## BIOANALYTICAL METHOD SUMMARY (BMS)

Doc No: FOR\_QM000496 - CP204A2

Version N°: 2.0

Page 2 of 2

Post-preparative stability:	181 hours in a polypropylene 96 well plate at 5°C	
Accreditation/ GLP compliance/ QA statements:	GLP Compliance as Assay Validation conforms to Celerion Standard Operating Procedures which were written in compliance with FDA: Guidance to Industry "Bioanalytical Method Validation"	
BMS completed by:		
Name:	Date:	Signature:
Erica Nachi	30-MAY-2013	Erica Nachi



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01



PMI RESEARCH &amp; DEVELOPMENT

## BIOANALYTICAL METHOD SUMMARY (BMS)

Doc No: FDR\_QM000499 - CR20442

Version: 2.0

Page 1 of 1

Biomarker: S-Phenyl Mercapturic Acid (SPMA)	Matrix: Human urine
MVR/SOP no. & date: SM1-382B / 05-Sep-2013	CRO/Laboratory: Celerion Switzerland
LLOQ: 0.0250 ng/mL	ULOQ: 6.35 ng/mL
Validation	<input type="checkbox"/> Full <input type="checkbox"/> Partial <input checked="" type="checkbox"/> Cross Comments (required for Partial/Cross): Validated parameters: Precision & Accuracy, Carry-over, Stress-test (pipetting robot), Comparison of cross-site quality control samples
Assay:	<input checked="" type="checkbox"/> Chromatographic <input type="checkbox"/> Ligand binding <input type="checkbox"/> Enzymatic <input type="checkbox"/> Other describe: <input type="checkbox"/> LC/MS <input checked="" type="checkbox"/> LC/MS/MS <input type="checkbox"/> GC/MS <input type="checkbox"/> GC/MS/MS <input type="checkbox"/> ELISA
Equipment and short description of extraction and analysis: An aliquot of human urine containing the analyte and internal standard (assay volume of 500 µL) was extracted using a solid phase extraction procedure. The extracted samples were analyzed by an HPLC equipped with an AB Sciex API 4000 <sup>TM</sup> mass spectrometer. Negative ions were monitored in the multiple reaction monitoring (MRM) mode. Quantification was performed using the peak area ratios of analyte versus IS for each pair of analyte and IS. The calibration curve fitting was done by 1/concentration <sup>2</sup> -weighted linear regression.	
Selectivity/Sensitivity/Matrix effect:	N/A
Accuracy:	Intra-run: 7.2 – 18.0% R.E. Inter-run: 6.3 – 10.0% R.E.
Precision:	Intra-run: 1.4 – 6.6% C.V. Inter-run: 2.2 – 12.9% C.V.
Recovery:	N/A
Freeze and thaw stability:	N/A
Short-term temperature stability:	N/A
Long-term stability:	N/A
Stock solution stability:	N/A
Post-preparative stability:	N/A
Accreditation/ GLP compliance/ QA statements:	GLP Compliance as Assay Validation conforms to Celerion Standard Operating Procedures which were written in compliance with FDA: Guidance to Industry "Bioanalytical Method Validation"
BMS completed by:	
Name: Matthias Jecklin, PhD	Date: 23 OCT 2013 Signature:





SPMA and SBMA in Human Urine  
Celerion Study AA99602-01



PMI RESEARCH &amp; DEVELOPMENT

## BIOANALYTICAL METHOD SUMMARY (BMS)

Doc No: FOR\_CM000498 - CR004A2

Version N°: 2.0

Page 1 of 2

Biomarker: SPMA		Matrix: Urine	
MVR/SOP no. & date: AA08877-02 / 29-MAY-2013		CRO/Laboratory: Celerion-Lincoln	
LLOQ: 25.0 pg/mL		ULOQ: 6250 pg/mL	
Validation	<input checked="" type="checkbox"/> Full <input type="checkbox"/> Partial <input type="checkbox"/> Cross Comments (required for Partial/Cross):		
Assay:	<input checked="" type="checkbox"/> Chromatographic <input type="checkbox"/> Ligand binding <input type="checkbox"/> Enzymatic <input type="checkbox"/> Other describe: <input type="checkbox"/> LC/MS <input checked="" type="checkbox"/> LC/MS/MS <input type="checkbox"/> GC/MS <input type="checkbox"/> GC/MS/MS <input type="checkbox"/> ELISA		
Equipment and short description of extraction and analysis: An aliquot of human urine containing the analyte and internal standard (IS) was extracted using a solid phase extraction procedure. The extracted samples will be analyzed using an HPLC equipped with an AB SCIEX API 4000™ triple quadrupole mass spectrometer using an ESI source. Negative ions will be monitored in the multiple reaction monitoring (MRM) mode. Quantitation was determined using a weighted linear regression analysis (1/x <sup>2</sup> ) of peak area ratios of the analyte and internal standard.			
Selectivity/Sensitivity/Matrix effect:		No significant matrix effect was observed in any of the 10 human urine lots that were fortified with SPMA near the concentration of the LLOQ (25.0 pg/mL) samples, in any of the 10 human urine lots that were fortified with SPMA near the concentration of a middle standard (250 pg/mL), or in 9 of the 10 human urine lots that were fortified with SPMA near the concentration of the high standard (2000 pg/mL) samples	
Accuracy:		Intra-batch: -14.0 to 6.7% R.E. Inter-batch: 0.0 to 0.6% R.E.	
Precision:		Intra-batch: 1.1 to 8.6% C.V. Inter-batch: 4.0 to 12.9% C.V.	
Recovery:		92% at 50.0 pg/mL in human urine 87% at 1000pg/mL in human urine 88% at 5250 pg/mL in human urine	
Freeze and thaw stability:		4 freeze (-20°C)-thaw (5°C) cycles in UV-shielded polypropylene tubes protected from light 4 freeze (-20°C)-thaw (ambient temperature) cycles in polypropylene tubes under yellow light	
Short-term temperature stability:		21 hours in UV-shielded polypropylene tubes at 5°C protected from light 5 hours in polypropylene tubes at ambient temperature under yellow light 21 hours in polypropylene tubes at 5°C protected from light	
Long-term stability:		76 days in polypropylene tubes at -20°C	
Stock solution stability:		57 days at approximately 500 µg/mL in methanol in a polypropylene container at -20°C	



SPMA and SBMA in Human Urine  
Celerion Study AA99602-01



PMI RESEARCH &amp; DEVELOPMENT

## BIOANALYTICAL METHOD SUMMARY (BMS)

Doc No: FOR\_QM000496 - CR204A2

Version N°: 2.0

Page 2 of 2

Post-preparative stability:	181 hours in a polypropylene 96 well plate at 5°C	
Accreditation/ GLP compliance/ QA statements:	GLP Compliance as Assay Validation conforms to Celerion Standard Operating Procedures which were written in compliance with FDA: Guidance to Industry "Bioanalytical Method Validation"	
BMS completed by:		
Name:	Date:	Signature:
Erica Nachi	30-MAY-2013	Erica J Nachi




SPMA and SBMA in Human Urine  
Celerion Study AA99602-01

---


#### Attachment 9 Chromatograms

Representative chromatograms from analytical run AA99602-01\_P1.


Total number of pages including this page: 95.







Project: AA9902-01  
Results Name: AA9902-01\_P1.rdbMethod Name: AA9902-01\_P1.qm7  
Analyst Version: 1.5.2

Page 2 of 94


Project: AA9902-01  
Results Name: AA9902-01\_P1.qmMethod Name: AA9902-01\_P1.qm  
Analyst Version: 1.5.2


Page 3 of 94

























































Project: AA9602-01  
Results Name: AA9602-01\_P1.rdbMethod Name: AA9602-01\_P1.qmf  
Analyst Version: 1.5.2


Page 20 of 94




















Project AA9902-01  
Results Name AA9902-01\_P1.rdbMethod Name AA9902-01\_P1.qm7  
Analyst Version 1.5.2


Page 26 of 94












Project: AA9602-01  
Results Name: AA9602-01\_P1.rdbMethod Name: AA9602-01\_P1.qmf  
Analyst Version: 1.5.2

Page 30 of 94





Project: AA99602-01  
Results Name: AA99602-01\_P1.rdbMethod Name: AA99602-01\_P1.qm7  
Analyst Version: 1.5.2


Page 32 of 94


























Project: AA99602-01  
Results Name: AA99602-01\_P1.qmMethod Name: AA99602-01\_P1.qm  
Analyst Version: 1.5.2


Page 40 of 94












Project: AA9902-01  
Results Name: AA9902-01\_P1.rdbMethod Name: AA9902-01\_P1.qm7  
Analyst Version: 1.5.2


Page 44 of 94















Project: AA9602-01  
Results Name: AA9602-01\_P1.rdbMethod Name: AA9602-01\_P1.qmf  
Analyst Version: 1.5.2


Page 49 of 94

















































































































































Project: AA99602-01  
Results Name: AA99602-01\_P1.rnbMethod Name: AA99602-01\_P1.qmf  
Analyst Version: 1.5.2

Page 92 of 94

